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INTRODUCTION
During the postpartum period, women are at high risk for both first-onset and recurrent mood 
disorder episodes (1-3). This thesis focuses on the treatment and course of mood disorders 
during pregnancy and the postpartum period, with a main focus on bipolar disorder and 
postpartum psychosis (bipolar spectrum disorder). In the next paragraphs of this chapter we 
will provide a brief clinical overview of postpartum mood disorders, followed by the study 
populations, aims and outline of this thesis.
 
Postpartum blues
The most prevalent mood disturbance (incidence approximately 50%) during the postpartum 
period is postpartum blues (i.e. “maternity blues”) (4). The onset is between 3 to 5 days 
postpartum and typical symptoms include: mood lability, tearfulness, irritability, anxiety and 
difficulty with clear thinking. Notably, feeling depressed is not a key symptom of postpartum 
blues (4). Postpartum blues is observed in a large number of countries and across different 
ethnicities (4, 5). Due to its self-limiting course (within a few hours – days) it is not considered as 
psychopathology (6). However, it is important to notice that postpartum blues is a risk factor for 
the occurrence of postpartum depression. In addition, it can be difficult to distinguish between 
postpartum blues and the initial presentation of postpartum psychosis (7, 8). 
 
Postpartum depression
Postpartum depression (often incorrectly referred to as “postnatal depression”) is a 
heterogeneous disorder with an incidence of approximately 10% (7, 9, 10). The onset is 
within one year postpartum, but in a substantial proportion of women the onset of postpartum 
depression is already before or during pregnancy (10). The depressive symptomatology can 
be mild and transient but also very severe and persistent, requiring a psychiatric admission 
(11). Postpartum depression is associated with a broad range of biological (e.g. age, chronic 
diseases), psychological (e.g. personality traits) and social (e.g. social economic status, social 
support) risk factors (7).The diagnostic criteria (adapted from the Diagnostics and Statistics 
Manual of Mental Disorders, fifth edition (DSM-5) (12)) are identical to depression outside 
the postpartum period and include at least five of the following symptoms (present for at least 
2 weeks): either depressed mood or anhedonia, together with insomnia (or hypersomnia), 
weight loss (or weight gain), psychomotor agitation (or retardation), fatigue, feelings of guilt, 
diminished ability to think or concentrate, or recurrent thoughts of death. The Edinburgh Postnatal 
Depression Scale (EPDS) (13) is a validated and useful 10-item self-reporting questionnaire 
that is often used to identify women with a high probability of postpartum depression.
 The most important clinical risk factor for postpartum depression is an episode of depression 
earlier in life and/or during pregnancy. However, a subgroup of women is at risk for a first-
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onset episode of postpartum depression (7, 14). Among those women, biological risk factors 
probably play a more important role (15-17). During the diagnostic phase it is very important 
to beware of potential somatic causes of depressive symptomatology, such as auto-immune 
thyroid dysfunction. This disorder is defined by auto-immune inflammation of the thyroid and the 
presence of thyroid auto-antibodies (most commonly thyroid peroxidase antibodies (TPO-ab)) 
(18). It is also essential to assess the presence of social and/or environmental stressors such 
as lack of social support, life-events and financial problems. Treatment options of postpartum 
depression are psychotherapy, mother-baby therapy and treatment with antidepressants (7). 
The vast majority of women have a favorable prognosis. However, postpartum depression can 
also represent an incipient bipolar disorder mood episode (19, 20).
 
Bipolar disorder
Bipolar disorder (manic depressive illness) is a disabling and chronic psychiatric mood disorder 
with a lifetime prevalence of 1-3%. The onset is typically in early adulthood and the illness is 
characterized by recurrent episodes of depression and (hypo)mania (21, 22). The postpartum 
period is an important trigger for both first-onset and recurrent bipolar disorder mood episodes 
(1, 2).
 The diagnostic criteria for bipolar depression are identical to the criteria for unipolar 
depression (see previous paragraph “postpartum depression”) (12). Mania is defined with the 
following diagnostic criteria (adapted from the DSM-5 (12)): a distinct period of abnormally 
and persistently elevated, expansive or irritable mood and persistently increased activity of 
energy lasting at least one week, together with three (or four if the mood is only irritable) of 
the following symptoms: inflated self-esteem or grandiosity, decreased need for sleep, more 
talkative than usual/pressure to keep talking, flights of ideas or subjective experience that 
thoughts are racing, distractibility, increased in goal directed activity or excessive involvement 
in activities with potentially harmful consequences (12). Sometimes, patients also suffer from 
mood-congruent delusions (e.g. manic-psychotic episode).
 In most cases, long-term maintenance treatment with medication is necessary to prevent 
future bipolar disorder mood episodes (22). Lithium is the most effective known mood stabilizer 
for the long-term prevention of recurrence in bipolar disorder (23). Other treatment options 
include valproate, carbamazepine, lamotrigine and second generation antipsychotics 
(olanzapine, quetiapine, risperidone) (23).
 Maintenance treatment during pregnancy might be required, especially in women 
with recent and/or severe mood episodes. This is a concern because in utero exposure to 
medication is potentially harmful for the unborn child. Mood stabilizers that are used for the 
long-term treatment of bipolar disorder have different profiles regarding the risk for neonatal 
adverse effects. In utero exposure to lithium is probably associated with a slightly increased risk 
of congenital heart defects (24, 25). Use of valproate and carbamazepine should be avoided 
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during pregnancy because of the increased risk of neural tube defects and other adverse 
neonatal outcomes. Regarding second generation antipsychotics and lamotrigine, there seems 
to be no association with congenital malformations (26). In general, the potential long-term 
adverse effects of in utero exposure to moodstabilizing medication in children are poorly studied. 
However, discontinuation of moodstabilizing medication during pregnancy is associated with 
an increased risk of recurrence (27), which may also be potentially harmful for the unborn child 
(28). Accordingly, women with bipolar disorder and their clinicians should carefully weigh the 
risks and benefits of medication use during pregnancy. During the postpartum period, women 
with bipolar disorder are far more likely to suffer from severe recurrence than women with any 
other psychiatric diagnosis (2). Importantly, recurrence during pregnancy further increases the 
risk of a postpartum mood episode (29). 
  The first weeks after delivery women are particularly vulnerable for mania/psychosis, 
while depressive episodes typically occur later on in the postpartum period (30). Studies 
that specifically assessed to what extend use of moodstabilizing medication is effective in the 
prevention of recurrence during the peripartum period are scarce. This is probably a result of 
ethical and practical concerns that are related to research in women during their childbearing 
ages. From a clinical point of view this is very problematic, because it hampers evidence-based 
decision making during this vulnerable period.
Postpartum psychosis
Postpartum psychosis is the most severe form of psychiatric illness following childbirth with an 
estimated incidence of 0.3-0.6 per 1000 births in the general population and an onset within 
four weeks postpartum (1, 31, 32). 
 Interestingly, the majority of women with postpartum psychosis do not have a history of 
psychiatric illness (33). Contrary to what the term postpartum psychosis suggests, the disorder 
is in general considered to be a mood disorder within the bipolar disorder spectrum because 
affective symptoms (either depressive or (hypo)manic symptoms or a mixed state) are a hallmark 
of the disease. The most important risk factors are primiparity, a previously established diagnosis 
of bipolar disorder and/or a history of postpartum psychosis (1, 2, 30). In contrast to postpartum 
depression, there is no clear evidence that environmental/social risk factors play an important 
role in the onset of postpartum psychosis. The first symptoms typically present within two weeks 
postpartum and include insomnia, irritability and increased motor activity. Afterwards, women 
present with more severe mood symptoms (either depressive or (hypo)manic symptoms or a 
mixed state), suicide/infanticide thoughts and psychotic symptoms (delusions, hallucinations). 
In addition, some women have one or more of the following atypical/delirious-like symptoms: 
alterations in level of consciousness, disorientation, depersonalization and derealisation (33, 
34). A psychiatric mother-baby admission is necessary for diagnostic evaluation (especially 
to assess potential somatic causes of postpartum psychosis), to reduce the risk of suicide/
Chapter 1
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infanticide, to optimize treatment and to enhance mother-baby interaction (34, 35).
 Cases of severe psychiatric illness with an acute onset postpartum have already been 
described in the medical literature for centuries and nowadays the term postpartum psychosis is 
commonly used by both clinicians and researchers (5, 36). However, postpartum psychosis is 
not classified as a separate disorder in either the International Classification of Diseases (ICD) 
or DSM-5 (34, 36). The main reason for the absence of a separate disease status is the close 
link between postpartum psychosis and bipolar disorder. In a substantial proportion of women, 
first-onset postpartum psychosis is the incipient episode of a bipolar disorder disease course (3, 
37). However, as stated by Bergink and colleagues (36) in a recent editorial, there are several 
arguments to maintain the diagnostic concept of postpartum psychosis: 1. It highlights childbirth 
as a highly specific and very significant trigger of psychiatric illness and the onset timing 
coincides with a period of several neurobiological changes. 2. Its distinct phenotype: although 
affective symptomatology is a hallmark of postpartum psychosis, the clinical presentation is 
often different than in bipolar disorder. For example, women with postpartum psychosis often 
have mood-incongruent delusions. 3. Its course: in contrast to women with bipolar disorder, 
a substantial group of women with postpartum psychosis is only vulnerable for the onset of 
psychiatric illness during the postpartum period. 
 Treatment of postpartum psychosis with a combination of antipsychotic medication and 
lithium is highly effective and at nine months postpartum the majority of women report good 
functional recovery (38, 39). As mentioned earlier, women with postpartum psychosis are 
at very high risk for mania or psychosis after a subsequent delivery. Fortunately, short-term 
prophylactic lithium use during the postpartum period is highly effective in the prevention of 
such episodes (29).
 
Study populations 
Women that were included in studies described in this thesis were selected from the following 
clinical or population-based cohorts:
1. The OPPER-study (Onderzoeksprogramma Postpartum Psychose, Erasmus MC 
Rotterdam): a prospective clinical cohort study (2005 – present) including patients with a 
postpartum onset of severe depression, mania and/or psychosis who are admitted to the 
psychiatric mother-baby unit of Erasmus MC in Rotterdam. The OPPER-study focuses on 
the etiology, phenomenology, risk factors, treatment and course (follow-up) of postpartum 
psychosis. 
2. The NP3-study (National Postpartum Psychosis Prevention study): a clinical cohort study. 
The aim of this study is to investigate the clinical outcome of pregnancies in women with 
a history of bipolar disorder and/or postpartum psychosis, with follow-up until 3.5 years 
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postpartum. The NP3-study primarily focuses on the risks and benefits of maintenance 
treatment during pregnancy and/or the postpartum period. The NP3-study consists of 
a retrospective cohort (2003 – 2013, Erasmus Medical Centre (Erasmus MC) Rotterdam 
and Leiden University Medical Centre (LUMC) and a prospective cohort with nationwide 
inclusion (2013 – present).
3. The HAPPY-study (Holistic Approach to Pregnancy and the first Postpartum Year, Tilburg 
University): a population based prospective cohort study (2013 – present) with follow-up of 
pregnant women throughout all trimesters of pregnancy and the first postpartum year. The 
HAPPY-study focuses on physiological and psychological determinants that may influence 
maternal and/or infant wellbeing during the peripartum period, with a specific focus on 
mental health (40). 
4. National Centre for Register Based Research (Aarhus University, Denmark): all 
live-births and residents in Denmark are registered in The Danish Civil Registration System, 
which provides the unique opportunity to link individual data of several civil and medical 
registers (41). A major advantage of register based population based cohort studies is that 
the whole population is eligible for inclusion, thereby eliminating the risk of selection bias.
Outline and aims of this thesis
In Part I of this thesis we focus on the postpartum period as a trigger for first-onset or recurrent 
mood disorder episodes. In chapter 2 we present a systematic review and meta-analysis. 
The aim of this study is to quantify the risk of postpartum recurrence/relapse among women 
with a history of bipolar disorder or postpartum psychosis. In addition, we summarize the 
current evidence regarding the efficacy of mood-stabilizing medication during pregnancy and 
the postpartum period. The aim of chapter 3 is to provide an overview of the diagnostic 
considerations, treatment and prevention of postpartum psychosis. With regard to prevention, 
we specifically highlight the differences between women with bipolar disorder and an isolated 
history of postpartum psychosis. The objective of chapter 4 is to identify subgroups of patients 
with postpartum psychosis based on symptom profiles, by using a patient centered analytic 
approach (OPPER-study). The aim of chapter 5 is to assess the association between the 
presence of thyroid peroxidase antibodies (TPO-ab) in early pregnancy and the risk of first-
onset postpartum depression (HAPPY-study).
 
Part II of this thesis focuses on dosing strategies and the efficacy of lithium use during 
pregnancy and the postpartum period among women with bipolar disorder. In chapter 6, we 
provide a general introduction on the history and clinical aspects of lithium therapy. The aim of 
chapter 7 is to quantify the timing and onset of fluctuations in lithium blood levels, that are a 
Chapter 1
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result of pregnancy-related physiological changes in renal function (NP3-study). In chapter 
8, we compare the efficacy of lithium and lamotrigine use during pregnancy in the prevention 
of postpartum episodes (Danish National registers). 
 
In chapter 9 we present the main conclusions of this thesis and summarize the current evidence 
regarding the risks and benefits of maintenance treatment during the peripartum period in 
women with bipolar disorder. Finally, we provide directions for future research. 
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ABSTRACT
Objective: Women with a history of bipolar disorder, postpartum psychosis, or both are at high 
risk for postpartum relapse. The aim of this meta-analysis was to estimate the risk of postpartum 
relapse in these three patient groups.
Method: A systematic literature search was conducted in all public medical electronic 
databases, adhering to the PRISMA guidelines. Studies were included if they reported 
postpartum relapse in patients diagnosed with bipolar disorder and/or a history of postpartum 
psychosis or mania according to DSM or ICD criteria or the Research Diagnostic Criteria. 
Results: Thirty-seven articles describing 5,700 deliveries in 4,023 patients were included 
in the quantitative analyses. The overall postpartum relapse risk was 35% (95% CI=29, 41). 
Patients with bipolar disorder were significantly less likely to experience severe episodes 
postpartum (17%, 95% CI=13, 21) than patients with a history of postpartum psychosis (29%, 
95% CI=20, 41). Insufficient information was available to determine relapse rates for patients 
with bipolar disorder and a history of postpartum episodes. In women with bipolar disorder, 
postpartum relapse rates were significantly higher among those who were medication free 
during pregnancy (66%, 95% CI=57, 75) than those who used prophylactic medication (23%, 
95% CI=14, 37). 
Conclusions: One-third of women at high risk experience a postpartum relapse. In women 
with bipolar disorder, continuation of prophylactic medication during pregnancy appears 
highly protective for maintaining mood stability postpartum. In women with a history of isolated 
postpartum psychosis, initiation of prophylaxis immediately after delivery offers the opportunity 
to minimize the risk of relapse while avoiding in utero medication exposure. 
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INTRODUCTION
The onset of severe psychiatric illness immediately after childbirth has been described 
extensively. In the 19th century, case reports described women with severe mania or psychosis 
after every delivery, including some with as many as 13 pregnancies (1). Interestingly, these 
women had isolated episodes of postpartum psychosis or mania without psychiatric episodes 
outside the postpartum period. Later studies confirmed the vulnerability to psychosis and mania 
specifically in the postpartum period, including a high postpartum relapse risk after subsequent 
pregnancies (2, 3). Accordingly, a history of isolated postpartum psychosis is widely considered 
a strong risk factor for future severe postpartum episodes.
 A second group at high risk for relapse in the postpartum period comprises women 
with a previous diagnosis of bipolar disorder. Patients with bipolar disorder are more likely 
to experience a puerperal psychiatric admission compared with patients with any other 
psychiatric diagnosis. Kendell et al. (4) were the first to quantify this risk in a population-
based cohort. They described a relapse risk of 16% for puerperal admission in patients with 
bipolar disorder, compared with 3% for patients with schizophrenia and 2% for patients 
with depression. More recently, Munk-Olsen et al. (5) replicated this finding in a birth 
register study by comparing the relative risk for puerperal admissions during the first month 
postpartum with admissions 11–12 months postpartum. They found a higher relative risk 
for relapse during the early postpartum period for patients with bipolar disorder (relative 
risk=37.2, 95% CI=13.6, 102.0), compared with patients with schizophrenia (relative risk=4.6, 
95% CI=2.5, 8.5) or other psychiatric disorders (relative risk=3.0, 95% CI=1.9, 4.7).   
 Women diagnosed with bipolar disorder are at high risk for postpartum episodes, including 
psychosis and mania. Moreover, first-onset psychosis or mania occurring in the postpartum 
period is sometimes found in retrospect to be the incipient episode of a lifelong diagnosis 
of bipolar disorder (6, 7). Importantly, however, retrospective long-term follow-up studies 
have shown that a substantial proportion of women with first-onset postpartum psychosis or 
mania do not have a bipolar illness course with manic and depressive episodes outside the 
postpartum period (6). Instead, these women have isolated postpartum psychosis: their risk of 
mania and psychosis appears to be limited to the postpartum period. Accordingly, increasing 
evidence suggests that isolated postpartum psychosis may represent a unique diagnostic entity, 
distinct from bipolar disorder (8). Previous studies have demonstrated important differences 
between isolated postpartum psychosis and bipolar disorder, in both acute treatment and 
medication prophylaxis (3, 8, 9). From a neurobiological perspective, it is likely that women 
with isolated postpartum psychosis have a selective vulnerability to the endocrine and 
immunological changes that follow childbirth, in contrast to women with bipolar disorder, for 
whom neurobiological triggers are also present outside the postpartum period (10, 11).   
 Estimation of relapse risks for women with isolated postpartum psychosis or bipolar 
disorder have been described in prospective, retrospective, and birth cohort studies. However, 
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the high variability of reported relapse rates across different studies has hampered efforts 
to obtain a precise quantification. For example, a Swedish birth register study described 
a postpartum relapse rate of 8.5% in patients with bipolar disorder, whereas an Italian 
retrospective cohort study found a prevalence rate of 75% in medication-free patients with 
bipolar disorder (12, 13). Similar difficulties in the interpretation of studies have arisen for 
patients with a history of postpartum episodes. For example, a 2012 prospective cohort study 
from the Netherlands reported a relapse rate of 14% in women with isolated postpartum 
psychosis, whereas a 2013 retrospective cohort study from the United Kingdom reported a 
relapse rate of 58% in patients with a history of postpartum psychosis (2, 3).   
 A weighted estimation of relapse risk is essential for clinicians and patients to perform a risk-
benefit analysis and should ideally include an estimate of the duration of the high-risk period. 
On the basis of these evidence-based prognoses, patients can be empowered to develop an 
individualized peripartum plan with their clinicians, covering the period from conception to 1 
year postpartum. Before conception, the magnitude of the estimated relapse risk often directly 
influences family planning. Previous studies have shown that women with first-onset postpartum 
mania or psychosis are less likely to have additional children. Moreover, women with bipolar 
disorder are known to have lower fecundity rates compared with the general population (14). 
The estimated risk of relapse is particularly relevant during pregnancy, in balancing the benefits 
of prophylactic medication with the risks of fetal medication exposure. In the postpartum 
period, decisions regarding pharmacotherapy and breastfeeding are strongly influenced by 
the estimated risk of relapse. 
 Clearly, the accuracy and reliability of the weighted estimation of relapse risk is 
a major determining factor underlying the benefit of this approach. Unfortunately, 
however, researchers and clinicians have limited knowledge about the relapse risk. An 
overestimation of relapse risk might lead to overly distressed future parents, excessive 
medication use, reduced rates of breastfeeding, or unnecessarily altered family planning. 
Underestimation of relapse risk might lead to ineffective relapse prevention strategies 
and delay referral for specialized perinatal care in which optimal coordination between 
obstetric and mental health care providers could otherwise be arranged (3). With even 
more severe consequences, underestimation of relapse risk would undoubtedly result in 
higher rates of quality of life impairment, acute inpatient hospitalization, and suicide (15).   
 In this study, we performed a systematic review and meta-analysis to examine the risk of 
postpartum relapse in women with a history of bipolar disorder, postpartum psychosis or mania, 
or both diagnoses. We compared the severity of episodes and the duration of postpartum 
follow-up and examined the association between relapse and prophylactic medication. We 
also identified methodological factors that account for heterogeneity across studies.
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METHOD
Literature search
The initial systematic literature search was performed on Aug. 26, 2013, in all large electronic 
medical databases, using the search terms “bipolar,” “postpartum,” “psychosis,” and “relapse” 
and “risk.” The search was updated on Jan. 6 and Nov. 11, 2014 (see the data supplement that 
accompanies this article).
Selection of studies
The selection procedure was conducted according to the PRISMA and MOOSE guidelines 
(16, 17). Studies were eligible for inclusion if they were written in English and if patients were 
diagnosed with bipolar disorder and/or a history of a psychotic or manic episode following 
childbirth according to DSM criteria, ICD criteria, or the Research Diagnostic Criteria (RDC) (18). 
Information about psychiatric relapse within 12 months postpartum was obtained (proportion of 
patients and/or deliveries). We defined relapse as psychosis, mania or hypomania, depression 
(or a mixed episode), and/or psychiatric hospitalization. All longitudinal study designs (cohort 
studies, randomized controlled trials, and birth register studies) were suitable for inclusion.
Data extraction 
Data were extracted by two independent observers (R.W. and A.M.K.) using a data extraction 
form. Observers were not blind to authors, institutions, or journals. In case of difference 
in assessment between the two observers, a decision was made with help from a third 
independent observer (V.B.). Relapse rates were extracted both for patients with a history 
of bipolar disorder and for those with a history of postpartum psychosis. Studies reporting 
incidence or prevalence rates were considered eligible for inclusion. As the numerator, 
relapse events, including psychosis, mania or hypomania, depression (or a mixed episode), 
and/or psychiatric hospitalization were counted. An event was defined as a severe relapse 
when an affective psychosis, mania, mixed episode, or relapse required hospitalization. As 
the denominator, we used the total number of deliveries (study outcome incidence rate) or 
patients (study outcome prevalence rate). For studies that included more than one delivery per 
patient, deliveries were considered independent events. In longitudinal studies of patients with 
a history of postpartum psychosis, only participants with subsequent deliveries were included. 
Studies that examined various diagnostic entities (e.g., bipolar disorder and schizophrenia) 
were included only if relapse outcomes were described for each diagnostic category. 
We screened all included studies for postpartum relapse rates with regard to prophylactic 
pharmacotherapy. We compared postpartum relapse rates between women with and 
without prophylactic medication use during pregnancy, the postpartum period, or both.  
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 If a study reported relapse rates at more than one time point during the postpartum period, 
the data were pooled to calculate an overall relapse rate. All included studies were part of 
the qualitative synthesis. In those sets of articles for which overlapping cohorts were used, 
only the most complete or most recent data set was included in the meta-analysis (quantitative 
synthesis). 
 
Quality Assessment 
The reviewers independently assessed the quality of the included studies, according to the GRADE 
guidelines (19). Potential bias was assessed with regard to the following quality criteria (20): 
definition of inclusion (DSM, ICD, RDC), definition of relapse (DSM/RDC/ICD, hospitalization, 
clinical interview, or unknown), handling of missing data, and year of publication.  
Procedure for meta-analyses
We used random-effects estimation and a 95% confidence interval to calculate an overall 
relapse rate. This provided the opportunity to compare relapse rates between patients with 
bipolar disorder and those with a history of postpartum psychosis and to assess the influence 
of pharmacotherapy on relapse. Random-effects analysis was used because it produces 
a more reliable estimate of the overall relapse rate than fixed-effects analysis in case of 
substantial heterogeneity (21). Univariate analyses were performed to assess the association 
of independent variables with the overall relapse rate. The association with categorical 
characteristics was assessed using random-effects estimation to calculate and compare the 
overall outcome per category. Q statistics and significance levels are reported. The association 
of continuous characteristics with outcome was assessed by performing mixed-effects meta-
regression analyses using unrestricted maximum-likelihood estimation, with log relapse rate 
as the response variable. We added 0.0001 in case of zero cell observations. Beta values 
with 95% confidence intervals and significance levels are reported. Statistical analyses were 
performed using the Comprehensive Meta-Analysis program, version 2.2.034 (22).   
Publication bias
Publication bias was visually assessed with a funnel plot and formally with the Egger test, 
to assess whether the relapse rate decreased with increasing sample size. Plots with a 
funnel shape are considered to occur only when publication bias is low or absent. Since 
nonsignificant studies are less likely to be published, studies in the bottom left-hand corner of 
the plot are often omitted (23).   
Risk of postpartum relapse in bipolar disorder and postpartum psychosis
25 
Ch
ap
te
r 2
Heterogeneity and sensitivity analyses
Cochran’s Q test and I2 statistics were used to quantify heterogeneity across studies. 
Heterogeneity was further explored by conducting sensitivity analyses. For this aim, we 
calculated the overall relapse rate using both fixed- and random-effects modeling and 
evaluated the impact of the modeling procedure on the overall relapse rate of all studies. We 
compared relapse rates based on the study quality criteria described in the Quality Assessment 
section above. In addition, we compared retrospective cohort, prospective cohort, and birth 
register studies; incidence rates and prevalence rates; one delivery per patient versus multiple 
deliveries per patient; qualitative versus quantitative synthesis; and duration of follow-up. For 
the analyses regarding the duration of follow-up, we categorized studies by the following 
thresholds: relapse within <4 weeks, <3 months, <6 months, and <12 months postpartum. 
Finally, we assessed the influence of the duration of follow-up as a continuous variable on 
relapse rate. 
RESULTS
Selection of studies
The literature search produced a set of 3,498 articles. After de-duplication, the set was 
narrowed to 2,137 articles, which were then reviewed in an interrater session (R.W. and 
A.M.K.) based on title and abstract, resulting in an initial selection of 307 articles. After full-
text assessment of the 307 articles, 48 were included in the qualitative synthesis. Screening 
for overlap in the investigated cohorts resulted in the exclusion of 11 studies. Therefore, 37 
articles were included in the quantitative synthesis; publication dates were between March 
1986 and October 2014 (articles published before March 1986 did not use DSM, ICD, or 
RDC criteria and were therefore not considered) (Figures 1 and 2). Interrater reliability was 
high (raw interrater agreement=94.7%, kappa=0.88, 95% CI=0.80, 0.96).
Study characteristics
In the quantitative selection (N=37 studies), the outcome of 5,700 deliveries in 4,023 patients 
was provided. We found an overall postpartum relapse risk of 35% (95% CI=29, 41). Twenty-
four studies focused on patients with bipolar disorder, 12 studies focused on patients with a 
history of postpartum psychosis, and one study described independent groups of patients with 
bipolar disorder and a history of postpartum psychosis (Figures 2 and 3A). The largest study 
described the outcome of 1,828 deliveries in the United Kingdom (24). Other large studies 
were conducted at centers in the United States (1,120 deliveries) (25), Sweden (786 deliveries) 
(12), Italy (276 women) (13) and Denmark (208 deliveries) (5). Detailed characteristics of all 
studies are provided in Table S1 of the data supplement. 
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FIGURE 1. Flowchart of the article selection process in a meta-analysis of risk of postpartum 
relapse in bipolar disorder and postpartum psychosis
Detailed characteristicsofall studiesareprovidedinTableS1 in
the online data supplement.
Postpartum Relapse Rates in Patients With
Bipolar Disorder
As shown in Figure 3A, patients with bipolar disorder had an
overall relapse risk of 37% (95% CI=29, 45) (25 studies, 5,105
deliveries, 3,495 patients). Three large studies and one small
study made a distinction between patients with bipolar I and
II disorders (13, 25–27). Two studies included only patients
with bipolar I disorder (28, 29) and one study enrolled only
patients with bipolar II disorder (30). No signiﬁcant differ-
ence in relapse rates was found between patients with bipolar I
and II disorders (bipolar I disorder: N=2,190, 45% [95% CI=32,
58]; bipolar II disorder: N=1,249, 50% [95% CI=35, 65]; Q=0.25,
df=1, p=0.62).
Postpartum Relapse Rates in Patients With a History of
Postpartum Psychosis or Mania
Patients with a history of postpartum psychosis had an overall
relapse risk of 31% (95% CI=22, 42) (13 studies, 595 deliveries,
528 patients) (Figure 3A). Eleven of the 13 studies included
only patients with ﬁrst-onset psychosis, and the other two
studies provided no information regarding psychiatric his-
tory prior to the onset of their postpartum psychosis. Of the
11 studies that included only patients with ﬁrst-onset post-
partumpsychosis, the longitudinal illness coursewas reported
in seven studies.
In three of these seven longitudinal follow-up studies,
patients with isolated postpartum psychosis were described
(54 deliveries, 54 patients) (3, 31, 32). The remaining four
studies (144 deliveries, 144 patients) reported that a propor-
tion of patients had nonpuerperal episodes during follow-up.
FIGURE 1. Flowchart of the Arti le Selection Process in a Meta-Analysis of Risk of Postpartum Relapse in Bipolar Disorder and
Postpartum Psychosis
Studies included in 
quantitative synthesis 
(meta-analyses) (N=37)
Publications excluded because of 
overlapping cohorts (N=11)
Records excluded (N=1,830)
• Irrelevant subject (N=1,314)
• Language not English (N=248)
• Study design not eligible (N=92) 
• Other (N=176)
Duplicates removed (N=1,361)
Full-text articles excluded (N=259)
• Reviews, overviews, guidelines (N=89)
• Outcome measure not relapse (N=81)
•  Other diagnostic groups, outcome only available for     
whole sample, irrelevant diagnoses included (N=38)
• Letters to the editor or commentaries (N=20)
• Diagnostic criteria insuffi  cient (N=7)
• Case reports (N=12)
• Congress/posters, no author response (N=2)
• Extra chapters of 2 studies published separately (N=9)
• Preliminary reports (only deﬁ nitive study included) (N=1)
Full-text articles 
assessed for eligibility           
(N=307)
Identifi cation
Screening
Eligibility
Included
Studies included in 
qualitative synthesis after 
interrater session (N=48)
Records identiﬁ ed 
through database search    
(N=3,498)
Records screened 
(N=2,137)
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Postpartum relapse rates in patients with bipolar disorder
As shown in Figure 3A, patients with bipolar disorder had an overall relapse risk of 37% (95% 
CI=29, 45) (25 studies, 5,105 deliveries, 3,495 patients). Three large studies and one small 
study made a distinction between patients with bipola  I and II disorders (13, 24-26). Two 
studies included only patients with bipolar I disorder (27, 28) and one study enrolled only 
patients with bipolar II disorder (29). No significant difference in relapse rates was found 
between patients with bipolar I and II disorders (bipolar I dis rd r: N=2,190, 45% [95% 
CI=32, 58]; bipolar II disorder: N=1,249, 50% [95% CI=35, 65]; Q=0.25, df=1, p=0.62).
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FIGURE 2. Postpartum relapse rate per study included in the qualitative and/or quantitative 
synthesis in a meta-analysis of risk of postpartum relapse in bipolar disorder and postpartum 
psychosisa
Therewas no signiﬁcant difference in postpartum relapse rate
between patients with bipolar disorder and patients with a
history of postpartum psychosis (Q=0.71, df=1, p=0.40). Het-
erogeneity was substantial in both diagnostic groups.
Postpartum Relapse Rates in Patients With Bipolar
Disorder and Previous Postpartum Episodes
Nine studies provided information on the prior history of
postpartum episodes (9/25, 36%). Two birth register studies
included only primiparous patients, who by deﬁnition did not
have a history of postpartum episodes (5, 11). Three studies
provided detailed information on patients with bipolar dis-
order and a prior history of postpartum episodes. The relapse
ratewas87%inonestudy(45/52patients) (13)and50%ineach
of the other two studies (2/4 patients [33], 4/8 patients [3]). In
the remaining four studies, 41%273% of patients with bipolar
disorder had a history of postpartum episodes (34–37). Alto-
gether, there is currently insufﬁcient available information
on relapse risk for women with bipolar disorder to permit
stratiﬁcation by their history of previous postpartumepisodes.
FIGURE 2. Postpartum Relapse Rate Per Study Included in the Qualitative and/or Quantitative Synthesis in a Meta-Analysis of Risk of
Postpartum Relapse in Bipolar Disorder and Postpartum Psychosisa
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Postpartum relapse rates in patients with a history of postpartum psychosis or 
mania
Patients with a history of postpartum psychosis had an overall relapse risk of 31% (95% CI=22, 
42) (13 studies, 595 deliveries, 528 patients) (Figure 3A). Eleven of the 13 studies included 
only patients with first-onset psychosis, and the other two studies provided no information 
regarding psychiatric history prior to the onset of their postpartum psychosis. Of the 11 studies 
that included only patients with first-onset postpartum psychosis, the longitudinal illness course 
was reported in seven studies. 
 In three of these seven longitudinal follow-up studies patients with isolated postpartum 
psychosis were described (54 deliveries, 54 patients) (3, 30, 31). The remaining four studies 
(144 deliveries, 144 patients) reported that a proportion of patients had nonpuerperal episodes 
during follow-up. There was no significant difference in postpartum relapse rate between 
patients with bipolar disorder and patients with a history of postpartum psychosis (Q=0.71, 
df=1, p=0.40). Heterogeneity was substantial in both diagnostic groups. 
FIGURE 3. Overall postpartum relapse rate for each diagnostic group in a meta-analysis of risk 
of postpartum relapse in bipolar disorder and postpartum psychosis
In a subanalysis, the risk of a severe postpartum episode
(affective psychosis, mania, mixed episode, or relapse re-
quiring hospitalization) was signiﬁcantly higher in patients
with a history of postpartum psychosis (29%, 95%CI=20, 41)
compared with patients with bipolar disorder (17%, 95%
CI=13, 21; Q=5.77, df=1, p=0.016) (Figure 3B). Two studies
were excluded because of insufﬁcient information regarding
the clinical severity of the postpartum episodes (34, 38).
Prophylactic Pharmacotherapy During the Peripartum
Period in Bipolar Disorder
In the quantitative synthesis, a total of ﬁve studies provided
sufﬁcient information to assess the association between
postpartum relapse and prophylactic pharmacotherapy
during both pregnancy and the postpartum period (3, 36, 37,
39, 40). In addition, three studies provided information on
pharmacotherapy during pregnancy (13, 27, 41), and three
studies described pharmacotherapy during the postpartum
period (34, 35, 42). Overall, patients with bipolar disorder
using prophylactic pharmacotherapy during pregnancy had a
signiﬁcantly lower relapse rate (N=60; 23%, 95% CI=14, 37)
compared with medication-free patients (N=385; 66%, 95%
CI=57, 75; Q=22.92, p,0.001) (Figure 4). Moreover, patients
with bipolar disorder using prophylactic pharmacotherapy
during the postpartum period had a lower relapse rate
(N=98; 29%, 95% CI=16, 47) compared with those who
remained medication free (N=107; 65%, 95% CI=55, 73;
Q=10.91, p=0.001). Of all 98 women reported as having used
medication postpartum, 38 women initiated prophylactic
medication during pregnancy (3, 37). Twenty-two patients
were medication free during pregnancy and initiated pro-
phylaxis immediately postpartum (3, 36, 37) (see Table S1 in
the online data supplement). Information regarding the
timingofmedication initiationwasunavailable for 38women.
Prophylactic Pharmacotherapy During the
Peripartum Period in Patients With a History of
Postpartum Psychosis
Five studies (5/13, 39%) provided information on pharmaco-
therapy during the peripartum period. During pregnancy, all
patients in these ﬁve studies were medication free. Of these
studies, threeprovided informationonprophylacticmedication
use during the postpartumperiod.One study reported a relapse
rate of 30% in 10 medication-free patients (3/10) (43). The
second study reported a relapse rate of 14% in 21 patients with
lithium prophylaxis (3/21) (44). In the third study, none of the
patients using lithium prophylaxis relapsed (0/20), compared
witharelapserateof44%(4/9) formedication-freepatients (3).
Publication Bias
There was no association between year of publication and re-
lapse rates (b=0.02, 95% CI=20.01, 0.05; Q=1.55, p=0.21). The
studiesreporting the lowest (9%)andhighest (75%)relapserates
(12, 13) were both published relatively recently (2007 and 2014,
respectively). A visual inspection of the funnel plot revealed that
theplotwasasymmetric,withaslightly largerproportionof the
medium-sized trials clustering to the left of the mean, but no
indicationofdecreasingevent rateswith increasing samplesize
(seeFigureS1 in theonlinedatasupplement).TheEggertestdid
not suggest the presence of publication bias (intercept=20.57,
95% CI=22.37, 1.24, p=0.53).
Heterogeneity and Sensitivity Analyses
Wecompared both the inclusion criteria (DSM, ICD, or RDC)
and the criteria for relapse (DSM/ICD/RDC, hospitalization,
FIGURE3. OverallPostpartumRel pseRate forEachDiagnosticGroup inaMeta-AnalysisofRiskofPostp rtumRelapse inBipolarDisorder
and Postpartum Psychosis
A. Overall relapsea rate postpartum per diagnostic group
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Bipolar disorderb
History of postpartum psychosisc
Overall
I2 for bipolar disorder=95%, I2 for postpartum psychosis=78%, df=1, Q=0.71, p=0.400
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B. Overall severe relapsed rate postpartum per diagnostic group
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aDeﬁnitions of relapse: psychosis, mania or hypomania, depression (or a mixed episode), and/or psychiatric hospitalization.
b Studies, k=25; deliveries, N=5,105; patients, N=3,495.
c Studies, k=13; deliveries, N=595; patients, N=528.
dDeﬁnitions of severe relapse: psychosis, mania, mixed episode, and/or psychiatric hospitalization.
e Studies, k=24; deliveries, N=5,078; patients, N=3,468.
f Studies, k=12; deliveries, N=531; patients, N=464.
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a Definitions of relapse: psychosis, mania or hypomania, depression (or a mixed episode), and/or psychiatric 
hospitalization.
b Studies, k=25; deliveries, =5,105; patients, N=3,495.
c Studi s, k=13; deliveries, N=595; patients, N=528.
d D finitions of severe relapse: psychosis, mania, mixed episode, and/or psychiatric hospitalization.
e Studies, k=24; deliveries, N=5,078; patients, N=3,468.
f Studies, k=12; deliveries, N=531; patients, N=464.
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Postpartum relapse rates in patients with bipolar disorder and previous 
postpartum episodes
Nine studies provided information on the prior history of postpartum episodes (9/25, 36%). 
Two birth register studies included only primiparous patients, who by definition did not have a 
history of postpartum episodes (5, 11). Three studies provided detailed information on patients 
with bipolar disorder and a prior history of postpartum episodes. The relapse rate was 87% 
in one study (45/52 patients) (13) and 50% in each of the other two studies (2/4 patients, 
(32) 4/8 patients (3)). In the remaining four studies, 41–73% of patients with bipolar disorder 
had a history of postpartum episodes (33-36). Together, there is currently insufficient available 
information on relapse risk for women with bipolar disorder to permit stratification by their 
history of previous postpartum episodes.
 In a subanalysis, the risk of a severe postpartum episode (affective psychosis, mania, mixed 
episode, or relapse requiring hospitalization) was significantly higher in patients with a history 
of postpartum psychosis (29%, 95% CI=20, 41) compared with patients with bipolar disorder 
(17%, 95% CI=13, 21; Q=5.77, df=1, p=0.016) (Figure 3B). Two studies were excluded 
because of insufficient information regarding the clinical severity of the postpartum episodes 
(33, 37).
Prophylactic pharmacotherapy during the peripartum period in bipolar disorder
In the quantitative synthesis, a total of five studies provided sufficient information to assess 
the association between postpartum relapse and prophylactic pharmacotherapy during both 
pregnancy and the postpartum period (3, 35, 36, 38, 39). In addition, three studies provided 
information on pharmacotherapy during pregnancy (13, 26, 40), and three studies described 
pharmacotherapy during the postpartum period (33, 34, 41). Overall, patients with bipolar 
disorder using prophylactic pharmacotherapy during pregnancy had a significantly lower 
relapse rate (N=60; 23%, 95% CI=14, 37) compared with medication-free patients (N=385; 
66%, 95% CI=57, 75; Q=22.92, p<0.001) (Figure 4). Moreover, patients with bipolar 
disorder using prophylactic pharmacotherapy during the postpartum period had a lower 
relapse rate (N=98; 29%, 95% CI=16, 47) compared with those who remained medication 
free (N=107; 65%, 95% CI=55, 73; Q=10.91, p=0.001). Of all 98 women reported as having 
used medication postpartum, 38 women initiated prophylactic medication during pregnancy 
(3, 36). Twenty-two patients were medication free during pregnancy and initiated prophylaxis 
immediately postpartum (3, 35, 36) (see Table S1 in the data supplement). Information 
regarding the timing of medication initiation was unavailable for 38 women.
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Prophylactic pharmacotherapy during the peripartum period in patients with a 
history of postpartum psychosis or mania
Five studies (5/13, 39%) provided information on pharmacotherapy during the peripartum 
period. During pregnancy, all patients in these five studies were medication free. Of these 
studies, three provided information on prophylactic medication use during the postpartum 
period. One study reported a relapse rate of 30% in 10 medication-free patients (3/10) 
(42). The second study reported a relapse rate of 14% in 21 patients with lithium prophylaxis 
(3/21) (43). In the third study, none of the patients using lithium prophylaxis relapsed (0/20), 
compared with a relapse rate of 44% (4/9) for medication-free patients (3).
FIGURE 4. Overall postpartum relapse rates in patients with bipolar disorder stratiﬁed by 
prophylactic pharmacotherapy during pregnancya
clinical interview, or unreported). Studies that included pa-
tients by DSM diagnoses showed higher relapse rates (41%,
95% CI=34, 48) compared with those using ICD diagnoses
(19%, 95% CI=12, 29) or RDC criteria (33%, 95% CI=23, 46)
(Q=11.74, df=2, p=0.003). Studies that deﬁned their relapse
criteria on the basis of DSM, ICD, or RDC criteria showed a
higher overall relapse rate (42%, 95% CI=35, 49) compared
with studies that used distinct criteria (hospitalization: 19%,
95% CI=12, 29; clinical interview: 33%, 95% CI=20, 50;
unreported criteria: 30%, 95% CI=13, 56) (Q=13.07, df=3,
p=0.004). No signiﬁcant difference was found in overall re-
lapse rates, depending on whether or not studies reported
their procedures for handling missing data (respectively, 35%,
95%CI=27, 45, and 34%, 95%CI=25, 44;Q=0.05, df=1, p=0.82).
Birth register studies reported lower relapse rates (15%,
95% CI=8, 27) compared with prospective and retrospective
cohort studies (33%, 95% CI=23, 45 and 41%, 95% CI=34,
49, respectively; Q=12.42, df=1, p=0.002), primarily because
of relatively high relapse rates in the retrospective cohort
studies. Twenty-eight studies reported incidence rates (3,297
patients), and the remaining nine studies reported preva-
lence rates (726patients).Nosigniﬁcantdifferencewas found
between studies that reported incidence rates (32%, 95%
CI=26, 40) and those that reported prevalence rates (43%,
95% CI=28, 60; Q=1.32, df=1, p=0.25).
In 10 studies, there were more deliveries than patients.
Together these studies described the outcome of 3,613 de-
liveries in 1,936 patients. There was no signiﬁcant difference
in relapse rates when comparing these 10 studies (33% 95%
CI=26, 41) with the 27 studies that limited inclusion to one
delivery per patient (35%, 95% CI=25, 47; Q=0.16, df=1, p=0.69).
No signiﬁcant difference was found between the quali-
tative and quantitative synthesis (Q=0.82, df=1, p=0.37). The
duration of postpartum follow-up ranged from 1 month to
12months across studies (see Table S1 in the data supplement).
However, the majority (89%) of studies deﬁned a threshold
between4weeksand6monthspostpartum.Regressionanalysis
revealed no signiﬁcant association between relapse risk and
duration of follow-up (b=0.02, 95% CI=20.06, 0.09; Q=0.23,
p=0.63). Furthermore, nodifferencewas foundbetweenstudies
that used different thresholds for the duration of follow-up
(Q=5.57, p=0.13). Results of the relevant sensitivity analyses are
shown in Figure 5.
DISCUSSION
Our meta-analysis demonstrated that patients with either a
historyof affectivepsychosis in thepostpartumperiodorbipolar
disorder are at high risk for postpartum relapse. We included
37 articles describing the outcome of 5,700 deliveries in 4,023
patientsandfoundanoverall relapseriskof35%(95%CI=29,41).
Postpartum Relapse Rates in Patients With
Bipolar Disorder
In women with bipolar disorder, we found an overall relapse
riskof 37%. In 17%of the cases, patients suffered fromaffective
psychosis, mania, mixed episodes, or relapses requiring hos-
pitalization, deﬁned as severe episodes. Accordingly, the
remainingpatientshadnonpsychotic affectiveepisodes (mostly
depressive and a limited number of hypomanic episodes).
In our subanalysis, we were able to include seven studies,
describing the outcome of 2,190 deliveries to patients with
bipolar Idisorderand1,249deliveries topatientswithbipolar II
disorder. Remarkably, wewere unable to detect a differential
relapse risk between patients with bipolar I and II disorders.
A previous study (24) found a higher relapse risk in patients
with bipolar I disorder compared with patients with bipolar
II disorder in the United Kingdom. However, as acknowl-
edgedby the authors, theyobserved fewhypomanic episodes,
possibly because of inherent difﬁculties in retrospectively
documenting hypomanic episodes and therefore biasing the
results toward a lower observed relapse risk in patients with
bipolar II disorder.
Most studies did not provide information on previous post-
partum episodes. The widespread clinical impression is that
women with bipolar disorder and previous postpartum epi-
sodes might fall within the highest risk category. Unfortu-
nately, we could not estimate the risks for this speciﬁc group.
Moreover, since we were not able to stratify patients with
bipolar disorder by a history of postpartum episodes, it is
unclear whether bipolar disorder and a history of postpartum
relapsecontribute linearlyornonlinearly to the relapse risk for
bipolar patients.
Postpartum Relapse Rates in Patients With a History of
Postpartum Psychosis or Mania
Few studies have focused on patients with a history of psy-
chosis in the postpartum period, likely because of both the
low prevalence and uncertainties regarding its diagnostic
status. We included 13 studies (595 deliveries, 528 patients),
for which the overall relapse risk was 31%. Notably, only
three studies included patients exclusively with isolated
postpartum psychosis (54 deliveries, 54 patients). In the
remaining 10 studies, a proportion of patientsmight have had
bipolar episodes before the onset of postpartum psychosis
(two studies) or after postpartum psychosis (eight studies),
although this information was not reported.
FIGURE 4. Overall Postpartum Relapse Rates in Patients With
Bipolar Diso der Stratiﬁed by Prophylactic Pharmacotherapy
During Pregnancya
Prophylactic pharmacotherapy during pregnancyb
Yes
No
I2 for yes=5%, I2 for no=36%, df=1, Q=22.92, p<0.001
Relapse
rate (%)
 23
 66
Lower
limit
 14
 57
Upper
limit
 37
 75
Total Nc
060
385
0% 50% 100%
aDeﬁnitions of relapse: psychosis, mania or hypomania, depression (or a
mixed episode), and/or psychiatric hospitalization.
bMedications included antipsychotics and mood stabilizers.
c Total N indicates the number of patients included in the analysis.
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a Definitions of rel pse: psychosis, mania or hypomania, depression (or a mixed episode), and/or psychiatric 
hospitalization.
b Medications included antipsychotics and mood stabilizers.
c Total N indicates the number of pati nts included in the analysis.
Publication bias
There was no association between year of publication and relapse rates (β=0.02, 95% 
CI=–0.01, 0.05, Q=1.55, p=0.21). The studies reporting the lowest (9%) and highest (75%) 
relapse rates (12, 13) were both published relatively recently (2007 and 2014, respectively). A 
visual inspection of the funnel plot revealed that the plot wa  asymm tric, ith a slightly larger 
proportion of the medium sized trials clustering to the left of the mean, but no indication of 
decreasing event rates with increasing sample size (see Figure S1 in the data supplement). The 
Egger test did not suggest the presence of publication bias (intercept =–0.57, 95% CI=–2.37, 
1.24, p=0.53). 
Heterogeneity an  sensitivity analyses
We compared both the inclusion criteria (DSM, ICD, or RDC) and the criteria for relapse 
(DSM/ICD/RDC, hospitalization, clinical interview, or unreported). Studies that included 
patients by DSM diagnoses showed higher relapse rates (41%, 95% CI=34, 48) compared 
with those using ICD diagnoses (19%, 95% CI=12, 29) r RDC criteria (33%, 95% CI=23, 
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46) (Q=11.74, df=2, p=0.003). Studies that defined their relapse criteria on the basis 
of DSM, ICD, or RDC criteria showed a higher overall relapse rate (42%, 95% CI=35, 
49) compared with studies that used distinct criteria (hospitalization: 19%, 95% CI=12, 
29; clinical interview: 33%, 95% CI=20, 50; unreported criteria: 30%, 95% CI=13, 56) 
(Q=13.07, df=3, p=0.004). No significant difference was found in overall relapse rates, 
depending on whether or not studies reported their procedures for handling missing data 
(respectively, 35%, 95% CI=27, 45, and 34%, 95% CI=25, 44; Q=0.05, df=1, p=0.82).  
 Birth register studies reported lower relapse rates (15%, 95% CI=8, 27) compared with 
prospective and retrospective cohort studies (33%, 95% CI=23, 45 and 41%, 95% CI=34, 49, 
respectively; Q=12.42, df=1, p=0.002), primarily because of relatively high relapse rates in 
the retrospective cohort studies. Twenty-eight studies reported incidence rates (3,297 patients), 
and the remaining nine studies reported prevalence rates (726 patients). No significant 
difference was found between studies that reported incidence rates (32%, 95% CI=26, 40) 
and those that reported prevalence rates (43%, 95% CI=28, 60; Q=1.32, df=1, p=0.25).  
FIGURE 5. Relevant sensitivity analyses in a meta-analysis of risk of postpartum relapse in 
bipolar disorder and postpartum psychosis
The overall relapse rate of patients with a history of
postpartumpsychosiswasnot signiﬁcantly different from the
relapse risk observed in patients with bipolar disorder, but
patients with a history of postpartum psychosis were more
likely to have severe postpartum relapse episodes compared
with patientswith bipolar disorder.We observed that studies
reported few nonsevere postpartum relapse episodes in
patients with a history of postpartum psychosis, which could
be due to selection and/or information bias. For example,
studies in women with a history of postpartum psychosis
might have been designed with an inclusion bias favoring
patients with severe manic or psychotic relapse but not de-
pression or hypomania. Accordingly, the 31% overall relapse
rate we found could be an underestimation.
Prophylactic Pharmacotherapy Is Highly Effective for
Relapse Prevention
Most studies of prophylactic pharmacotherapy for bipolar
disorder and postpartum psychosis have focused on lithium.
In contrast, data regarding the prophylactic efﬁcacy of
lamotrigine, olanzapine, quetiapine, and risperidone are
scarce (see Table S1 in the data supplement). In womenwith
bipolar disorder, we were able to stratify postpartum relapse
rates by pharmacotherapy during pregnancy in 445 women.
Women without prophylactic pharmacotherapy during
pregnancy had a postpartum relapse rate of 66%, compared
with 23% forwomenwithprophylaxis (Figure4).Medication
prophylaxis during pregnancy in women with bipolar
disorder appears important
not only to maintain mood
stability during pregnancy
(45) but also for postpartum
relapse prevention. However,
the beneﬁts of prophylactic
pharmacotherapy during pre-
gnancy should be weighed
against the potential adverse
effects of in utero medication
exposure.
Available data were insuf-
ﬁcient to allow us to evaluate
the efﬁcacy of pharmacother-
apy when it is initiated im-
mediately after delivery as a
prophylaxisstrategyinwomen
with bipolar disorder. To-
gether, our ﬁndings suggest
a protective effect of lithium
throughout pregnancy and the
postpartum period.
Two studies (60 patients)
described the efﬁcacy of pro-
phylactic pharmacotherapy
in women with a history of
postpartumpsychosis (3, 44).
Both studies reported that
initiation of prophylactic lithium immediately postpartum
after a medication-free pregnancy—and thus eliminating the
risk of in utero medication exposure—is highly effective for
relapse prevention.
Clinical Predictors of Relapse
Another possible predictor of relapse is parity. Previous
studies showed that primiparity is a risk factor for relapse in
the early postpartum period (26, 46). Di Florio et al. (26)
found that this effect was not due to women with a history of
postpartum episodes being less likely to have additional
children. In addition, Munk-Olsen et al. (46) found a higher
risk for aﬁrst-timepsychiatric episode after a seconddelivery
with increasing time between the births of the ﬁrst and
second children. In the present meta-analysis, we were not
able to stratify for parity. Therefore, the interpretation of an
overall relapse risk requires some caution, especially when
comparingpatientswithbipolar disorderwhocouldbe either
primiparous or multiparous with patients with a history of
postpartum psychosis, who are by deﬁnition not primipa-
rous. Notably, as mentioned by Di Florio et al. (26), it is
possible that the association betweenprimiparity andrelapse
is confounded by the higher proportion of multiparous
patients using prophylactic pharmacotherapy.
Several additional predictors for postpartum relapse have
been described previously, including relapse during preg-
nancy (3, 47), psychiatric history (13, 48), family history (49),
and obstetric complications (50, 51). The assessment of the
FIGURE 5. Relevant S nsitivi y A alyses in a Meta-A alysis of Risk of Postpartum Relapse in Bipolar
Disorder and Postpartum Psych is
41
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33
42
19
33
30
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41
37
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24
30
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49
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34
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0,354
0,047
1,260 
0,402
4,038 
1,091
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2,143
Inclusion criteria
DSM
ICD
RDC
(df=2, Q=11.74, p=0.003)
Relapse criteria
DSM/ICD/RDC
Hospitalization
Clinical interview
Unreported criteria
(df=3, Q=13.07, p=0.004)
Study design
Birth register study
Prospective cohort
Retrospective cohort
(df=2, Q=12.42, p=0.002)
Duration of follow-upb
1 month
3 months
6 months
12 months
(df=3, Q=5.57, p=0.134) 0% 50% 100%
Upper
limit
Relapse
rate (%)
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limit Total Na
a Total N indicates the number of deliveries included in the analysis.
bFour studies reported relapse at several time points and were included in two or three categories.
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a Total N indicates the number of deliveries included in the analysis.
b Four studies reported relapse at several time points and were included in two or three categories.
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 In 10 studies, there were more deliveries than patients. Together these studies described 
the outcome of 3,613 deliveries in 1,936 patients. There was no significant difference in 
relapse rates when comparing these 10 studies (33% 95% CI=26, 41) with the 27 studies that 
limited inclusion to one delivery per patient (35%, 95% CI=25, 47; Q=0.16, df=1, p=0.69).  
 No significant difference was found between the qualitative and quantitative synthesis 
(Q=0.82, df=1, p=0.37). The duration of postpartum follow-up ranged from 1 month to 12 
months across studies (see Table S1 in the data supplement). However, the majority (89%) of 
studies defined a threshold between 4 weeks and 6 months postpartum. Regression analysis 
revealed no significant association between relapse risk and duration of follow-up (β=0.02, 
95% CI=-0.06, 0.09; Q=0.23, p=0.63). Furthermore, no difference was found between 
studies that used different thresholds for the duration of follow-up (Q=5.57, p=0.13). Results of 
the relevant sensitivity analyses are shown in Figure 5.
DISCUSSION
Our meta-analysis demonstrated that patients with either a history of affective psychosis in the 
postpartum period or bipolar disorder are at high risk for postpartum relapse. We included 37 
articles describing the outcome of 5,700 deliveries in 4,023 patients, and found an overall 
relapse risk of 35% (95% CI=29,41). 
Postpartum relapse rates in patients with bipolar disorder
In women with bipolar disorder, we found an overall relapse risk of 37%. In 17% of the cases, 
patients suffered from affective psychosis, mania, mixed episodes, or relapses requiring 
hospitalization, defined as severe episodes. Accordingly, the remaining patients had nonpsychotic 
affective episodes (mostly depressive and a limited number of hypomanic episodes).  
 In our subanalysis, we were able to include seven studies, describing the outcome of 2,190 
deliveries to patients with bipolar I disorder and 1,249 deliveries to patients with bipolar II 
disorder. Remarkably, we were unable to detect a differential relapse risk between patients 
with bipolar I and II disorders. A previous study (24) found a higher relapse risk in patients 
with bipolar I disorder compared with patients with bipolar II disorder in the United Kingdom. 
However, as acknowledged by the authors, they observed few hypomanic episodes, possibly 
because of inherent difficulties in retrospectively documenting hypomanic episodes and therefore 
biasing the results toward a lower observed relapse risk in patients with bipolar II disorder. 
 Most studies did not provide information on previous postpartum episodes. The widespread 
clinical impression is that women with bipolar disorder and previous postpartum episodes 
might fall within the highest risk category. Unfortunately, we could not estimate the risks for 
this specific group. Moreover, since we were not able to stratify patients with bipolar disorder 
by a history of postpartum episodes, it is unclear whether bipolar disorder and a history of 
postpartum relapse contribute linearly or nonlinearly to the relapse risk for bipolar patients. 
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Postpartum relapse rates in patients with a history of postpartum psychosis or 
mania
Few studies have focused on patients with a history of psychosis in the postpartum period, 
likely because of both the low prevalence and uncertainties regarding its diagnostic status. We 
included 13 studies (595 deliveries, 528 patients), for which the overall relapse risk was 31%. 
Notably, only three studies included patients exclusively with isolated postpartum psychosis (54 
deliveries, 54 patients). In the remaining 10 studies, a proportion of patients might have had 
bipolar episodes before the onset of postpartum psychosis (two studies) or after postpartum 
psychosis (eight studies), although this information was not reported.
 The overall relapse rate of patients with a history of postpartum psychosis was not 
significantly different from the relapse risk observed in patients with bipolar disorder, but 
patients with a history of postpartum psychosis were more likely to have severe postpartum 
relapse episodes compared with patients with bipolar disorder. We observed that studies 
reported few nonsevere postpartum relapse episodes in patients with a history of postpartum 
psychosis, which could be due to selection and/or information bias. For example, studies in 
women with a history of postpartum psychosis might have been designed with an inclusion 
bias favoring patients with severe manic or psychotic relapse but not depression or hypomania. 
Accordingly, the 31% overall relapse rate we found could be an underestimation.
Prophylactic pharmacotherapy is highly effective for relapse prevention
Most studies of prophylactic pharmacotherapy for bipolar disorder and postpartum 
psychosis have focused on lithium. In contrast, data regarding the prophylactic efficacy of 
lamotrigine, olanzapine, quetiapine, and risperidone are scarce (see Table S1 in the data 
supplement). In women with bipolar disorder, we were able to stratify postpartum relapse 
rates by pharmacotherapy during pregnancy in 445 women. Women without prophylactic 
pharmacotherapy during pregnancy had a postpartum relapse rate of 66%, compared with 
23% for women with prophylaxis (Figure 4). Medication prophylaxis during pregnancy in 
women with bipolar disorder appears important not only to maintain mood stability during 
pregnancy (44), but also for postpartum relapse prevention. However, the benefits of 
prophylactic pharmacotherapy during pregnancy should be weighed against the potential 
adverse effects of in utero medication exposure.
 Available data were insufficient to allow us to evaluate the efficacy of pharmacotherapy 
when it is initiated immediately after delivery as a prophylaxis strategy in women with bipolar 
disorder. Together, our findings suggest a protective effect of lithium throughout pregnancy and 
the postpartum period.
 Two studies (60 patients) described the efficacy of prophylactic pharmacotherapy in 
women with a history of postpartum psychosis (3, 43). Both studies reported that initiation 
of prophylactic lithium immediately postpartum after a medication-free pregnancy—and thus 
eliminating the risk of in utero medication exposure—is highly effective for relapse prevention.
Chapter 2 
34 
Clinical predictors of relapse
Another possible predictor of relapse is parity. Previous studies showed that primiparity is a 
risk factor for relapse in the early postpartum period (45, 46). Di Florio et al. (46) found that 
this effect was not due to women with a history of postpartum episodes being less likely to 
have additional children. In addition, Munk-Olsen et al. (45) found a higher risk for a first-
time psychiatric episode after a second delivery with increasing time between the births of the 
first and second children. In the present meta-analysis, we were not able to stratify for parity. 
Therefore, the interpretation of an overall relapse risk requires some caution, especially when 
comparing patients with bipolar disorder who could be either primiparous or multiparous, with 
patients with a history of postpartum psychosis who are by definition not primiparous. Notably, 
as mentioned by Di Florio et al. (46), it is possible that the association between primiparity 
and relapse is confounded by the higher proportion of multiparous patients using prophylactic 
pharmacotherapy.
 Several additional predictors for postpartum relapse have been described previously, 
including relapse during pregnancy (3, 47), psychiatric history (13, 48), family history (49), 
and obstetric complications (50, 51). The assessment of the weight of each of these factors 
enables clinicians to establish individualized prevention plans for the high-risk postpartum 
period. Unfortunately, these variables have been understudied and therefore could not be 
included in this meta-analysis as effect modifiers or confounders. 
Heterogeneity across studies
There was considerable heterogeneity across studies, both in their design and in their inclusion 
and relapse criteria. In contrast to population-based studies, selection bias may have occurred 
in both prospective and retrospective cohort studies. Our sensitivity analyses demonstrated that 
retrospective studies reported significantly higher relapse rates compared with birth register 
and prospective studies. Notably, an important source of selection bias in retrospective cohort 
studies is nonsystematic sample recruitment. For example, the largest study we examined 
involved the retrospective analysis of a U.K. cohort of patients with bipolar disorder from which 
74% of the patients were recruited via sources such as public media and patient organizations 
(24). As acknowledged by the authors, this may have led to an overestimation of relapse 
risk. In addition, retrospective studies have considerable potential for information bias because 
of long intervals between the relapse episode and data collection. Conversely, prospective 
studies are inherently biased toward underestimation of relapse risk because of selection bias, 
since patients with a poor prognosis are less likely to visit an outpatient clinic during pregnancy 
or to participate in a clinical study.
 Birth register studies are more likely to provide estimates of relapse rates that are free of 
selection and information bias. Moreover, they have superior external validity because they 
are based on nationwide registers. However, a limitation of birth register studies is the precision 
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of the available diagnostic information, in particular, the likely absence of data regarding less 
severe episodes that do not require contact with mental health care specialists, since available 
information is only based on women who actively sought care. Given that relapse was 
defined in all birth register studies using the criteria of an inpatient psychiatric admission, it is 
not surprising that the relapse rates were lower in birth register studies compared with cohort 
studies.
 The majority of patients were included based on DSM or ICD criteria. The substantial 
difference in relapse rates between patients diagnosed using DSM versus ICD criteria is most 
likely the result of underlying study designs, rather than the criteria themselves. Almost all studies 
using ICD criteria were birth register studies (5, 12), while DSM criteria were used in the largest 
cohort studies (24, 25).
 Among the studies included in this meta-analysis, the duration of postpartum follow-up was 
highly variable, ranging from 4 weeks to 1 year, with the majority of studies having a follow-
up interval in the range of 3-6 months. We did not find a statistically significant contribution of 
follow-up duration to relapse rate, which is consistent with the uniquely high relapse risk in the 
early postpartum period. In particular, the highest risk period for patients with bipolar disorder 
and/or a history of postpartum psychosis occurs within the first 3 months postpartum (5, 24).
Research implications
Over the past three decades, postpartum relapse rates in women with a history of bipolar 
disorder or postpartum psychosis have remained consistently high. Ongoing efforts to elucidate 
the risk and protective factors for these severe postpartum episodes hold considerable potential 
for substantially lowering the risk of postpartum relapse. Based on our data, we were not able 
to quantify the risk of relapse for women with both bipolar disorder and a history of postpartum 
episodes. Whether these risk factors combine linearly or interact nonlinearly remains to be 
determined. Future studies should be designed to quantify the relapse risk for potentially distinct 
subgroups of women with a history of isolated postpartum psychosis or mania, bipolar disorder, 
and both bipolar disorder and (severe) postpartum episodes. This classification should be based 
on information on parity and all previous postpartum and nonpostpartum episodes. Notably, 
birth register studies might be of substantial importance in obtaining these outcomes given 
their population-wide and naturalistic implementation without selection or information bias.
 In addition, there is an urgent need for more detailed data on the efficacy of prophylactic 
pharmacotherapy, including type, dosing, timing and duration of medication use. Randomized 
controlled trials are likely to be very difficult to implement. Therefore, large-scale naturalistic 
prospective cohort studies may be the most practical approach to obtaining these data. Ideally, 
both maternal and neonatal outcomes should be included, given that postpartum psychiatric 
episodes are likely to influence the long-term outcome not only of the mother but also of her 
children.
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Clinical implications
In no other situation in psychiatry is it possible to define the moment of illness onset as precisely 
as in postpartum relapse, which offers the unique possibility of an individualized postpartum 
relapse prevention plan drafted in collaboration between women and their health care 
providers. Minimally, relapse prevention planning should include 1) medication prophylaxis 
during pregnancy and after delivery; 2) an obstetric birth plan, including preference regarding 
the mode of delivery; 3) progressive intervention strategies beginning from the earliest possible 
signs of prodromal symptoms for relapse; 4) neonatal medical evaluation for children with 
in utero medication exposure; 5) preference for baby feeding; 6) strategies to assist women 
in obtaining adequate sleep, maintain a stable circadian rhythm, limit their stress, support 
maternal-newborn bonding, and enjoy their newborn experience.
Conclusions
In this meta-analysis, we found an overall postpartum relapse risk of 37% in women with bipolar 
disorder and 31% in women with a history of postpartum psychosis. The distinction between 
women with bipolar disorder and those with a history of postpartum psychosis is of substantial 
clinical relevance, as patients with bipolar disorder were significantly less likely to experience 
severe episodes postpartum (17%) compared with patients with a history of postpartum 
psychosis (29%). Moreover, for women with bipolar disorder, continuation of prophylactic 
medication during pregnancy appears to be critically important for maintaining mood stability 
after delivery. In contrast, for women with a history of isolated postpartum psychosis, the 
initiation of prophylaxis immediately after delivery appears to be highly effective for relapse 
prevention and eliminates the risk of in utero medication exposure. Women have multiple 
contacts with health services during pregnancy, which provide a compelling opportunity for 
prevention of postpartum psychiatric episodes. Postpartum relapse prevention plans should be 
drafted for all women at high risk.
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DATA SUPPLEMENT
Search, selection, and data extraction procedures
A systematic electronic literature search was performed by a medical information specialist 
on August 26th 2013 supplemented with the search updates on January 6th and November 
11th 2014, in all large medical electronic databases: Embase, MEDLINE, Cochrane, Web-
Of-Science, PsycINFO and Google Scholar. The following search terms were used: “risk”, 
“relapse”, “recurrent”, “recur*”, “bipolar disorder”, “bipolar”, “bipolar*”, “manic”, “mania”, 
“pregnancy”, “pregnant”, “puerperium”, “pregnan*” “puerper*”, “puerperal disorder”, 
“post natal”, “postnatal”, “postnatal care”, “perinatal period”, “perinatal care”, “puerperal 
psychosis”, “post partum”, “postpartum”, “psychosis”, “puerperal psychosis”, “psycho*” 
and “English”. Exclusion search terms were: “conference”, “abstract”, “conference paper”, 
“conference review”, “editorial”, “erratum”, “case study”, and “case report”. On January 6th 
and November 11th 2014, search updates were performed to locate publications after the 
initial search. Furthermore, relevant textbooks and bibliographies of reviews and retrieved 
papers were searched to identify any additional papers. 
 All papers were handled and screened for duplicates with the citation manager EndNote 
(1). At first, papers eligible for inclusion were screened in an inter-rater session. Two reviewers 
(RW and AMK) independently screened all titles and abstracts for eligibility, after which full 
text articles were assessed. Mismatches between these reviewers were discussed with an 
independent psychiatrist (VB). Inter-rater agreement was calculated, by which a kappa of 
0.61-0.80 reflected substantial, and a kappa of 0.81-1.00 nearly perfect, agreement (2). 
When data was reported in an inconclusive format, the full text of the paper was screened for 
additional clarification. If necessary, authors were contacted to request additional data. If more 
papers published about the same cohort, the most complete/recent publication was included 
in the quantitative synthesis.
REFERENCES
1.  EndNote X5.0.1 Thomson Reuters 1988-2014.
2.  Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 
2005;37(5):360-3.
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FIGURE S1. Funnel plot of standard error by logit event rate in quantitative synthesis
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ABSTRACT
Background: Postpartum psychosis is a severe psychiatric disease which occurs in the 
early postpartum period after 1 - 2 per 1000 deliveries. Patients with a history of postpartum 
psychosis and/or bipolar disorder are at extreme high risk of relapse postpartum. 
 
Aim: To discuss diagnostic considerations, treatment and the prevention of postpartum 
psychosis, and to give clinical recommendations.  
Methods: Literature search with PubMed and relevant textbooks.
 
Results: Inpatient psychiatric admission enables the clinician to ensure the safety of mother 
and baby, perform physical and neurological examination, and laboratory analysis to exclude 
known organic causes for acute psychosis. Antipsychotic and lithium and ECT are effective 
treatment options. Women with postpartum psychosis compared to those with bipolar disorder 
had a substantial difference in their clinical outcomes and prophylaxis requirements. 
Conclusion: Inpatient screening for somatic (co)morbidity is essential in patients with 
postpartum psychosis. With adequate treatment, almost all patients achieve complete remission 
and the prognosis is optimistic. Initiation of prophylaxis immediately postpartum in women with 
a history of postpartum psychosis with lithium was highly effective for preventing postpartum 
relapse.
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SAMENVATTING
Achtergrond: Postpartumpsychose is een ernstig ziektebeeld dat ontstaat binnen vier weken 
post partum na 1 à 2 op de 1000 bevallingen. Patiënten met in de voorgeschiedenis een 
postpartumpsychose en/of een bipolaire stoornis hebben een sterk verhoogd risico op het 
ontstaan van een postpartumpsychose.
 
Doel: Bespreken van diagnostiek, behandeling en preventie van postpartumpsychose. Per 
onderwerp aanbevelingen doen voor de klinische praktijk.
 
Methode: Literatuuronderzoek met PubMed, relevante boeken en naslagwerken.
 
Resultaten: Bij vermoeden van een postpartumpsychose kan met een psychiatrische opname 
eventueel gevaar voor moeder en kind worden afgewend en is uitgebreide diagnostiek mogelijk 
ter uitsluiting van somatische (co)morbiditeit. Antipsychotica, lithium en elektroconvulsietherapie 
zijn effectieve behandelopties. Het medicamenteuze beleid ter preventie van een recidief van 
postpartumpsychose verschilt bij patiënten met in de voorgeschiedenis een postpartumpsychose 
en patiënten met een bipolaire stoornis. 
 
Conclusie: Een postpartumpsychose vereist een psychiatrische opname waarbij specifieke 
aandacht dient uit te gaan naar de aanwezigheid van somatische (co)morbiditeit. Door adequate 
medicamenteuze behandeling herstellen vrijwel alle patiënten met een postpartumpsychose 
volledig en is de prognose gunstig. Een recidief van een postpartumpsychose is goed te 
voorkomen met lithiumprofylaxe post partum. 
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INLEIDING
De postpartumperiode gaat gepaard met een sterk verhoogd risico op het ontstaan van 
ernstige psychiatrische ziekte. Bij vrouwen met een blanco psychiatrische voorgeschiedenis 
ontstaat na 1 à 2 op de 1000 bevallingen een postpartumpsychose (1). Bij patiënten met een 
bipolaire stoornis of een postpartumpsychose in de voorgeschiedenis loopt dit risico op tot 23-
44% (2, 3). Naast eerder doorgemaakte psychiatrische ziekte in de kraamtijd is primipariteit 
de belangrijkste beschreven risicofactor voor het ontstaan van een postpartumpsychose (1, 4).
 Een postpartumpsychose kan zich snel en onvoorspelbaar ontwikkelen en ontstaat binnen 
vier weken na de bevalling. Echter, meestal manifesteren de symptomen zich al in eerste week 
na de bevalling. Na enkele symptoomvrije dagen ontstaan er bijvoorbeeld slaapstoornissen, 
prikkelbaarheid, ontremming en achterdocht. Vervolgens worden vaak na ongeveer een 
week ernstiger psychiatrische verschijnselen waargenomen, bijvoorbeeld verwardheid, 
hallucinaties, wanen, gestoorde realiteitsbeleving, symptomen van manie of depressie en soms 
ook desoriëntatie en een wisselend bewustzijn (4, 5). 
 Diagnostiek en behandeling vinden om veel redenen bij voorkeur plaats tijdens een 
moeder-kindopname (6), tweede keus is een opname op een psychiatrische afdeling van 
een algemeen ziekenhuis. Op deze manier wordt eventueel gevaar voortkomend uit suïcidale 
gedachten of gedachten gericht op infanticide afgewend en kan adequate somatische en 
psychiatrische diagnostiek plaatsvinden. In sommige gevallen is het aanvragen van een Bopz-
maatregel hiervoor noodzakelijk. Naast farmacologische behandeling, zijn het herstellen 
van de slaaphygiëne, verbeteren van de moeder-kind interactie en het betrekken van het 
steunsysteem belangrijke onderdelen van de behandeling. 
 In dit artikel bespreken wij de diagnostiek, behandeling en preventie van postpartumpsychose 
aan de hand van recente literatuur. Er worden aanbevelingen gedaan voor de klinische 
praktijk.  
METHODE
Met PubMed zochten wij naar relevante artikelen, waarbij de volgende zoektermen werden 
gebruikt: ‘post partum, peripartum, postpartum psychosis, bipolar disorder, diagnosis, 
treatment, prevention’. Daarnaast werd informatie verkregen met relevante handboeken en 
naslagwerken.
RESULTATEN
Diagnostiek
Postpartumpsychose wordt niet als opzichzelfstaande diagnose beschreven in Diagnostic 
and Statistical Manual of Mental Disorders. Het gevolg hiervan is dat er in publicaties vaak 
Ch
ap
te
r 3
Postpartumpsychose in de klinische praktijk
55 
slecht gedefinieerde termen en inconsistente classificaties worden gebruikt. Historisch gezien is 
postpartumpsychose echter wel vaak als aparte entiteit beschreven met termen zoals ‘puerperal 
insanity’ en ‘puerperal psychosis’. Hiermee werd al in de klassieke oudheid verwezen naar het 
plotseling, onverwacht ontstaan van ernstige psychiatrische ziekte in het kraambed (7). 
 Patiënten met een doorgemaakte postpartumpsychose of een bipolaire stoornis 
hebben het hoogste risico op een postpartumpsychose (2, 8). De meeste patiënten die een 
postpartumpsychose doormaken hebben echter een blanco psychiatrische voorgeschiedenis. 
Bij deze groep is de postpartumpsychose soms de eerste manifestatie van een onderliggende 
stoornis in het bipolaire spectrum. Retrospectief onderzoek suggereert dat dit bij 35-65% van die 
vrouwen het geval is (9). Hieruit vloeit voort dat bij een substantieel deel van de patiënten die een 
postpartumpsychose doormaken, uiteindelijk geen bipolaire stoornis wordt gediagnosticeerd. 
De kwetsbaarheid voor ernstige psychiatrische ziekte beperkt zich in dit geval tot de kraamtijd. 
Het verdient daarom onze voorkeur om bij patiënten die een eerste postpartumpsychose hebben 
doorgemaakt nog geen bipolaire stoornis te diagnosticeren. De diagnose “psychose of manie 
(stemmingsstoornis) niet anderszins omschreven (NAO), begin post partum”, is in dit geval een 
betere diagnostische classificatie. Uiteraard dient de diagnose wel te worden aangepast naar 
‘bipolaire stoornis’ wanneer er een ernstige stemmingsepisode buiten het kraambed optreedt. 
 Postpartumpsychose wordt over het algemeen beschouwd als een stemmingsstoornis 
en niet als een primair psychotische stoornis. De term postpartumpsychose kan daardoor 
enige verwarring geven. Stemmingssymptomen (depressie, manie of een combinatie van 
beide) behoren namelijk tot de kernsymptomen van postpartumpsychose. Daarnaast is er 
qua familiaire belasting en het beloop overlap met de bipolaire stoornis (10). 
 Bij vermoeden van een postpartumpsychose dient de huisarts of psychiater uit de eerste lijn de 
patiënt te verwijzen voor een psychiatrische opname (11). Het belangrijkste argument hiervoor 
is dat het gevaar van suïcide en infanticide kan worden afgewend. In het Engelse rapport ‘Why 
mothers die’ is beschreven dat er tussen 2000 en 2002 bij 9 van de 26 suïcides post partum sprake 
was van een psychotische episode. In 5 gevallen was er sprake van een ernstige depressieve 
episode en in 4 gevallen was er in deze groep naast suïcide ook sprake van infanticide (12).
 Behalve om het gevaar af te wenden biedt een opname de beste mogelijkheden voor 
snelle diagnostiek en behandeling, hetgeen van belang is omdat het klinisch beeld van 
uur tot uur en van dag tot dag vaak sterk kan wisselen. Tijdens opname dienen zo snel 
mogelijk algemeen lichamelijk onderzoek en bloedonderzoek te worden uitgevoerd om 
een onderliggende somatische oorzaak uit te sluiten. Differentiaaldiagnostisch moet worden 
gedacht aan infecties, eclampsie, postpartumthyreoïditis (13), paraneoplastische encefalitis 
(14), primaire hypoparathyreoïdie (15), vitamine deficiënties (met name van vitamine B1, B12 en 
foliumzuur), cerebrovasculaire accidenten en een drugsgeïnduceerde psychose (11). Tevens 
zijn er gevalsbeschrijvingen gepubliceerd over het ontstaan van postpartumpsychose door 
ureumcyclusstoornissen (16) en citrullinemie type I (17).  
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 De kraamtijd is een periode waarin auto-immuunschildklierziekten relatief vaak voorkomen 
(postpartumthryreoïditis ook wel auto-immuun- of hashimoto-thryreoïditis genoemd). Bij 
vrouwen met postpartumpsychose is er enige aanwijzing voor een verhoogde prevalentie 
van auto-immuunschildklierziekte vergeleken met een controlegroep kraamvrouwen uit de 
algemene bevolking (13). Het is daarom zinvol om naast de schildklierfunctie (thyroïdstimulerend 
hormoon; TSH) ook thyroïdperoxidase (TPO)-antistoffen te bepalen. Als deze verhoogd zijn 
dient de schildklierfunctie frequent gecontroleerd te worden, zeker als gestart wordt met lithium. 
Het is zinvol de screening 6 maanden post partum te herhalen omdat schildklierproblemen ook 
later nog kunnen optreden. 
 Als er sprake is van cognitieve symptomen, een delierachtig beeld of neurologische 
symptomen dient men bedacht te zijn op de aanwezigheid van een NMDA-encefalitis (NMDA: 
N-methyl-D-asparaginezuur) (18). Screening op NMDA-antistoffen in serum of liquor is dan 
geïndiceerd. Verder dient bij een atypische presentatie en/of afwijkingen bij lichamelijk 
en neurologisch onderzoek laagdrempelig verder onderzoek plaats te vinden middels 
beeldvorming. Een overzicht met aanbevelingen wat betreft de diagnostiek is opgenomen in 
Tabel 1. 
TABEL 1. Diagnostiek van postpartumpsychose
-  Het vermoeden van een postpartumpsychose vormt een opname-indicatie, indien mogelijk een 
moeder-kindopname.
-  Doe navraag naar aanwezigheid van suïcide- of infanticidegedachten.
-  Stel na een eerste postpartumpsychose de diagnose ‘psychose of manie   (stemmingsstoornis) 
NAO, begin post partum’ en nog niet de diagnose ‘bipolaire I-stoornis’.
-  Voer een uitgebreide somatische screening uit, bestaande uit:
1.  Volledig lichamelijk en neurologisch onderzoek.
2. Urineonderzoek (sediment, op indicatie urinescreening op drugs).
3. Aanvullend bloedonderzoek: infectieparameters (leukocytengetal, CRP), elektrolyten 
(inclusief calcium), lever- en nierfunctie, creatinine, ureum,thyroïdstimulerend hormoon (TSH), 
thyroïdperoxidase(TPO-)antistoffen (schildklierparameters 6 maanden post partum herhalen) 
en op indicatie de vitaminestatus (B1, B12 en foliumzuur).
4.  Op indicatie aanvullend onderzoek middels beeldvorming en autoantistofbepalingen in 
serum en/of liquor (waaronder NMDA-autoantistoffen). 
 
Behandeling
Medicatie is de hoeksteen in de behandeling van een postpartumpsychose. Daarnaast zijn 
structuur, slaaphygiëne, optimalisering van de moeder-kindinteractie en aandacht voor de 
partner en de familie van de patiënte van groot belang. 
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Medicatie en ECT 
Weinig is bekend over de medicamenteuze behandeling van postpartumpsychose. Er zijn 
in totaal 11 gevalsbeschrijvingen verschenen en 9 naturalistische studies gedaan waarvan 
er slechts 3 meer dan 10 patiënten includeerden (19). Er bestaan dan ook geen specifieke 
richtlijnen voor de medicamenteuze behandeling van postpartumpsychose. Vanwege de 
relatie tussen postpartumpsychose en bipolaire stoornis, kan de richtlijn voor de behandeling 
van acute manie aangehouden worden in de acute fase van een postpartumpsychose. Bij 
patiënten bij wie reeds een bipolaire stoornis is gediagnosticeerd, is het uiteraard ook van 
belang om informatie in te winnen over de farmacologische respons ten tijde van eerdere 
ziekte-episodes. 
 De meeste patiënten met een postpartumpsychose hebben echter een blanco 
psychiatrische voorgeschiedenis. In het Erasmus MC worden deze patiënten al langere tijd 
succesvol behandeld volgens een vast farmacologisch algoritme. Allereerst wordt gestart 
met benzodiazepinen. Bij een klein deel van de patiënten leidt herstel van het slaap-waak 
ritme alleen al tot herstel. Tijdens de behandeling met alleen benzodiazepinen kan verdere 
diagnostiek plaatsvinden. Wanneer de psychiatrische symptomen na enkele dagen niet 
afnemen wordt gestart met een antipsychoticum. Haloperidol (2-5 mg per dag) is daarbij het 
middel van eerste keus vanwege de beschreven snelle antimanische effecten (20). Daarnaast 
kent haloperidol relatief weinig interacties, is er veel ervaring met de lange termijn effecten 
en is het middel in alle toedieningsvormen beschikbaar. Er is helaas nog geen onderzoek 
gepubliceerd dat specifiek is gericht op het behandeleffect van andere antipsychotica dan 
haloperidol bij patiënten met een eerste postpartumpsychose. 
 Indien behandeling met antipsychotica niet leidt tot sterke klinische verbetering wordt na 
twee weken lithium toegevoegd (bloedspiegel tussen de 0.8 – 1.2 mmol/l). Overigens worden 
benzodiazepinen gedurende de behandeling zo snel als mogelijk geleidelijk afgebouwd. Met 
dit farmacotherapeutisch behandelalgoritme bereikte 98% van de patiënten complete remissie 
(21). Als patiënten niet reageren op medicatie of wanneer er sprake is van ernstige katatonie, 
is electroconvulsietherapie (ECT) aangewezen (22).  
 In de literatuur is er weinig bekend over de medicamenteuze behandeling van 
postpartumpsychose met depressieve kenmerken, ook wel postpartumdepressie met 
psychotische kenmerken genoemd. Een depressie met psychotische kenmerken buiten de 
kraamtijd wordt volgens de richtlijnen depressie behandeld. Uit de klinische praktijk komt 
echter naar voren dat gebruik van antidepressiva bij patiënten in de post partum periode kan 
leiden tot een verslechtering van het psychiatrische beeld (23, 24). Wij raden daarom gebruik 
van antidepressiva af bij patiënten met een postpartumdepressie met psychotische kenmerken. 
We adviseren deze groep patiënten te behandelen met een antipsychoticum en lithium (23). 
Een andere behandeloptie is ECT (22). 
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 Na complete remissie van psychotische en affectieve symptomen wordt de medicatie 
gecontinueerd waarbij remissie is opgetreden: bij patiënten die goed herstelden op een 
antipsychoticum alleen, werd het antipsychoticum als onderhoudsbehandeling gecontinueerd. 
Bij patiënten behandeld met een antipsychoticum en lithium (omdat zij onvoldoende herstelden 
op een antipsychoticum alleen) werd het antipsychoticum middels afbouw gestaakt en lithium 
als onderhoudsbehandeling gegeven. 
 Het is niet bekend hoelang medicatie (antipsychoticum en/of lithium) na de actieve ziekte 
episode dient te worden gecontinueerd. In het Erasmus MC wordt gemiddeld negen maanden 
na de actieve ziekte-episode begonnen met geleidelijke afbouw van psychofarmaca, indien 
patiënte stabiel is en geen bipolaire stoornis gediagnosticeerd is. Uit ons onderzoek komt 
naar voren dat een onderhoudsbehandeling met lithium beter beschermt tegen terugval dan 
een antipsychoticum. We adviseren daarom onderhoudsbehandeling met lithium gedurende 
minimaal een half jaar (21). 
Borstvoeding
Het geven van borstvoeding wordt in het algemeen ontraden bij vrouwen die opgenomen 
zijn met een postpartumpsychose. Door het psychotische beeld zijn zij vaak niet in staat op 
een veilige en adequate wijze hun kind te voeden. Borstvoeding en nachtelijke verzorging 
van de baby verstoren het slaap-waakritme, hetgeen niet bevorderlijk is voor het herstel of de 
toestand zelfs kan doen verslechteren. Daarnaast worden psychofarmaca uitgescheiden in 
de moedermelk (25). Aangeraden wordt geen dopamineagonisten (bromocriptine) voor te 
schrijven om de melkproductie te remmen omdat dit psychotische verschijnselen kan induceren 
(7). Als gevolg van het staken van borstvoeding is het extra van belang te letten op de 
eventuele aanwezigheid van mastitis. Pijnklachten door stuwing kunnen worden behandeld 
met paracetamol tot 4000 mg/dag. 
Aanvullende begeleiding 
Naast medicamenteuze behandeling, dient structuur geboden te worden middels een rust- en 
activiteitenschema. Op moeder-baby units slapen moeders en baby’s gescheiden van elkaar 
en zijn de activiteiten hoofdzakelijk gecentreerd rondom het (zo nodig onder begeleiding) 
verzorgen van de baby en het moederschap. Er dient specifieke aandacht te zijn voor de 
optimalisering van de moeder-kindinteractie (26). Het is belangrijk de partner te betrekken 
bij de opname met ondersteuning, psycho-educatie en in de loop van de opname een of 
meerdere systeemgesprekken. Een overzicht met aanbevelingen wat betreft de behandeling is 
opgenomen in Tabel 2. 
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TABEL 2. Behandeling postpartumpsychose 
1.  Overweeg enkele dagen monotherapie met benzodiazepinen. Op deze  manier kan het effect 
van slaaphygiëne worden geëvalueerd en kan diagnostiek plaatsvinden.
2.  Start bij geen/onvoldoende afname van psychiatrische symptomen meteen antipsychoticum 
(haloperidol 2-5 mg of een atypisch antipsychoticum).
3.  Voeg lithium toe, streefspiegel 0,8-1,2 mmol/l bij persisterende symptomen, maar ook als 
terugvalpreventie.
4. Overweeg bij onvoldoende respons op medicamenteuze behandeling elektro-convulsietherapie 
(ECT). Overweeg bij ernstige katatonie om ECT  als eerste behandeling in te zetten.
- Het voorschrijven van antidepressiva wordt sterk afgeraden, ook als depressieve symptomen 
op de voorgrond staan (psychotische depressie).
-  Ondersteuning middels dagstructuur en slaaphygiëne zijn van groot belang.
-  Tijdens de opname heeft het de voorkeur borstvoeding te staken in verband met het herstel 
van slaap-waakritme en de uitscheiding van psychofarmaca in de moedermelk.
-  Let op de eventuele aanwezigheid van mastitis.
-  Start niet met lactatieremmers.
-  Besteed voldoende aandacht aan optimalisering van de moeder-kindinteractie.
-  Ongeveer negen maanden na de actieve ziekte-episode kan ervoor worden gekozen 
medicatie voorzichtig af te bouwen als patiënte stabiel is en er geen bipolaire stoornis is 
gediagnosticeerd.
 
Preventie
Sinds halverwege de vorige eeuw worden al (voornamelijk observationele) studies gepubliceerd 
die het hoge risico (25-50%) op een recidief van een postpartumpsychose beschrijven na een 
volgende bevalling (27, 28). Daarnaast zijn studies met grote patiëntenaantallen gepubliceerd 
die een hoog risico op een nieuwe ziekte episode post partum beschrijven bij patiënten met 
een bipolaire stoornis. Ongeveer 1 op de 4 vrouwen met een bipolaire stoornis die voor het 
eerst zwanger worden, maakt een ernstige episode post partum door (3, 8).
 Bij patiënten met een eerdere postpartumpsychose en bij bipolaire patiënten is slaapgebrek 
mogelijk een belangrijke risicofactor voor terugval post partum (29). 
 Tot op heden is er weinig onderzoek verricht naar de effectiviteit van profylactische 
behandeling. Retrospectief onderzoek in kleine patiëntengroepen is gedaan met lithium, 
valproïnezuur en olanzapine. Lithiumprofylaxe resulteerde in lagere recidiefpercentages, 
valproïnezuur was niet effectief en er is meer onderzoek nodig naar profylaxe met olanzapine 
om hierover conclusies te kunnen trekken (19). 
 In het Erasmus MC werden 70 vrouwen met een hoog risico op postpartumpsychose 
behandeld in een programma ter preventie van een recidief postpartumpsychose (2). Daarmee 
bleven 29 vrouwen die een postpartumpsychose hadden doorgemaakt (maar nooit een 
manie of psychose buiten de kraamtijd) stabiel tijdens hun zwangerschap, zonder medicatie. 
Vrouwen die meteen na de bevalling startten met lithium of antipsychotica kregen geen van 
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allen een recidief van postpartumpsychose. Bij 44% van de vrouwen die geen preventieve 
medicatie gebruikten, was wel sprake van psychiatrische terugval. De profylactische medicatie 
werd tot drie maanden post partum gecontinueerd. Vrouwen met een postpartumpsychose 
in de voorgeschiedenis (en geen psychose of manie op andere tijden) kunnen dus het beste 
onmiddellijk na de bevalling starten met profylactische behandeling (eerste keus is lithium) om 
terugval te voorkomen. Blootstelling van de foetus aan psychofarmaca kan bij deze patiënten 
dus worden voorkomen.  
 Vrouwen met een bipolaire stoornis bleken helaas soms wel instabiel tijdens de 
zwangerschap, voornamelijk de vrouwen die geen medicatie gebruikten. Na de bevalling 
kregen juist de vrouwen met een bipolaire stoornis die instabiel waren tijdens de zwangerschap 
vaker een postpartumpsychose. Onze bevindingen komen overeen met eerder onderzoek 
waaruit blijkt dat staken van lithium tijdens de zwangerschap gepaard gaat met een verhoogd 
risico op terugval (30). Tevens blijkt dat terugval tijdens de zwangerschap een belangrijke 
risicofactor is voor het ontstaan van een ziekte-episode post partum (31). 
 Samenvattend heeft het bij patiënten met een bipolaire stoornis de voorkeur om 
profylactische medicatie tijdens de zwangerschap te continueren, om de moeder stabiel 
te houden. Echter, het gebruik van psychofarmaca (en de keuze welke) dient te worden 
afgewogen tegen de risico’s voor het ongeboren kind. 
 Wat betreft de stemmingsstabilisatoren is lithium vanwege de laagste kans op teratogeniteit 
eerste keus (32). We adviseren valproïnezuur te staken vanwege het hoge risico op 
neuralebuisdefecten (33). Het kan overwogen worden lamotrigine te continueren als patiënten 
stabiel zijn bij gebruik van deze medicatie. Wat betreft antipsychotica is haloperidol het middel 
van eerste keus. Tot slot kan in het algemeen worden gesteld: vermijd polyfarmacie en zoek 
naar de laagst effectieve dosering. 
 Het gebruik van psychofarmaca tijdens de zwangerschap gaat gepaard met een 
hoog risico (20-30%) op ontwenningsverschijnselen bij de pasgeborene. Om deze reden 
wordt klinische observatie van de pasgeborene gedurende de eerste 48 uur post partum 
geadviseerd (34). Er is geen evidentie voor de meerwaarde van profylactische behandeling 
tijdens de zwangerschap bij medicatievrije patiënten met een bipolaire stoornis die al langere 
tijd psychiatrisch stabiel zijn. Bij deze patiënten is er zeker een duidelijke indicatie om direct 
post partum te starten met lithiumprofylaxe. In de klinische praktijk adviseren we vaak om in de 
loop van het derde trimester te starten ter voorkoming van terugval door stress en slaapgebrek 
rondom de bevalling en zodat patiënten post partum sneller een adequate bloedspiegel 
bereiken. Een overzicht met aanbevelingen wat betreft de preventie is opgenomen in Tabel 3. 
 De met de patiënt gemaakte afspraken kunnen op een gestructureerde manier worden 
vastgelegd in een behandelplan ter preventie van postpartumpsychose (zie een voorbeeld in 
Tabel 4). Op deze manier is relevante informatie voor alle betrokkenen duidelijk en makkelijk 
toegankelijk.
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TABEL 3. Preventie van postpartumpsychose
Patiënten met in de voorgeschiedenis een postpartumpsychose:
-  Vrouwen met een postpartumpsychose in de voorgeschiedenis (en geen psychose of manie 
op andere tijden) kunnen het beste onmiddellijk na de bevalling starten met profylactische 
behandeling om terugval te voorkomen. 
-  De meeste evidentie is er voor het starten met lithium. Bepaal de bloedspiegel op dag 2, 5 en 
12 post partum en houd een streefspiegel aan van 0,8-1,2 mmol/l. Bepaal op dag 12 tevens 
thyroïdstimulerend hormoon (TSH) en TPO-antistoffen.
-  Er is ook enige evidentie dat het profylactisch gebruik van een antipsychoticum effectief is.
-  Continueer profylactische medicatie in ieder geval tot drie maanden post partum.
Patiënten met een bipolaire stoornis:
-  Continueer medicatie tijdens zwangerschap en in de post partum periode om het risico op 
terugval zo laag mogelijk te houden. Echter, weeg het gebruik van deze medicatie (en de keuze 
welke) af tegen de risico’s voor het ongeboren kind.
-  Vermijd polyfarmacie en zoek de laagst mogelijke effectieve dosering.
-  Staak valproïnezuur of switch naar lithium in verband met het hoge risico op teratogeniteit. 
-  Wanneer patiënten met een bipolaire stoornis stabiel zijn zonder medicatie voor de zwangerschap, 
is er geen duidelijke indicatie om in het begin van de zwangerschap zonder psychiatrische 
klachten alsnog met medicatie te starten. Start bij deze groep in het laatste trimester of direct post 
partum met profylaxe.
-  De meeste evidentie is er voor het starten met lithium. We adviseren de spiegel te bepalen op dag 
2, 5 en 12 post partum en houd een streefspiegel aan van 0,8-1,2 mmol/l. Bepaal op dag 12 
tevens TSH en TPO antistoffen. 
 
CONCLUSIE
Postpartumpsychose is een ernstig ziektebeeld waarbij er een risico bestaat op suïcide of 
infanticide. Een psychiatrische opname is daarom geïndiceerd, bij voorkeur op een moeder-
babyafdeling. Bij de diagnostiek is het van belang onderscheid te maken tussen patiënten met 
alleen een postpartumpsychose en patiënten met een bipolaire stoornis. Bij een substantieel 
deel van de patiënten met een voorgeschiedenis met alleen een post partum psychose blijft 
de kwetsbaarheid voor een (manisch) psychotische ontregeling beperkt tot de post partum 
periode. Daarmee is hun prognose gunstiger dan die van patiënten met een bipolaire 
stoornis. Daarnaast is het van belang somatische oorzaken van psychose of manie uit te 
sluiten en bedacht te zijn op de aanwezigheid van somatische comorbiditeit. Medicatie is 
het belangrijkste onderdeel van de behandeling. Benzodiazepinen, antipsychotica en lithium 
hebben een plek bij de acute behandeling. Er zijn aanwijzingen dat lithium, in tegenstelling 
tot een antipsychoticum, effectief is als onderhoudsbehandeling de eerste 9 maanden post 
partum. Patiënten met in de voorgeschiedenis een postpartumpsychose en/of een bipolaire 
stoornis hebben een hoog risico op psychiatrische terugval postpartum na een volgende 
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zwangerschap. Bij een volgende zwangerschap biedt het starten van profylaxe direct na 
de bevalling voldoende bescherming tegen psychiatrische terugval bij patiënten met een 
postpartumpsychose in de voorgeschiedenis. Blootstelling van de foetus aan psychofarmaca 
kan bij deze patiënten worden voorkómen. Patiënten met een bipolaire stoornis staken bij 
voorkeur niet de onderhoudsbehandeling tijdens de zwangerschap. Met goede psychiatrische 
zorg herstellen patiënten met een postpartumpsychose over het algemeen snel en is de 
prognose gunstig. 
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TABEL 4. Voorbeeld van een behandelplan ter preventie van een postpartum psychose 
Naam: 
Gravida; Para; 
Aterme datum: 
Psychiatrische diagnose: 
Psychiatrische voorgeschiedenis: 
Vermeld ook of patiënte klachten had tijdens eerdere zwangerschap of na een eerdere partus. 
Somatische diagnose: 
Obstetrische voorgeschiedenis: 
Vermeld eventuele bijzonderheden tijdens eerdere bevallingen. 
Huidige zwangerschap: 
Medische complicaties en of patiënte stabiel is tijdens deze zwangerschap. 
Medicatie tijdens de zwangerschap: 
Huidige medicatie inclusief startdatum, spiegels en mogelijke gevolgen ongeboren kind. 
Bevalling: 
Vermeld of er een inleiding of sectio is gepland, gemaakte afspraken met betrekking tot pijnstilling en 
waar de bevalling gaat plaatsvinden. Vermeld ook de naam van de gynaecoloog.
Borstvoeding:
Patiënte geeft wel/geen borstvoeding. Lactatieremmers zijn gecontra-indiceerd.  
Verpleegkundige/ partner neemt de nachtvoeding over. 
Medicatie na de bevalling: 
De eerste avond na de bevalling wordt om …. lithium / antipsychotica / andere medicatie verhoogd/
gestart in een dosering van …
In het geval van lithium: 
de spiegel wordt bepaald op dag 2, 5 en 12 post partum. De streefspiegel is tussen 0,8-1,0 mmol/l. 
Op dag 12 tevens thyroïdstimulerend hormoon (TSH) en vrij thyroxine (fT4) en TPO-antistoffen 
bepalen. Slaapmedicatie (middel en dosering) wordt standaard/ op indicatie aangeboden voor de 
nacht en evt. verhoogd bij slaapproblemen. Indien medicatie gebruikt werd tijdens de zwangerschap: 
De baby zal direct na de bevalling door de kinderarts worden onderzocht i.v.m. psychofarmacagebruik 
en gedurende …uur geobserveerd worden op ontwenningsverschijnselen. (Bij lithium: 
in navelstrengbloed zal de lithiumspiegel, TSH, fT4 en thyroïdstimulerend immunoglobuline (TSI) 
bepaald worden). 
Signaleringsplan: 
Nazorg: 
Hoe lang medicatie te continueren?
Psychiater Mw……… (naam patiënte, en handtekening)
Kopie: 
- Huisarts Behandelend gynaecoloog
- Patiënte zelf Behandelaren in de ggz
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ABSTRACT 
Objectives: Postpartum psychosis (PP) is known for its clear onset but its phenotype has never 
been clearly described in a cohort. The aim of this study was to describe PP symptomatology, 
and to identify subgroups of patients based on symptom profiles.
 
Methods: We prospectively assessed a wide range of symptoms in cases of PP in a cohort of 
women (N=130) admitted to the Mother-Baby inpatient unit. Using a person-centered analytic 
approach, we distinguished mutually exclusive subgroups of women. Subgroups were related 
to demographic and clinical characteristics.
Results: The most prevalent symptoms of PP were irritability (73%), abnormal thought content 
(72%), and anxiety (71%). Suicidal and infanticidal ideation was present in 19% and 8% of 
patients, respectively. Delusions and hallucinations often had a negative content. Latent class 
analysis revealed three symptom profiles, a manic (34%), depressive (41%) or atypical (25%) 
profile, respectively. The manic profile is characterized by manic symptoms and agitation, the 
depressive profile by depressive and anxiety symptoms and the atypical profile by disturbance 
of consciousness and disorientation. In women with a depressive profile, treatment was started 
2 weeks later (p=0.049) and more often voluntarily, than in manic and atypical women 
(p=0.037).
Conclusions: We distinguished subgroups of PP patients with a manic, depressive, and atypical 
profile. Disturbance of consciousness, disorientation, and depersonalization/derealisation 
were less prevalent than previously suggested in the literature. Instead, the depressive profile 
was the most prevalent, but the depressive profile can easily remain undetected, which could 
lead to treatment delay and risk of suicide/infanticide. Within the manic profile, irritability was 
highly prevalent and occurred more often than elevated mood.
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INTRODUCTION
Since antiquity, young women have been described with a first onset acute severe psychiatric 
illness after childbirth. Over time, several names have been given to this postpartum disease 
such as “mania lactea”, “amentia”, “puerperal insanity”, “puerperal psychosis”, “puerperal 
mania”, “dreamlike delirium” and finally “postpartum psychosis” (PP). Since the 19th century 
PP has been widely appreciated as a severe disease, requiring acute intervention. Moreover, 
epidemiologic studies consistently report a greatly increased risk in psychiatric inpatient 
admissions within 6 weeks after childbirth compared to any other period in a woman’s life (1, 2). 
Many of these first onset severe postpartum episodes are, in retrospect, the initial presentation of 
bipolar disorder. Therefore, there is general consensus that PP falls within the bipolar spectrum. 
Importantly however, not all postpartum episodes serve as starting point for bipolar disorder; 
some women have isolated PP with severe episodes only after childbirth. For this reason, in 
2016, the international classification of rare diseases “orphanet” has recognized PP as a 
distinct and rare disease within the bipolar spectrum with an incidence of 0.5/1000 (3).   
 Several authors have described the atypical phenotypic characteristics of PP, e.g. delirium 
like symptoms, misrecognition of people, depersonalization, non-auditory hallucinations and 
bizarre delusions (4-7). These enigmatic symptoms have captivated the minds of clinicians 
and researchers but the occurrence of these symptoms has never been quantified. In an effort 
to further define the phenotype of this disorder, we provide detailed phenotypic information 
on symptomatology in 130 women consecutively admitted with PP. In addition, our study was 
designed to determine homogeneous subgroups of patients based on coherent symptom 
patterns.
METHOD
Participants
The study was approved by the Medical Ethical Committee of the Erasmus Medical Center, 
Rotterdam. Participants in this study were recruited from the Onderzoeksprogramma 
Postpartum Psychose Erasmus MC Rotterdam (OPPER-cohort), as described previously (8). The 
study was conducted and results are reported according to the STrengthening the Reporting 
of OBservational Studies in Epidemiology (STROBE) guidelines (9). Briefly, OPPER is a 
prospective study of women with an onset of psychotic and/or manic symptoms within 6 weeks 
postpartum, who did not experience manic or psychotic symptoms during pregnancy. Between 
August 2005 and January 2015, all women admitted to the Mother-Baby inpatient unit of 
the Department of Psychiatry of the Erasmus Medical Center were screened for inclusion. The 
Mother-Baby unit treats female patients with severe psychopathology in the postpartum period 
(0−6 months after parturition). A total of 285 women were screened, of whom 130 (46%) met 
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the inclusion criteria, and were subsequently included in the OPPER-cohort. All participants 
provided written informed consent after receiving a complete description of the study.
Assessment of psychiatric symptoms
Psychiatric symptoms were assessed by highly trained mental health professionals through 
standardized questionnaires and clinical diagnostic interview, all of which have been 
previously used within perinatal populations and in studies of PP. A total of 58 symptoms were 
assessed through questionnaires, diagnostic interview and review of medical records (see 
Supplementary Table 1 for a detailed description of symptoms and assessment).
Diagnostic interview and questionnaires
The Structured Interview for DSM-IV Axis I Disorders (SCID) was administered during admission. 
The Young Mania Rating Scale (YMRS), Edinburgh Postpartum Depression Scale (EPDS), and 
Hamilton Rating Scale for Depression (HAM-D) were administered weekly. For the purpose of 
these analyses, symptoms assessed using the YMRS, EPDS and HAM-D were scored as being 
present at their most severe occurrence. 
 Manic symptoms were assessed using the YMRS. With regards to depressive 
symptomatology, most symptoms were elicited from the EPDS, since the EPDS is developed 
for women in the postpartum period specifically (10). Remaining depressive symptoms were 
assessed using selected items from the HAM-D (early morning awakening, loss of libido, loss 
of appetite, psychomotor agitation and retardation) and SCID (diurnal worsening of mood).
 The presence of psychotic and catatonic symptoms were elicited from the SCID. Finally, 
medical records were reviewed for seven additional symptoms previously described in the 
PP literature, which were not included in the YMRS, EPDS, HAM-D or SCID: disturbance of 
consciousness/perplexity, inattention, disorientation, depersonalization/derealisation, 
delusions related to pregnancy and childbirth, obsessive thoughts related to the child, and 
thoughts of infanticide.
 The presence of symptoms was independently rated by two experienced psychiatry 
residents (MV and RW). Mean interrater reliability was substantial (κ=.69±0.39) (11). Kappas 
ranged from 0.39 to 1.00 for individual symptoms with the exception of ‘obsessive thoughts 
concerning the child’ for which the kappa was poor (κ= -0.05±0.05) due to the low prevalence 
of the symptom.
Statistical analysis
The data were analyzed using latent class analysis (LCA), a subtype of finite mixture modeling 
that is person-centered (as opposed to variable-centered) and is used to discover or confirm 
homogenous subtypes (or classes) of people from a multivariate dataset (for a non-technical 
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overview see Charak et al. (12), and seminal references (13-15)). Whereas more traditional 
types of cluster analysis, such as discriminant analysis, describe the relationship among 
observed variables, LCA models also include unobserved variables. Persons are assigned to 
a certain class according to membership probabilities which are estimated directly from the 
model. LCA is powerful technique; it can handle (any combination of) continuous, categorical, 
or count data, and can handle a violation of the assumptions of homogeneity, linearity and 
normality of the data. In clinical samples, non-conformity of the data is often reality. As such, 
LCA is less vulnerable to bias (15). These techniques are increasingly being used in psychiatric 
phenomenology (16, 17) as they aim to increase homogeneity within a class and maximize 
heterogeneity between classes of individuals who have similar patterns of symptoms. The model 
fit and final class resolution should be distinct and conceptually and clinically meaningful (12-
14). The term LCA is typically used when the variables studied are categorical and latent profile 
analysis (LPA) is used when the variables studied are continuous, which was the case in this 
study. 
 First, symptoms were grouped into clusters based on clinical domains and a confirmatory 
factor analysis (CFA) was used to evaluate the factor structure thus formed; goodness of fit 
was assessed using the Comparative Fit Index (CFI), Tucker-Lewis Index (TLI) (values >0.90 
indicate good fit), root mean square error of approximation (RMSEA)(values <0.08 indicate 
acceptable fit) and weighted root mean square residuals (WRMR) (<1.0 indicates good fit) 
(18). Details of the CFA modelling procedure and fit are reported in Supplement 2.
 Next, we calculated aggregated factor scores, i.e. the proportion of symptoms present for 
each factor, and used these as input for the LPA using robust maximum likelihood estimation 
(MLR). Goodness of fit was assessed using Akaike’s and (adjusted) Bayesian Information criteria 
(AIC and (adjusted) BIC, respectively). Lower values indicate a better fit. The distinctiveness of 
the profiles is evaluated using entropy, where a higher proportion indicates a clearer distinction 
between profiles (>80% desirable), log likelihood, Vuong−Lo−Mendell−Rubin likelihood ratio 
(VLMR) test, and bootstrap likelihood ratio (BLR) test. The VLMR and BLR tests examine whether 
a model with k profiles fits significantly better than a model with k−1 profiles (12-14). The best 
fitting CFA and LCA models were chosen based on goodness-of-fit measures, in combination 
with clinical experience, and interpretability of the derived factors and classes. Finally, potential 
associations between obtained profiles and variables were formally tested using chi-square for 
categorical variables, ANOVA for continuous variables, and the Kaplan−Meier test for time-
dependent variables.
 In total 3.7% of data were missing with 39 cases having missing data. For our statistical 
analyses, missing values were substituted by their series median after assessing for randomness. 
This was done by creating a missing-indicator variable and relating it to the other values in our 
dataset.
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RESULTS
Demographics
The sample comprised 130 women, admitted with PP between August 2005 and January 2015. 
The mean age of these women was 31.4 years (SD= 4.8). The majority were of Dutch descent 
(N=116; 89%) and had a college education (N=105; 81%). 76% of the women (N=99) were 
primiparous. Thirty women (n=30) had experienced mania or psychosis outside the perinatal 
period. Of these women, 22 had a history of affective psychosis and eight women a history 
of brief non-affective psychosis. One of these women had also experienced a postpartum 
episode following a previous delivery. Most women (n=100) had not experienced mania or 
psychosis outside the postpartum period (isolated PP). Of these 100 women, 25 women were 
multiparous of whom 15 women had had a previous severe postpartum episode. Median 
admission duration was 56 days (95% CI 50-62 days). In total 63 women (48%) were 
admitted involuntary (civil detention). The most prevalent legal grounds for civil detention were 
related to the safety of the newborn, i.e. the risk of neglecting the baby (45/63, 71%) and the 
risk of causing the baby serious harm or committing infanticide (31/63, 49%). In 30 women 
(30/63, 48%), self-neglect was cited as a legal ground; suicide risk or risk of causing serious 
self-harm was mentioned in 28 (28/63, 44%) detained women. One woman had attempted 
suicide prior to admission.
Prevalence of symptoms
In Figure 1 we present the prevalence of the assessed psychiatric symptoms. Each symptom 
was either present or absent during admission. 
 Depressive and anxiety symptoms were present in the majority of patients. Suicidal thoughts 
were present in approximately one out of five patients. Classical melancholic symptoms were 
not highly prevalent. 
 Within the manic spectrum, irritability was highly prevalent (73%) and occurred more often 
than elevated mood (39%). Decreased need for sleep and increased rate of speech were 
present in half of the patients.
 Disorganized behavior occurred in one out of four patients. Disorientation was present in 
20% of women, and disturbance of consciousness in 10%. Catatonic symptoms were observed 
in 5% of women (five women with mutism, and one with excessive motor activity, other catatonic 
symptoms were not observed). In total 72% of women had abnormal thought content. Most 
prevalent were persecutory delusions, and delusions of reference. In total 49 women (39%) 
reported auditory hallucinations, of whom 12 women (9%) heard commentary voices and 
eight women (6%) voices conversing with each other. Visual hallucinations were present in one 
out of three patients. 
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 Pregnancy- and childbirth-related delusions were present in a quarter of the women. In 
particular, twelve women thought that their child was dead or would die, six women were 
convinced that the child was not theirs and five women believed that they were pregnant. 
Grandiose or spiritual delusions related to the child were rare: only one woman thought that 
her child had a special talent and two women were convinced that a deceased relative was 
reincarnated in the child. Obsessive thoughts concerning the child (mostly anxiety of harming 
the child) were present in 12 women (9%). Infanticide thoughts (for example, dropping the 
baby when holding it or choking the child) were reported by ten women (8%). Four of them 
also had suicidal thoughts.
FIGURE 1. Prevalence of psychiatric symptoms in women (n=130) with postpartum 
psychosis during admission presented per symptom factor4  |     KAMPERMAN Et Al.
and BLR test suggested that three profiles fit the data better than 
two profiles. Four profiles resulted in an overall worsening of the fit 
measures. Based on goodness- of- fit indices and clinical meaningful-
ness, we concluded that our best model contained three distinct latent 
profiles	(log	likelihood=135;	AIC=−176;	BIC=−41;	adjusted	BIC=−189;	
entropy=86%). We labeled these profiles the manic, depressive and 
atypical symptom profiles (see Figure 2).
Profile	1:	the	manic	profile.	A	total	of	34%	(n=44)	of	the	women	
had this profile. The manic profile is characterized by a high prevalence 
of manic symptoms combined with symptoms of agitation (propor-
tions were .57 and .59, respectively), and a relatively low prevalence 
of anxiety and depression (proportions were .38 and .16, respectively).
Profile	 2:	 the	 depressive	 profile.	 A	 total	 of	 41%	 (n=54)	 of	 the	
women had this profile. The depressive profile is characterized by a 
high prevalence of depressive and anxiety symptomatology (propor-
tions were .66, and .80, respectively), and a relatively low prevalence 
F IGURE  1 Prevalence of psychiatric symptoms in women (n=130) with postpartum psychosis during admission presented per symptom 
factor. Eleven symptom factors are: anxiety, depression, melancholia, agitation, mania, atypical, catatonia, disorganization, delusions, 
hallucinations, and child-related symptoms. Symptoms with a zero prevalence (i.e. thought withdrawal, erotomanic delusion, stupor, peculiarities 
of movement, and echolalia/echopraxia) are not included in the figure. Other delusions, auditory hallucinations and other hallucinations 
represent symptom categories (see Supporting Information Table S1). *indicates symptoms that are not included in subsequent latent class 
analysis (see Supporting Information Table S2)
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TABLE  1 Latent profile analysis procedure and model fit
Number of latent profiles 
included in the model 2 3 4 5
Log likelihood 96 135 152 150
AIC −122 −176 −187 −158
BIC −22 −41 −17 45
Adjusted	BIC −132 −189 −204 −179
Entropy 98% 86% 85% 84%
VLMR testa P=.284 P=.062 P=.446 P=.768
BLR testa P<.001 P<.001 P=.013 P>.999
aA	significant	result	indicates	that	a	model	with	k profiles fits better than a 
model with k	−	1	profiles.
AIC,	 Akaike’s	 information	 criterion;	 BIC,	 Bayesian	 information	 criterion;	
BLR,	 bootstrap	 likelihood	 ratio;	 VLMR,	Vuong−Lo−Mendell−Rubin	 likeli-
hood ratio.
Eleven symptom fa t rs are: anxiety, depression, melancholia, agitation, mania, atypical, catatonia, isorganization, 
delusions, hallucinations, and child-related symptoms. Symptoms with a zero prevalence (i.e. thought withdrawal, 
erotomanic delusion, stupor, peculiarities of movement, and echolalia/echopraxia) are not included in the figure. 
Other delusions, auditory hallucinations and other hallucinations represent symptom categories (see supporting 
i formation Supplementary Table 1). *indicates symptoms that are not included in subsequent latent class analysis 
(see supporting information Supplementary Table 2).
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 Symptoms are presented in accordance to the factor structure resulting from the CFA 
modeling procedure. A series of alternative models have been tested. The best fit in 
both clinical and statistical terms was found for a model consisting of 11 symptom factors: 
anxiety, depression, melancholia, agitation, mania, atypical (disturbance of consciousness 
and disorientation), disorganization, catatonia, delusions, hallucinations, and child-related 
symptoms. The model showed an acceptable fit with the data (χ2=970; df=764; p<0.001; 
CFI=.84; TLI=.81; RMSEA =0.046 (95%CI: 0.036-0.054); WRMR=1.21). See Supplement 2 
for details on CFA modelling procedure and fit.
Symptom profiles
Table 1 presents the results of the LCA. Although AIC, BIC, and adjusted BIC values indicated 
better fit of two profiles, the VLMR- test and BLR test suggested that three profiles fit the data 
better than two profiles. Four profiles resulted in an overall worsening of the fit measures. Based 
on goodness-of-fit indices and clinical meaningfulness we concluded that our best model 
contained three distinct latent profiles (log likelihood= 135; AIC= −176; BIC =−41; adjusted 
BIC = −189; entropy=86%). We labeled these profiles the manic, depressive and atypical 
symptom profiles (see figure 2). 
TABLE 1. Latent profile analysis procedure and model fit 
Number of latent profiles included in the model 2 3 4 5
Loglikelihood 96 135 152 150
AIC -122 -176 -187 -158
BIC -22 -41 -17 45
Adjusted BIC -132 -189 -204 -179
Entropy 98% 86% 85% 84%
VL MR testa P=0.284 P=0.062 P=0.446 P=0.768
BLR testa P<0.001 P<0.001 P=0.013 P>0.999
aA significant result indicates that a model with k profiles fits better than a model with k − 1 profiles.
AIC, Akaike’s information criterion; BIC, Bayesian information criterion; BLR, bootstrap likelihood ratio; VLMR, Vuong−
Lo−Mendell−Rubin likelihood ratio.
Profile 1: the manic profile. A total of 34% (n=44) of the women had this profile. The manic 
profile is characterized by a high prevalence of manic symptoms combined with symptoms 
of agitation (proportions were .57 and .59, respectively), and a relatively low prevalence of 
anxiety and depression (proportions were .38 and .16, respectively).
 Profile 2: the depressive profile. A total of 41% (n=54) of the women had this profile. 
The depressive profile is characterized by a high prevalence of depressive and anxiety 
symptomatology (proportions were .66, and .80, respectively), and a relatively low 
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prevalence of symptoms of agitation and mania (proportions were .34 and .23, respectively). 
The depressive profile is in many respects the opposite of the manic profile.
 Profile 3: the atypical profile. A total of 25% (n=32) of the women had this profile. 
Disturbance of consciousness and disorientation (factor atypical) were exclusively found in 
the atypical profile (the proportion was .60), alongside a high prevalence of anxiety (.69), 
depression (.37), agitation (.54) and mania (.47). Either disturbance of consciousness or 
disorientation (factor atypical) was present in all women with this profile, and 18% (six out of 
32 women) had both symptoms present.
FIGURE 2. Symptom profiles based on latent class analysis 
     |  5KAMPERMAN Et Al.
of symptoms of agitation and mania (proportions were .34 and .23, 
respectively). The depressive profile is in many respects the opposite 
of the manic profile.
Profile	3:	the	atypical	profile.	A	total	of	25%	(n=32)	of	the	women	
had this profile. Disturbance of consciousness and disorientation (factor 
atypical) were exclusively found in the atypical profile (the proportion 
was .60), alongside a high prevalence of anxiety (.69), depression (.37), 
agitation (.54) and mania (.47). Either disturbance of consciousness or 
disorientation (factor atypical) was present in all women with this pro-
file, and 18% (six out of 32 women) had both symptoms present.
Table 2 describes the demographic and clinical characteristics 
related to the three profiles and statistically assesses differences be-
tween them. The three subgroups of women with the profiles did not 
differ in terms of demographic characteristics; however, more women 
with the manic profile had been diagnosed with a bipolar disorder prior 
to their first pregnancy. Of these 30 women, 16 (54%) were classified 
as having the manic profile, 10 (33%) as having the depressive profile, 
and four (13%) as having the atypical profile. The women in the profile 
subgroups did not significantly differ with respect to the treatment 
outcome (remission rates ranged from 82 to 94%), but women in the 
manic profile subgroup reached symptom remission approximately 4 
days earlier after initiating treatment. Women with the depressive pro-
file received treatment significantly later than women with the other 
two profiles; the average time from symptom onset to treatment was 
23 days, almost 2 weeks longer than for women with a manic or atyp-
ical profile. Hospitalization of the majority of the women with the de-
pressive profile took place voluntarily, while women in the mania and 
atypical profile subgroups were more often admitted through civil de-
tention. In line with the symptomatology of the profiles, risk for suicide 
or serious self- harm was more frequent in women with the depressive 
profile, i.e. 58% of women with the depressive profile presented these 
risks vs 32% of women with the manic profile and 47% of women with 
the atypical profile. Women with the atypical profile were more often 
committed to prevent self- neglect, i.e. 63% of those with the atypical 
profile vs 36% of those with the manic profile, and 47% of those with 
the depressive profile. However, none of these differences reached 
significance.
4  | DISCUSSION
PP is one of the few disorders in psychiatry for which the primary 
etiological event is known (i.e. childbirth), which is an important 
phenotypic characteristic of the disorder. The characteristic acute 
postpartum onset and clinical presentation have been exquisitely 
described by experts in the field, but prospective, well- characterized 
symptom assessment in a larger cohort has been lacking. Here we 
have performed a detailed assessment of symptomatology during the 
acute phase and we have identified three symptom profiles using la-
tent cluster analysis. The first profile is best characterized as a manic 
(34%), the second as a depressive (41%) and the third as an atypical 
symptom profile (25%).
4.1 | Affective symptoms
Our results confirm the affective nature of the disease because manic, 
depressive and other affective symptoms are highly prevalent. For both 
the manic and atypical symptom profiles, dysphoric manic symptoms 
F IGURE  2 Symptom	profiles	based	on	latent	class	analysis.	Included	symptoms	per	factor	are	as	follows.	Anxiety:	anxiety	or	worrying,	
and panic or scare. Depression: feelings of guilt, depressed mood, insomnia, loss of libido, and suicide thoughts. Melancholia: anhedonia, early 
morning	awakening,	psychomotor	retardation,	loss	of	appetite,	and	worse	mood	in	the	morning.	Agitation:	irritability,	psychomotor	agitation,	
and disruptive/aggressive behavior. Mania: decreased need for sleep, increased rate/amount of speech, increased motor activity or energy, 
grandiose	delusion,	elevated	mood,	and	increased	sexual	interest.	Atypical:	disorientation	and	disturbance	of	consciousness.	Disorganization:	
disorganized behavior, disorganized speech, inappropriate appearance, and inappropriate affect. Delusions: persecutory, delusions of reference, 
other (religious, guilt or jealous), somatic, being controlled, and bizarre delusions. Hallucinations: auditory (including commentary voices, and two 
or more voices), visual, tactile, and other (tactile and olfactory). Child- related: delusions, obsessive thoughts, and infanticide thoughts. Catatonia: 
extreme negativism or mutism, and excessive motor activity
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Included symptoms per factor are as follows. Anxiety: anxiety or worrying, and panic or scare. Depression: feelings 
of guilt, depressed mood, insomnia, loss of libido, and suicide thoughts. Melancholia: anhedonia, early morning 
awakening, psychomotor retardation, loss of appetite, and worse mood in the morning. Agitation: irritability, 
psychomotor agitation, and disruptive/aggressive behavior. Mania: decreased need for sleep, increased rate/amount 
of speech, increased motor activity or energy, grandiose delusion, elevated mood, and increased sexual interest. 
Atypical: disorientation and i turbance of consciousness. Disorganiz tion: disorganized behavi r, disorganized 
speech, inappropriate appearance, and inappropriate affect. Delusions: persecutory, delusions of reference, other 
(religious, guilt or jealous), somatic, being controlled, and bizarre delusions. Hallucinations: auditory (including 
commentary voices, and two or more voices), visual, tactile, and other (tactile and olfactory). Child-related: delusions, 
obsessive thoughts, and infanticide thoughts. Catatonia: extreme negativism or mutism, and excessive motor activity
 Table 2 describes the demographic and clinical characteristics related t  the thre  profiles 
and statistically assesses differences between them. The three subgr ups of women with th  
profiles did not differ in terms of demographic characteristics, h w ver, mor  women with 
the manic profile had been diagnosed with a bipolar disorder prior t  their first pregnan y. 
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Of these 30 women, 16 (54%) were classified is having the manic profile, 10 (33%) as having 
the depressive profile, and four (13%) as having the atypical profile. The women in the profile 
subgroups did not significantly differ with respect to the treatment outcome (remission rates 
ranged from 82 to 94%), but women in the manic profile subgroup reached symptom remission 
approximately 4 days earlier after initiating treatment. Women with the depressive profile 
received treatment significantly later than women with the other two profiles; the average time 
from symptom onset to treatment was 23 days, almost 2 weeks longer than for women with 
a manic or atypical profile. Hospitalization of the majority of the women with the depressive 
profile took place voluntarily, while women in the mania and atypical profile subgroups were 
more often admitted through civil detention. In line with the symptomatology of the profiles, 
risk for suicide or serious self-harm was more frequent in women with the depressive profile, 
i.e. 58% of women with the depressive profile presented these risks vs 32% of women with the 
manic profile and 47% of women with the atypical profile. Women with the atypical profile 
were more often committed to prevent self-neglect, i.e. 63% of those with the atypical profile 
vs 36% of those with the manic profile, and 47% of those with the depressive profile. However, 
none of these differences reached significance.
DISCUSSION 
PP is one of the few disorders in psychiatry for which the primary etiological event is known (i.e. 
childbirth), which is an important phenotypic characteristic of the disorder. The characteristic 
acute postpartum onset and clinical presentation have been exquisitely described by experts 
in the field, but prospective, well-characterized symptom assessment in a larger cohort has 
been lacking. Here we have performed a detailed assessment of symptomatology during the 
acute phase and we have identified three symptom profiles using latent cluster analysis. The first 
profile is best characterized as a manic (34%), the second as a depressive (41%) and the third 
as an atypical symptom profile (25%).
Affective symptoms
Our results confirm the affective nature of the disease because manic, depressive and other 
affective symptoms are highly prevalent. For both the manic and atypical symptom profiles, 
dysphoric manic symptoms and agitation were more prevalent than euphoric mania. This has 
been reported previously in women with a history of bipolar disorder with a postpartum relapse 
(19, 20). The low prevalence of “classical euphoric mania” could be a gender characteristic 
because mixed episodes are more common in women compared to men (21, 22). In addition, 
this could be seen as a specific characteristic of the postpartum period. Remarkably, anxiety 
was highly prevalent in all three symptom profiles, especially in depressive profile. We suspect 
that affective symptoms such as anxiety, irritability and agitation are particularly prevalent 
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in postpartum psychiatric episodes compared to non-postpartum episodes (4, 23), and it is 
tempting to speculate that these symptoms are related to the endocrine and physiological 
changes that occur after delivery (24, 25).
Delusions and hallucinations
Delusions and hallucinations were present in a majority of the patients, which is in line with a 
high prevalence of psychotic symptoms in first manic episodes outside the postpartum period 
(26). The most prevalent delusions were paranoid delusions and delusions of reference. More 
specific to this disease was the occurrence of childbirth related delusions in 24% of women with 
PP. Occasionally these were delusions of grandiosity (‘my child is the new messiah’) but mostly 
the content of these pregnancy- and childbirth-related delusions was negative. Interestingly, 
the prevalence of childbirth related delusions was much higher in India, where 78% of women 
with PP reported these kind of delusions (27). The lower prevalence in our study may be due 
to cultural differences and is quite similar to the prevalence found in a British study (28). It is 
quite possible that mothers keep their psychotic thoughts regarding their child or childbirth well 
hidden.
 Schneiderian first-rank symptoms were rare, as described previously (5, 6). Lastly, we report 
a prevalence of visual hallucinations of 34%, which is in concordance with a retrospective 
case series from The Netherlands (4). Visual hallucinations are uncommon in bipolar episodes 
outside the postpartum period (29).
Symptoms typical for postpartum psychosis?
Previous studies have described disturbance of consciousness, disorientation, severe inattention 
and depersonalization/derealization as important symptoms of PP (4-7, 19, 30-34). Notably, 
there might be a bias towards reporting these symptoms in case reports, case series or 
retrospective studies, because these symptoms are remarkable and extraordinary.
 In our latent class analysis, disorientation, disturbance of consciousness, and disorganization 
clustered together into a single profile. More specifically, all patients with this profile (n=32) had 
at least one of the two symptoms: disturbance of consciousness and/or disorientation. These 
symptoms were exclusively present in this profile. Disturbance of consciousness, disorientation 
but also visual hallucinations are common characteristics of delirium in somatically ill patients. 
The presence of these symptoms suggests an undetected organic cause (6). Despite a thorough 
somatic screening of all patients, we could identify this organic cause [N-methyl D-aspartate 
(NMDA) receptor encephalitis] in two women only (35). Remarkably, only one of these had 
this atypical profile, the other had a manic profile.
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Risk of suicide and infanticide
Prior to admission, potential risks of suicide and infanticide were important justifications for both 
voluntary and involuntary patient admissions. Importantly, almost half of our cohort consisted 
of women with involuntary admission. The initial legal grounds for the involuntary admission 
were civil detention to prevent acute danger for the safety of the patients or others (including 
risk of suicide, homicide, causing serious harm to herself/ others or neglecting selfcare or care 
of the baby). One woman committed a life threatening suicide attempt prior to admission. 
During admission, 19% of women reported suicidal thoughts. Higher rates of suicidal thoughts 
and attempts in women with postpartum mental illness have been found in previous studies 
(4, 6, 32). The cultural and socio-economic background of our patient cohort might have 
contributed to this finding (36).
 Ten women (8%) reported thoughts of infanticide during admission. In an Indian study in 50 
women with severe postpartum mental illness, nearly half of the patients reported infanticide 
ideas. Main risk factors were depression and psychotic symptoms (37). In a study in the USA, 
homicidal ideation and behavior were present in respectively 33 and 14% (6), and a British 
study found a prevalence of 9% (28). Taken together, these findings indicate that clinicians 
should always inquire, harming her infant or harming other children.
Strengths and limitations
One of the strengths in this study is the use of data from the largest clinical cohort of women 
diagnosed with PP (34). Data were collected prospectively, over the course of admission. In 
doing so, we were able to avoid recall bias in symptom reporting. A potential limitation is the 
use of the EPDS. With regards to depressive symptomatology, we chose self-reported EPDS 
items over clinician rated symptoms since the EPDS has been developed for women in the 
postpartum period specifically (10, 38). Obtaining self-reported depressive symptomatology 
via EPDS might have led to subjective reporting, which could have hindered the identification 
of more severe depressive symptoms, including suicidal thoughts. A subset of symptoms was 
elicited from the medical records. Reliability regarding the presence of these symptoms was 
therefore dependent on the quality of reporting by the treating clinician. From our weekly 
assessments, we have scored the presence of symptoms at their most severe occurrence. In 
doing so, we were able to capture a broad array of symptoms present during admission (7, 39), 
but we could not capture the rapid fluctuations of symptomatology within patients (the so called 
“kaleidoscopic” picture). Because of our sample size, latent class analyses were conducted 
using aggregated symptoms, i.e. the proportion of symptoms present for each symptom factor. 
This form of data reduction enabled us to distinguish clinically relevant symptom profiles, but 
also forced us to make assumptions about the relationship among symptoms. Finally, in our 
analyses, patients might have been misclassified to the latent symptom profiles, resulting in an 
underestimation of the relationship between illness course and symptom profile.
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Conclusions
PP is a severe disorder; its inclusion as distinct disorder within the bipolar spectrum in the list 
of rare disorders is an important recognition for the women affected. If women are given this 
initial “postpartum diagnosis”, they will not be misclassified as “bipolar” too early in their 
disease course. One of the major challenges in this field is the ability to predict which women 
will experience multiple episodes (bipolar disorder) and which women have an isolated 
postpartum episode. In our study we were able to distinguish three phenotypic clusters. At this 
point, we do not know whether these are predictive to the disease course. Because of the low 
prevalence of the disorder, an international collaborative effort, including data sharing, is vital 
for consistent assessment and follow-up of women with first onset PP. Hopefully, this will lead to 
predictors of the disease course.
 We showed that disturbance of consciousness, disorientation, and depersonalization/
derealization were less prevalent than previously suggested in the literature. These symptoms 
remain enigmatic and clearly warrant further neuroscientific research. In first onset PP, euphoric 
manic symptoms were less prevalent compared to bipolar episodes. Instead, irritability seems 
to be a hallmark of the disease. Lastly, we showed that depressive symptomatology was at 
least as prevalent as manic symptomatology. This is an important diagnostic consideration, and 
clinicians should think of PP when a woman presents with acute severe depression, anxiety or 
agitation postpartum, even if psychotic symptoms are not present yet. Adequate recognition of 
these symptoms could lead to shorter disease episodes and prevent tragic outcomes such as 
suicide or infanticide.
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Supplement 2. Confirmatory factor analysis procedure and model fit
All 58 assessed symptoms were re-grouped into a smaller substantive based subsets by a panel 
of psychiatrists. This was a prerequisite, since the number of unique symptoms outnumbered 
the number of patients in our sample. Then, a confirmatory factor analysis (CFA) was used 
to evaluate the factor structure. Symptoms with zero prevalence (i.e. “thought withdrawal”, 
“erotomanic delusion”, “stupor”, “peculiarities of movement”, and “echolalia/echopraxia”), 
and symptoms that lacked a clear clinical definition (i.e. “language and thought disorder”, 
“abnormal thought content”) were excluded from analyses. We started with Model 1, 
consisting of 10 factors. Next the factor structure (number of factors and content of factors) was 
optimized in a series of adaptations using modification indices (>10.0), R-squared (<0.10), and 
(negative) residual variances of the estimated parameters. Modifications were only performed 
if they were clinically justifiable and did not influence the estimates of other parameters in the 
model. The fit of the models was evaluated using clinical judgement on the interpretability of 
the factors, and statistical goodness-of-fit indices, e.g. Comparative Fit Index, Tucker-Lewis 
Index, Root Mean Square Error of Approximation and Weighted Root Mean Square Residuals. 
Fit is considered good in case of a Ch2/df ratio < 1.5; RMSEA < 0.06, CFI and TLI > 0.95, 
and WRMR <1.0 (1-4). The best fitting model based on clinical and statistical criteria, was 
Model 3, consisting of the following conjunctive symptom factors (n=11): anxiety, depression, 
melancholia, agitation, mania, atypical, catatonic symptoms, disorganization, delusions, 
hallucinations and child-related symptoms. Factor structures and model fit indices of the best 
fitting and alternative models are reported in Supplementary Table 2.
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SUPPLEMENTARY TABLE 2. Modelling procedure and resulting model fit
Model 1 Model 2 Model 3c Model 4 Model 5
Model
Description
Model 1 minus 4 
symptomsb 
Model 2
plus additional 
factor
Model 3 using 
5 aggregated 
symptom clustersd 
and single item 
factors excluded 
Model 4 with 
inclusion of 3 
single item factors
Number of 
factors
10 10 11 8 11
Factors Depression
Melancholia
Agitation
Mania
Atypical
Disorganization
Delusions
Hallucinations
Child-related 
Catatonia
Identical Identical +
Anxiety
Anxiety
Depression
Melancholia
Agitation
Mania
Disorganization
Delusions
Hallucinations
Anxiety
Depression
Melancholia
Agitation
Mania
Disorganization
Delusions
Hallucinations 
Single symptom 
factors:
Atypical
Child-related
Catatonia
Performance 
estimatorsa
Chi2 1136 990 970 468 588
df 900 774 764 377 470
Chi2/df 1.26 1.28 1.27 1.24 1.25
p <0.001 <0.001 <0.001 0.001 0.002
RMSEA 
(90% CI)
0.045
(0.036-0.053)
0.046
(0.037-0.055)
0.046
(0.036-0.054)
0.043
(0.029-0.055)
0.044
(0.031-0.055)
CFI 0.81 0.83 0.84 0.89 0.85
TFI 0.79 0.81 0.81 0.87 0.84
WRMR 1.24 1.24 1.21 1.04 1.10
a Fit is considered good in case of a Ch2/df ratio < 1.5; RMSEA < 0.06, CFI and TLI > 0.95, and WRMR <1.0 (Bentler, 
1990; Hu & Bentler 1998; 1999; Tucker & Lewis, 1973).
b Excluded symptoms based on statistical and clinical criteria:
- “lack of insight” in factor Mania. 
- “inattention” and “depersonalization/derealisation” in factor Atypical. 
- “language/thought disorder” in factor Catatonia. 
c Final model, used in analyses
d Symptom aggregation with dichotomous (disjunct) scoring of the resulting symptom clusters (a score of 1 indicates 
that at least one of listed symptoms was present). Clusters are presented per factor the symptoms originate from:
- Factor Atypical: “disturbances of consciousness”, “disorientation”.
- Factor Delusions: “delusions of reference”, “persecutory delusion”, “somatic delusion”, “bizarre delusions”, 
“other delusions”.
- Factor Hallucinations: “tactile hallucinations”, “other hallucinations”.
- Factor Child-related: “child-related delusions”, “child-related obsessive thoughts”, “infanticide thoughts”.
- Factor Catatonia: “extreme negativism or mutism”, “excessive motor activity”.
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ABSTRACT
Background: During the postpartum period, women are at risk for the new onset of both 
auto-immune thyroid disorders and depression. The presence of thyroid peroxidase antibodies 
(TPO-ab) during early gestation is predictive for postpartum auto-immune thyroid dysfunction. 
The aim of this study was to investigate the association between TPO-ab status during early 
gestation and first-onset postpartum depression.
Methods: Prospective cohort study (n=1075) with follow-up during pregnancy up to one 
year postpartum. Thyroid function and TPO-ab status were measured during early gestation. 
Depressive symptomatology was assessed during each trimester and at four time points 
postpartum with the Edinburgh Depression Scale (EDS). Women with antenatal depression 
were not eligible for inclusion. Self-reported postpartum depression was defined with an EDS 
cut-off of ≥13.
Results: The cumulative incidence of self-reported first-onset depression in the first postpartum 
year was 6.3%. A positive TPO-ab status was associated with an increased risk for self-reported 
first-onset depression at four months postpartum (adjusted OR 3.8; 95% CI 1.3-11.6), but not at 
other postpartum time points. Prevalence rates of self-reported postpartum depression declined 
after four months postpartum in the TPO-ab positive group, but remained constant in the TPO-
ab negative group. 
Limitations: Depression was defined with a self-rating questionnaire (EDS).
Conclusions: Women with an increased TPO-ab titer during early gestation are at increased 
risk for self-reported first-onset depression. The longitudinal pattern of self-reported postpartum 
depression in the TPO-ab positive group was similar to the typical course of postpartum TPO-
ab titers changes. This suggests overlap in the etiology of first-onset postpartum depression 
and auto-immune thyroid dysfunction. Thyroid function should be evaluated in women with 
first-onset postpartum depression.
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INTRODUCTION
Postpartum depression is a disabling and heterogeneous disorder with a huge variety in 
biological, psychological and social risk factors (1). In addition, there is substantial difference 
in the onset timing, severity and course of postpartum depression (2, 3). The most important risk 
factor for postpartum depression is a depressive episode earlier in life or during pregnancy. 
In a large study among women with postpartum depression, approximately 60% of women 
reported an onset of their episode before pregnancy or during the antenatal period (4).
 Antenatal depression occurs during an entirely different immune and endocrine state 
than postpartum depression and may therefore have a different origin (5). Interestingly, the 
postpartum period is a high risk period for more severe and first-onset episodes of depression 
(6). Therefore, it is important to consider onset timing when studying risk factors for postpartum 
depression (4).  The postpartum period is also associated with an increased risk for the new onset 
of auto-immune thyroid disorders (7). The presence of thyroid peroxidase antibodies (TPO-ab) 
during early gestation is a clear marker for the occurrence of postpartum auto-immune thyroid 
dysfunction, induced by the typical postpartum rebound phenomena of TPO-ab titers (8-11). 
Interestingly, TPO has also been named as a predictor for postpartum depression (12).
 Four studies reported an association between an increased TPO-ab titer during early 
gestation and depression postpartum (13-16). However, none of these studies focused on first-
onset depression and three out of four studies did not take into account antenatal depression 
(13, 15, 16), while one study only briefly mentioned this in a sub analysis (14). Together, as 
acknowledged by Dama and colleagues in their recent review, in previous studies antenatal 
depression may have confounded the association between a TPO-ab positive status during 
pregnancy and postpartum depression (12). Accordingly, the current study was designed to 
investigate the association between a positive TPO-ab status during early gestation and first-
onset postpartum depression. We hypothesized that women are particularly at increased risk 
for first-onset depression three to four months postpartum, during the typical rebound of TPO-
ab titers.
 
METHOD
Participants
Participants were included in the Holistic Approach to Pregnancy and the first Postpartum year 
(HAPPY) study, a large prospective cohort that is described in detail elsewhere (17). In sum, 
the HAPPY-study focuses on maternal wellbeing during pregnancy and the postpartum period. 
During a recruitment period of 18 months (2013-2014), Dutch-speaking pregnant women were 
informed about the study during their first trimester appointment at 17 community midwives 
offices in the South-East of the Netherlands. Women with a non-singleton pregnancy or history 
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of a severe psychiatric disorder were not eligible for inclusion. We excluded women with a 
self-reported lifetime history of depression as well as all women with depression during the full 
course of their pregnancy. In addition, women with a known thyroid disease at baseline as well 
as other endocrine/auto-immune disorders were not eligible for inclusion. The HAPPY-study 
was approved by the Medical Ethical Committee of the Maxima Medical Centre Veldhoven 
and the Psychology Ethics Committee of Tilburg University (protocol number EC-2012.25).
Data collection, procedures and definitions
This study is reported in line with the STROBE guidelines (18). Questionnaires were used to 
collect baseline demographic information, as well as relevant medical, obstetric, psychological 
and lifestyle data. If applicable, data were verified with medical records. Standardized blood 
measurements were performed at 10-12 weeks gestation and included TPO-ab, as well as 
thyroid releasing hormone (TSH) and free thyroxine (FT4). Measurements were performed in 
Li-heparin plasma using electrochemiluminescence assays (Cobas® e 601, Roche Diagnostics, 
Mannheim Germany). We defined a positive TPO-ab status with the commonly used threshold 
of >20 IU/ml (19). This cut-off is probably not appropriate throughout the full course of 
pregnancy (12). Therefore, we performed the TPO-ab measurement during early pregnancy, 
before downsizing of maternal auto-immune processes emerges (8).
 Depressive symptomatology was assessed repeatedly every trimester and four times during 
the postpartum period (6 weeks, and 4, 8, and 12 months) using the Edinburgh Depression 
Scale (EDS). The EDS is validated to detect women with a high probability of major depression 
both during pregnancy and postpartum. In this study, self-reported depression was defined 
with the following validated EDS cut-off scores: trimester 1, ≥11; trimester 2 and 3, ≥10; (20); 
postpartum period ≥13 (21-23). Women who scored above the trimester cut-offs during the 
course of their pregnancy were not eligible for inclusion in our study. 
 Our primary outcome measure was the occurrence of first-onset self-reported depression 
(i.e. incidence of new cases) at four months postpartum. Women with an increased TPO-ab 
titer during early gestation show a subsequent decline of their titer throughout pregnancy, 
with a typically rebound between three to five months postpartum and a gradual decline 
afterwards (9-11). Therefore, we considered four months postpartum to be the most optimal 
time point available to assess a possible association between a positive TPO-ab status during 
early gestation and the occurrence of first-onset self-reported depression postpartum. First-
onset self-reported depression at other postpartum time points (6 weeks, 8 and 12 months) 
were used as secondary outcome measures. 
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Statistical methods
SPSS (version 24, IBM) was used for the statistical analyses. Binary logistic regression was 
used to evaluate the association between TPO-ab status during the first trimester (exposure) 
and the incidence of new cases of self-reported depression at four months postpartum (primary 
outcome), and at 6 weeks, 8 months and 12 months postpartum (secondary outcomes). To 
facilitate interpretation of the results, we plotted point prevalence rates of self-reported 
postpartum depression (EDS ≥13) over time (at 6 weeks, 4, 8 and 12 months postpartum) 
according to TPO-status. A multiple logistic regression analysis was performed to adjust for 
potential confounders. Based on previous literature, we included the following confounding 
variables: anxiety during pregnancy (Generalized Anxiety Disorder (GAD-7) scale sum score 
at 12 weeks gestation, continuous), age (years, continuous) and preterm delivery (<37 weeks 
of gestation, dichotomous) (12), primiparity (dichotomous) (1, 24) and recent life-events (self-
reported, dichotomous) (14). In addition, we considered the following confounding variables: 
mode of delivery (vaginal delivery or cesarean section), health problems of the baby (self-
reported, dichotomous) and social support during the postpartum period (Tilburg Support 
Scale sum score, continuous). All potential confounding variables were introduced both 
separately and simultaneously into the unadjusted model to verify a potential effect on our 
exposure of interest (TPO-ab status). Logistic regression analyses were evaluated with Wald 
tests (χ2, distribution, α=0.05). Results are presented with crude and adjusted odds ratio’s 
(OR’s) together with corresponding 95% confidence intervals.
 Additionally, we tested whether a positive TPO-ab status during pregnancy was associated 
with differences in mean TSH and FT4 concentrations by using T-tests. TSH data was log-
transformed to meet the assumption of normality, and log transformed mean TSH values are 
reported. Cohen’s d are used to report the size of the effect (25). Finally, we used a sensitivity 
analysis to assess the robustness of the findings. For this aim, we changed the dichotomous TPO-
ab variable into a categorical variable (3 categories: ≤ 20 IU/ml; 21-100 IU/ml; ≥101 IU/ml).
 Women were included in the final study sample if 1) at least two out of three pregnancy 
EDS scores were available and 2) the EDS score at four months postpartum (primary outcome 
measure) was available. 
 As a result of our data selection strategy we did not have any missing data on our primary 
outcome measure (EDS score ≥13 at 4 months postpartum). During pregnancy, the proportion 
of missing EDS measures varied between 1.7% and 2.5%. Regarding the secondary outcome 
measures, the proportion of missing data varied between 8.3% and 23.3%. Missing data was 
handled with the multiple imputation algorithm as implemented in SPSS version 24 (IBM). 
Ten imputed datasets were created and all predictor and outcome variables were used for 
imputation modelling. Analyses were run on the imputed data and pooled estimates are 
reported (26). To explore the impact of the imputation procedure on our results, we repeated 
all analyses using the original dataset.
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RESULTS
Study sample
A detailed overview of the participant selection process is presented in Figure 1. In total, 
n=3160 Dutch-speaking pregnant women were informed about the HAPPY-study, of which 
71.8% (n=2269) provided informed consent. A self-reported lifetime history of depression 
(n=300) and one or more EDS scores above the trimester specific cut-offs during pregnancy 
(n=386) were the most important reasons for exclusion. Of the women that were eligible for 
this study (n=1364), follow-up data at four months postpartum was available for n=1075 
(78.8%) women. According to the baseline demographic study characteristics (Table 1), 
the vast majority of women had the Dutch nationality, a high educational level, a paid job 
and was married or living together. Most baseline characteristics did not differ substantially 
between women that were included and excluded because of missing follow-up data during 
pregnancy or at four months postpartum (n=289, 21.2%). However, excluded women showed 
a higher prevalence of unplanned pregnancies (7.8% versus 3.7%), preterm delivery (6.6% 
versus 3.5%), smoking during pregnancy (8.6% versus 2.6%) and a lower prevalence of high 
education level (50.8% versus 69.3%).
  
FIGURE 1. Flow chart inclusion
Pregnant women eligible for 
inclusion HAPPY-study n=3160  
  
  
Provided informed consent 
n=2269 
Refused participation (n=891)  
Included in the HAPPY-study 
n=2124  
Excluded (missing data was not eligible for multiple imputation): 
- Pregnancy (n=25)
 - Postpartum (n=264)
 
Eligible for this study  
n=1364 
Available for analyses  
n=1075 
Excluded after additional eligibility screening : 
- Self reported life -time history of depression (n=300)  
- Depression during pregnancy (one ore more EDS  
  scores above trimester specific cutoffs) (n=386)  
- (History of) thyroid dysfunction (n=47)  
- Use of selective serotonin reuptake inhibitor ( n=16)  
- Auto -immune disease ( n=11) 
Excluded:  
- No  
- n=68)  
- No gestational blood measurements available (n=15)  
questionnaires completed (n=62)
Only first questionnaire completed (
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TABLE 1. Baseline characteristics (n=1075)
Mean (SD) n (%)a
Age (years) 30.4 (3.5)
Gestational age (days)  278 (10)
Preterm delivery (<37 weeks) 38 (3.5)
Married or living together 1044 (99.0)
High educational level
b
764 (69.3)
Dutch nationality 1038 (98.4)
Paid job 1014 (96.2)
Primiparous 525 (49.9)
Unplanned pregnancy 39 (3.7)
Smoking during pregnancy 27 (2.6)
Alcohol consumption during pregnancy 13 (1.2)
a In case of missing data (maximum n=22), valid percentages are presented
b Bachelor and/or master degree
Thyroid measurements and EDS scores during pregnancy
In total, 121 out of 1075 women (11.3%) had a positive TPO-ab status (>20 IU/ml) at 12 
weeks of gestation. The median of the positive TPOA-ab measurements was 74.0 IU/ml, with 
an inter quartile range (IQR) of 29.0 – 170.0. In the full sample, we observed a median TSH 
blood level of 1.4 mU/L (IQR 1.0-2.1 mU/l) and median FT4 of 14.4 pmol;/L (IQR 13.4-15.4 
pmol;/L). 
 TSH concentrations were significantly higher in the group with a positive TPO-AB status 
(log-transformed mean 0.3 mU/L, SD 0.4) compared to the group with a negative TPO-ab 
status (log-transformed mean 0.1 mU/L, SD 0.3); t(1073) = -4.9, p<0.0001, cohen’s d=0.43, 
medium effect size). FT4 concentrations were significantly lower in the group with a positive 
TPO-AB status (mean 14.2 pmol/L, SD 1.8) than in de group with a negative TPO-ab status 
(mean 14.6 pmol/L, SD 1.7; t(1073)=2.2, p=0.028, Cohen’s d=0.23, small effect size). 
 We excluded women with an EDS score above the trimester specific cut-offs, which resulted 
in the following mean EDS scores of the remaining women: trimester 1, 2.7 (SD 2.5); trimester 
2, 3.4 (SD 2.6); trimester 3, 3.3 (SD 2.6). Mean EDS-scores did not significantly differ between 
women with a positive versus negative TPO-ab status during any of the trimesters.
 
The association between thyroid peroxidase antibodies status and first-onset 
postpartum depression
In the total sample, 6.3% (68/1075) of the women fulfilled the definition of self-reported 
postpartum depression at one or more of the four assessments during the first postpartum year 
(n=43 once; n=16 twice; n=6 three times; n=3 four times). 
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 At four months postpartum, we observed a risk of self-reported first-onset postpartum 
depression of 5.0% (6/119) among women with a positive TPO-ab status, compared to 1.5% 
(14/934) among women with a TPO-ab negative status (crude OR 3.5, 95% CI 1.3–9.4, 
p=0.016). This effect remained significant after adjustment for potential confounders (see 
method section) (adjusted OR 3.8, 95% CI 1.3-11.6, p=0.017).
 The association between TPO-ab status and self-reported first-onset depression was not 
significant at 6 weeks, 8 months and 12 months postpartum. The point prevalence rates of 
self-reported postpartum depression according to TPO-ab status at all postpartum assessments 
are presented in Figure 2. After a peak of self-reported postpartum depression at four months 
postpartum among women with a positive TPO-ab status, the point prevalence rates of self-
reported postpartum depression linearly declined from 5.8% (7/121) to 0.8% (1/121) at 12 
months postpartum. Among women with a negative TPO-ab status, the prevalence rates of 
self-reported postpartum depression remained relatively constant across all time points in the 
first postpartum year (2.1%, 20/954 – 3.0%, 29/954).
 A sensitivity analysis showed that the direction of the association between TPO-ab and self-
reported first-onset depression at four months postpartum remained constant after changing 
our dichotomous exposure TPO-ab status into a categorical covariate (≤ 20 IU/ml; 21-100 
IU/ml; ≥101 IU/ml). Repeating the analyses in the original (non-imputed) dataset supported 
our findings regarding the direction, size and significance of the reported associations.
FIGURE 2. Point prevalence rates of self-reported postpartum depression (EDS≥13) across 
the first postpartum year according to TPO-ab status during pregnancy (n=1075)
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DISCUSSION
In this large prospective cohort study including n=1075 women, the cumulative incidence of 
self-reported first-onset postpartum depression during the first postpartum year was 6.3%. 
A positive TPO-ab status during pregnancy was associated with a threefold increased risk 
of self-reported first-onset depression at four months postpartum but not at other postpartum 
time points. Point prevalence rates of self-reported postpartum depression declined after four 
months postpartum among women with a TPO-ab positive status, but remained constant among 
women with a TPO-ab negative status throughout the first postpartum year. These findings 
suggest a link between the typical postpartum rebound phenomena of the maternal immune 
system and first-onset postpartum depression.
 Previous studies reported a substantially higher overall risk for postpartum depression (i.e. 
regardless of TPO-abs status). For example, in the study of Harris and colleagues (15), 27.3% 
(66/242) of the women had an EDS score ≥13. In the study of Kuijpens and colleagues (14), 
an even higher proportion of women (117/291, 40.2%) was classified with a clinical diagnosis 
of postpartum depression during one or more assessments (according to the RDC-criteria). 
This is probably due to the high proportion of women with depression in history or depression 
during pregnancy. In the same study, the association between an increased TPO-ab titer at 12 
weeks gestation and postpartum depression remained significant after exclusion of women with 
an episode of depression earlier in life and/or at 12 weeks gestation (sub-analysis (n=191), 
OR 2.9, 95% CI 1.8-4.3). This is in in line with the odds ratio that we observed at four months 
postpartum (OR 3.8, 95% CI 1.3-11.6). However, in contrast to our study, Kuijpens et al. did 
not focus on first-onset depression since women with depression during the second and/or 
third trimester were not excluded. In addition, the onset timing of postpartum depression was 
not reported. Our study was not confounded by antenatal depression and we could therefore 
show evidence for a causal link between the new occurrence of thyroid autoimmunity and 
depression postpartum.
 There is accumulating evidence that immune system dysregulation is one of the underlying 
biological mechanisms that play an important role in the etiology of depression (5, 27). A 
mechanism that may be specifically related to first-onset postpartum depression, is the shift from 
immune tolerance during pregnancy towards a pro-inflammatory state during the postpartum 
period (5, 28). Interestingly, self-reported postpartum depression prevalence rates of the 
women with a positive TPO-ab status showed a pattern that is similar to the typical course of 
postpartum TPO-ab titers (9-11, 29): particular highly increased levels during the early (four 
months) postpartum period and a subsequent decrease (but still above the threshold) up to one 
year postpartum. 
 There is a well described link between the postpartum rebound of TPO-ab titers and clinical 
thyroid dysfunction (30). Consequently, among women with a positive TPO-ab status during 
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pregnancy, first-onset postpartum depression may be related to a transient hypothyroid phase 
of postpartum thyroid dysfunction (31). Interestingly, the results of a previous study from Harris 
and colleagues (15) revealed that a positive TPO-ab status postpartum was predictive for 
an increase in depressive symptomatology postpartum, regardless of the presence of thyroid 
dysfunction. An explanation for this phenomenon could be that immune activation postpartum 
leads to increased risk of depression instead of clinical thyroid dysfunction. Interestingly, a 
disturbance in the suppression and activation of several T-cell subpopulations have been 
associated with both increased TPO-ab titers and psychiatric disorders (30, 32-34). Therefore, 
T-cell abnormalities may also play a shared role in the etiology of postpartum depression and 
postpartum thyroid dysfunction. 
Clinical considerations
The postpartum period is known to be a trigger for first-onset psychiatric disorders (6). In this 
study we were able to identify a new risk factor for the occurrence of self-reported first-onset 
postpartum depression at four months postpartum. The findings of the current study support the 
general statement that the etiology of postpartum depression is multifactorial. There seems to be 
a sub-group of women (especially during the first four months) in whom thyroid auto-immunity 
plays a role in the development of depressive symptomatology. We follow the view that thyroid 
function should be evaluated during the postpartum period if women present with first time 
depressive symptomatology. Measurement of thyroid-stimulating hormone is a first diagnostic 
step for the detection of thyroid dysfunction.
 Another clinical consideration is the increased risk for women with increased TPO-ab titers 
for both thyroid dysfunction (particularly hypothyroidism) and depression later in life (8, 35, 
36) The risk for hypothyroidism is especially high for women with both increased TPO-ab titers 
and TSH concentrations, even if TSH concentrations are still within the normal range (19, 35). 
 
Strengths, limitations and directions for future research
To our knowledge, this is the first study that evaluated the association between TPO-ab titers 
during early gestation and (self-reported) first-onset postpartum depressive episodes. We 
included a large number of women and adjusted for potential confounders. However, our 
study also has several limitations. First, we did not assess TPO-ab titers, thyroid function and 
immune system parameters during the postpartum period. Consequently, it is unknown, to what 
extend thyroid dysfunction and immune system dysregulation was present among women with 
self-reported first-onset postpartum depression. Second, we used a self-rating questionnaire 
(EDS) to define depression. Therefore, it is unclear which proportion of the women with an EDS 
above the cut-off in our sample would fulfill the criteria of a clinically established diagnosis of 
postpartum depression. Third, we were not able to adjust for the presence of sexual child-abuse, 
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which is a potential confounder of the studied association (37). Finally, the findings of our 
study are not generalizable to women with a psychiatric history and/or women with antenatal 
depression, because we designed our study to investigate first-onset episodes of depression. 
Future studies on first-onset depression should also include longitudinal assessments of thyroid 
function (including TPO-ab titers) and immune system parameters (e.g. screening for potential 
abnormalities in T-cell subpopulations) during the postpartum period. This strategy will be 
helpful to further understand the role of immune system dysregulation in first-onset postpartum 
depression. 
 
Conclusions
In this large prospective cohort study, we demonstrated that women with a positive TPO-ab 
status during early gestation are at increased risk for self-reported first-onset depression at four 
months postpartum. This period coincides with the typical postpartum rebound phenomena of 
the maternal immune system, which suggests an overlap in the etiology of first-onset postpartum 
depression and auto-immune thyroid dysfunction. Evaluation of thyroid function is essential in 
the clinical assessment of first-onset postpartum depression.
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History
Lithium is listed in the periodic table of elements as an alkali metal and was discovered in 1817 
by Johan August Arfwedson, a Swedish chemist who identified lithium-aluminum-silicate in 
the mineral petalite (1, 2). The word lithium derives from “lithos” (Greek), which means stone. 
Lithium is an abundant element, mined as a salt at numerous places all over the world and is 
isolated with electrolysis and solar evaporation. It is used as a flux during processes such as 
welding and the production of glass but is most commonly known as a component of batteries 
and medication (lithiumcarbonate) (2).
 Lithium salts were first used as medication in 1847 by Alfred Baring Garrod, an internist 
working in London who discovered that lithium could be used to dissolve uric acid in the blood 
of patients that suffered of gout and rheumatoid arthritis (3). The first psychiatric report about 
lithium for the treatment of mania was published in 1871 by William Hammond, a professor 
in New York. It was about 80 years later when John Cade, a psychiatrist in Melbourne, 
considered the presence of uric acid as the cause of “psychotic excitement” in patients with 
mania. He published a trial about the effectiveness of lithium citrate in ten patients. A few 
years later, Erik Strömgren (psychiatrist) and Mogens Schou (medical doctor and clinical 
biochemist), both working at the Aarhus University psychiatric clinic in Denmark, conducted 
one of the first clinical trials in psychiatry (lithium versus placebo) (4, 5). The results of this study 
were published in 1954 and firmly demonstrated the efficacy of lithium therapy in the treatment 
of mania (5). After the Coleman flame photometer was introduced in 1958, lithium blood levels 
could be measured more precisely and lithium was increasingly used in psychiatry (3). 
 In the subsequent decades, multiple trials and follow-up studies demonstrated that lithium 
was highly effective for the treatment of mania and (to a lesser extent) depression, but also as 
maintenance treatment for bipolar disorder. Finally, lithium is the only pharmaceutical that has 
been associated with a decrease in suicide risk (3, 6).
Current use in psychiatry
Nowadays, lithium has the largest evidence base for both the acute and maintenance treatment 
of bipolar disorder (6). However, studies from several countries including the United States, 
United Kingdom, Sweden and Denmark demonstrated that lithium use has declined over the 
last decades (7-10). During the same period, there has been a huge increase in polypharmacy 
(e.g. combination with antidepressants) and prescriptions of other mood stabilizing medication 
such as lamotrigine, olanzapine and quetiapine (introduced in 1991, 1996 and 1997 
respectively) (11).
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 Aggressive marketing of (new) pharmaceuticals that received approval for the treatment 
of bipolar disorder is probably the most important reason for the shift from lithium towards 
other moodstabilizing medication (11, 12). Other proposed reasons are concerns regarding 
potential (severe) side effects, the necessity of blood level monitoring and lack of education 
about lithium therapy among psychiatry residents (11, 13).
Mechanisms of action
Over the last decades, there has been an exponential increase in publications focusing on the 
potential mechanisms of action of lithium in bipolar disorder (14). 
 A consistent finding among longitudinal imaging studies is that lithium use is associated 
with an increase in grey matter volume in regions that are part of the fronto-limbic network 
(15, 16). This finding suggests that lithium may have neuroprotective/neuroproliferative 
effects. Interestingly, this hypothesis is supported by (pre-)clinical studies that indicated that 
lithium inhibits apoptosis by activating neuroprotective and anti-inflammatory pathways. For 
example, lithium inhibits glycogen synthase kinase 3β (GSK-3). This enzyme regulates multiple 
neuroprotective cellular processes and is involved in circadian rhythm gene expression. In 
addition, inhibition of GSK3 modifies several neuronal systems (14, 16). Furthermore, lithium 
increases brain-derived neurotrophic factor (BDNF), a neuroprotective protein that can induce 
modification of neuronal structures (14, 16).
 Recent studies indicate that lithium has pre- and post-synaptic effects and modifies both 
excitatory (dopamine, glutamate) and inhibitory (GABA) neurotransmitter systems (14). 
However, it is still unknown how these effects result in the clinical effects of lithium among 
patients with bipolar disorder.
 
Clinical practice
Lithium is absorbed in the upper gastro-intestinal tract and reaches its maximum blood level 
concentration 1.5 - 2 hours after administration (4 - 6 hours for sustained-release formulation). 
Afterwards, lithium slowly crosses the blood-brain barrier and is excreted through the kidneys 
(17, 18). The elimination half-life time of lithium is one to three days and a steady state is reached 
after approximately 5 days (19). 
 Lithium has a small and clearly defined therapeutic window (0.6-1.2 mmol/l). Consequently, 
blood level monitoring is necessary to avoid both sub-therapeutic and increased/toxic blood 
levels. When lithium is initiated in the acute phase of a manic or depressive episode, it is 
necessary to aim at high blood levels (0.8-1.2 mmol/l), while lower blood levels (0.6-0.8 
mmol/l) are sufficient when lithium is used as maintenance treatment (19, 20). Lithium blood 
level monitoring should be performed 3 and 5 days after the initiation of lithium therapy, 5-7 
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days after each dose adjustment and every 3-6 months in patients with stable lithium blood 
levels. Obviously, it is important to take into account individual patient characteristics (e.g. 
age, compliance, potential interactions, proposed target blood level) when deciding on the 
exact frequency of blood level monitoring (20, 21). Finally, immediate blood level monitoring 
is required if patients present with severe side-effects or signs of lithium toxicity, which typically 
include: vomiting, worsening tremor, vertigo, ataxia, dysarthria, somnolence, confusion, 
fasciculation, nystagmus and ultimately seizures and coma (13, 19).
 The most common side effects of lithium (when dosed within the therapeutic range) 
are: nausea, diarrhea polydipsia, polyuria, fatigue, tremors, sexual dysfunction, cognitive 
impairment and abdominal pain (13, 19, 22). It is important to realize that some side effects may 
disappear over time and are often dose related (20, 23). In case of disabling and persisting 
side-effects that do not diminish after lowering the lithium dose, further strategies to manage 
side effects include: changing the time of administration, switching to a different formulation, 
use of antidotes for specific side effects and finally a switch to other moodstabilizing medication 
(13, 23). The most important potential long term side effects of lithium are a gradual decline in 
renal function, hypothyroidism and weight gain. Therefore, it is necessary to perform regular 
monitoring of renal clearance (creatinine, estimated glomerular filtration rate (eGFR)), thyroid 
function (thyroid stimulation hormone (TSH)) and body weight (13, 20, 22).
 Lithium is often prescribed in multiple daily doses (e.g. 2 d.d. 400 mg instead of 1 d.d. 800 
mg) to avoid peak blood level related side-effects. However, the evidence for the benefits of 
multiple daily dosing is not convincing and it may decrease compliance. Therefore, there is 
growing consensus to prescribe lithium in one daily dosage (17, 20).
 It has been proposed that use of sustained-release formulations (Priadel©, camcolit©) 
results in more stable lithium blood levels than immediate release formulations, thereby 
decreasing both side effects and the risk of a potential decline in renal function (18). However, 
clear evidence for this potential advantages is lacking and it has been argued that the term 
“sustained” (or “prolonged”) is actually misleading because peak blood levels are only 
delayed and not necessarily lower (17, 19). Nevertheless, sustained release formulations can 
be beneficial because they have a coating which may prevent irritability of the stomach and 
masks the unpleasant taste of lithium salt. In addition, sustained release formulations are only 
available in 400 mg capsules (10.8 mmol li+), which may prevent potential dosing mistakes (20).
 Finally, it is important to be aware of somatic illness (e.g. dehydration) and potential drug 
interactions that can induce lithium blood level alterations. For example, diuretics, non-steroidal 
anti-inflammatory drugs (NSAID’s), and angiotensin converting enzyme (ACE) inhibitors will 
increase lithium blood levels, while lithium can enhance extra-pyramidal effects of antipsychotic 
co-mediation (19). 
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Lithium use during pregnancy and the postpartum period
In part II of this thesis we present a study on lithium dosing strategies during pregnancy and the 
postpartum period (chapter 7), followed by a study in which we compared the efficacy lithium 
and lamotrigine use during pregnancy in the prevention of postpartum episodes (chapter 8). 
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ABSTRACT 
Background: Lithium is challenging to dose during pregnancy.
Aims: To provide guidance for dosing lithium during pregnancy.
Method: Retrospective observational cohort study. Data on lithium blood level measurements 
(n=1101), the daily lithium dose, dosing alterations/frequency and creatinine blood levels 
were obtained from 113 pregnancies of women receiving lithium treatment during pregnancy 
and the postpartum period. 
Results: Lithium blood levels decreased in the first trimester (–24%, 95% CI –15 to –35), 
reached a nadir the second trimester (–36%, 95% CI –27 to –47), increased in the third 
trimester (–21%, 95% CI –13 to –30) and were still slightly increased postpartum (+9%, 95% 
CI +2 to +15). Delivery itself was not associated with an acute change in lithium and creatinine 
blood levels.
Conclusions: We recommend close monitoring of lithium blood levels until 34 weeks of 
pregnancy, then weekly until delivery and twice weekly for the first 2 weeks postpartum. We 
suggest creatinine blood levels are measured to monitor renal clearance. 
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INTRODUCTION
Lithium is currently the most effective mood stabilizer and widely used as a first-line treatment in 
bipolar spectrum disorder. It has beneficial treatment effects during manic episodes, is associated 
with a reduction in suicide risk and is highly effective for relapse prevention (1). However, 
lithium needs to be dosed very carefully because of its narrow therapeutic window. In clinical 
practice, serum measurements provide crucial guidance to avoid both sub-therapeutic (<0.5 
mmol/L) or toxic (>1.2 mmol/L) blood levels (2-5). In addition, it is important to check for renal 
dysfunction, natrium depletion, dehydration and drug interactions, which can all cause lithium 
blood level changes (5, 6). Dosing of lithium is particularly challenging during pregnancy as a 
result of the normal physiological adaptations of renal function. During pregnancy, increased 
glomerular filtration rate (GFR) leads to substantial reductions in lithium blood levels and 
an increased risk of relapse (7). Therefore, clinicians are often inclined to increase patients’ 
lithium dose during pregnancy in an effort to maintain adequate prophylactic blood levels. 
However, later in pregnancy and during the early postpartum period when GFR returns to 
preconceptional levels, the increased lithium dose can result in toxic lithium blood levels (7, 
8). Toxic lithium levels are concerning not only for the mother, but particularly for the infant 
in whom the adverse neonatal effects of lithium, such as hypoglycaemia, cardiac arrhythmia, 
thyroid dysfunction and neonatal lithium toxicity are dose-related (9, 10). Moreover, during 
the early postpartum period, lithium dosing is challenging because of the very high risk for 
postpartum relapse (37%, 95% CI 29–45%) in women with bipolar disorder (11). Therefore, 
increased therapeutic lithium blood levels are warranted during this high-risk period. Current 
clinical guidelines provide limited details regarding the optimal approach for monitoring lithium 
blood levels during pregnancy and the postpartum period. Therefore, in an effort to define 
an evidence-based strategy for dosing lithium during pregnancy, we investigated a cohort of 
women (n=85 representing n=113 pregnancies) for whom lithium blood levels were measured 
(n=1101) longitudinally during pregnancy and the postpartum period.
METHOD
Participants
All women referred to the psychiatric and obstetric out-patient clinics of Erasmus University 
Medical Centre and Leiden University Medical Centre between January 2003 and May 2015 
were evaluated for eligibility to participate in this retrospective observational cohort study. 
Women were included if they used lithium during pregnancy and at least one lithium blood 
level measurement was obtained. This study was approved by the Institutional Review Boards 
of the Erasmus University Medical Centre (MEC-2013-319 ABR NL.45670.078.130) and 
Leiden University Medical Centre (P15.182).
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Data collection and procedures 
This study was conducted and reported in accordance with the STROBE guidelines (12). 
Data were extracted from medical records and processed with data manager OpenClinica 
(13). For each woman, we obtained lithium blood level measurements and all prescribed 
medication during the period from 25 weeks before conception through 25 weeks postpartum, 
including the daily lithium dose, dosing alterations and the dosing frequency. We extracted 
creatinine blood levels to evaluate whether alterations in lithium blood levels were consistent 
with alterations in the GFR. In addition, we obtained relevant demographic, psychiatric and 
obstetric data for each woman and her corresponding pregnancies included in the study. Each 
lithium blood level measurement represented one observation. Lithium-citrate (Litarex© 564 
mg = 6 mmol lithium) dosages were multiplied by 0.395 in order to obtain lithium-carbonate 
prescription equivalents (400 mg = 10.8 mmol lithium). The peripartum time course of lithium 
blood levels were synchronized between women based upon the date of delivery. Perinatal 
time windows were defined as preconception (25 weeks preceding the estimated date of 
conception), first trimester (week 0-13), second trimester (week 14-26), third trimester (week 
27-40) and postpartum (25 weeks following delivery).
Statistical analysis
Data management and descriptive statistics were performed using SPSS version 21.0. Linear 
mixed-effect modelling was implemented using the procedure MIXED to account for both 
the non-independence of repeated lithium blood level measurements within individuals, 
and differences between women in the observation frequencies and time intervals. Since 
our primary hypothesis was that pregnancy-induced changes in GFR are responsible for 
corresponding alterations in lithium blood level, we used lithium blood level as our primary 
outcome measure, and time (representing gestational age) and lithium dose as our main 
predictor variables. We also considered the daily frequency of lithium administration, preterm 
birth (<37 weeks), parity status and number of included pregnancies per woman as candidate 
predictors. Models with linear, quadratic and cubic effects of time and piecewise models with 
transition points at conception and delivery were fitted to capture the longitudinal effect of 
pregnancy-related alterations of GFR on lithium blood levels. We also used a mixed model 
analysis to study the effect of pregnancy on renal function. Creatinine blood levels were used 
as the response variable with time as a predictor. Finally, we evaluated the association between 
renal dysfunction (creatinine >90 µmol/L, dichotomous predictor variable) and lithium blood 
levels (response variable) among those measurements for which a corresponding creatinine 
blood level was available within a maximum of two weeks prior to obtaining the lithium blood 
measurement. Model selection was based on maximum likelihood tests (nested models) and 
Akaike’s iInformation criterion (AIC). Sensitivity analyses were performed to assess if the 
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modelling of lithium blood levels over time was affected by the manner in which we computed 
the change in lithium blood levels. The standard approach was compared with time-lag models, 
autoregressive models, and change or variance-covariance models. Individual effects in the 
model were examined using Wald’s test with α = 0.05.
RESULTS
Study characteristics
We identified 89 women that were eligible for study inclusion. Four women were excluded 
because lithium blood measurements were not available in their medical records as testing 
was performed at another centre. In total, we included 85 women that were referred to 
the specialized out-patient university clinics of Rotterdam (n=59) and Leiden (n=26). The 
most common psychiatric diagnosis was a bipolar spectrum disorder (n=75, 88.2%). The 
remaining women (n=10) were diagnosed with a schizoaffective disorder, depressive disorder 
or borderline personality traits. There were 61 women with a single pregnancy, 22 women 
with two pregnancies, 1 woman with three and 1 woman with five pregnancies. In total, we 
have evaluated 113 pregnancies and 1,101 lithium blood level measurements. In these 113 
cases, lithium was either initiated during pregnancy as treatment for an episode (n=12), or as 
a change in mood stabilizer to reduce the risk of teratogenicity (n=1) or lithium was initiated 
prior to conception and maintained during pregnancy and the postpartum period (n=100).
 Ten women relapsed despite continuous lithium use during pregnancy and the 
postpartum period. Of these ten women, five relapsed during pregnancy, of whom three 
also relapsed postpartum. Five women relapsed exclusively in the postpartum period.  
 The parity of the women during each of the included pregnancies was: parity 0 (n=54), 
parity 1 (n=35), parity 2 (n=12), parity ≥3 (n=12). The mean age at the time of delivery was 
34.5 (s.d. 4.21) years. In 22 pregnancies (19.5%), the delivery was classified as preterm birth 
(<37 weeks’ gestation). Overall, the deliveries occurred at a median –7 days (IQR –18 to +1) 
prior to the estimated term date.
Course of lithium blood levels in the peripartum period
The distribution of lithium blood level measurements (n=1101) were as follows: preconception 
(n=46), first trimester (n=93), second trimester (n=232), third trimester (n=374) and postpartum 
(n=356). Preconception lithium blood level measurements were unavailable for most pregnancies 
(n=89, 78.8%) since the majority of women were referred during the first or second trimester.   
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FIGURE 1. Course of lithium blood level/dose ratio during the peripartum period
 
Delivery is represented by the vertical line (i.e. day zero).
 
During pregnancy, lithium citrate (Litarex©, slow release) was used during n=40 pregnancies 
and lithium carbonate (Camcolit©, Priadel© or generic lithium) was used during n=73 
pregnancies. As shown in Table 1, dosing strategies varied over time. Both the mean and 
variance of lithium dose was increased relative to preconception levels during the second 
and third trimester and postpartum period. Multiple (≥2) daily dosing of lithium was used 
in nearly all pregnancies (n=111, 98.2%), of which most transitioned to single daily dosing 
immediately after delivery (n=79) while the remainder continued using multiple daily dosing 
in the postpartum period (n=32). Two women (n=2, 1.8%) used single daily dosing throughout 
pregnancy and the postpartum period.
 The longitudinal pattern of observed lithium blood levels is presented in Figure 1. In order 
to reliably compare lithium blood levels, we normalized lithium blood levels to the total daily 
dose. The lowest normalized lithium levels occurred during the second trimester, in gestational 
week 17. Notably, women were prescribed the highest total mean daily dose during the second 
trimester (Table 1). A substantial proportion of lithium blood levels were definitely below the 
therapeutic threshold for effective mood stabilization (<0.5 mmol/L): preconception (7/46, 
15.2%), first trimester (58/93, 62.4%), second trimester (144/232, 62.1%), third trimester 
(144/374, 38.5%) and postpartum (35/356, 9.8%).Mixed effect models with response 
variable lithium blood levels were fitted, leading to a final model with time (categorical) and the 
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corresponding prescribed lithium dose as predictor covariates (fixed effects). Other candidate 
predictors, including the frequency of daily lithium administration, preterm birth, parity and the 
number of included pregnancies per woman, did not significantly improve the performance 
of the model. The results of the final model are presented in Table 2. At a standardized daily 
dose of 1000 mg, mean lithium blood levels were lower in all trimesters compared with the 
preconception period. The second trimester was associated with the largest decrease in lithium 
blood levels (–36%, 95% CI –27 to –47).
  
TABLE 1. Lithium dosing strategies in the peripartum period
Lithium blood 
measurements, n
Lithium dose 
(mg), mean (s.d.)
Dosing scheme, n(%)
1 daily dose ≥ 2 daily doses
Preconception 46 925 242 14 30.4 32 69.6
Trimester 1 93 922 252 11 11.8 82 88.2
Trimester 2 232 1100 357 15 6.5 217 93.5
Trimester 3 374 1090 323 10 2.7 364 97.3
Postpartum 356 1034 270 291 81.7 65 18.3
TABLE 2. Mean lithium blood levels at a given dose of 1000 mga
Lithium blood level (mmol/L),  
mean (95% CI)
Change (%), 
 mean (95% CI)b
Preconception 0.66 (0.61 to 0.71) Reference
Trimester 1 0.50 (0.40 to 0.60) –24 (–15 to –35)
Trimester 2 0.42 (0.32 to 0.52) –36 (–27 to –47)
Trimester 3 0.52 (0.43 to 0.62) –21 (–13 to –30)
Postpartum 0.72 (0.62 to 0.81) +9 (+2 to +15)
a Linear mixed model analysis. Preconception is reference category.  
  Naïve model: lithium blood level = intercept + dose.  
  Final model: lithium blood level = intercept + dose + time (categorical).
  Restricted log likelihood ratio test: c2 = 439.5, df=4, p<0.00001.
b Intervals for the % change are ranges based on the 95% confidence interval of the lithium blood level.
 To quantify the influence of delivery on lithium blood levels, we restricted our analysis by 
comparing lithium blood level measurements during the final week of pregnancy (n=47) and 
the first postpartum week (n=186). However, including this categorical time covariate within the 
naïve model containing dose as the only predictor covariate did not significantly improve the 
performance of the model (restricted log likelihood ratio test: χ2=3.5, df=1, p=0.174). A graph 
of the observed data is presented in Figure 1 of the data supplement. Sensitivity analyses were 
performed to evaluate the robustness of the final model. There were no significant differences in 
the beta estimates between the various models tested. Moreover, model performance did not 
improve by including centre (Erasmus Medical Centre or Leiden University Medical Centre), 
Chapter 7
122 
number of days between conception and the first lithium blood measurement, or time between 
the estimated and actual dates of delivery as covariates.
Renal function
In total, 620 creatinine blood levels were included. In 84% of all pregnancies (n=95), at least 
one creatinine measurement was available. A graph of the observed data is presented in 
Figure 2 of the data supplement. We obtained the following mean creatinine blood levels using 
a mixed model analysis (response variable, creatinine blood levels; predictor covariate, time): 
preconception (70 µmol/L, 95% CI 66–74), first trimester (58 µmol/L, 95% CI 50-66), second 
trimester (56 µmol/L, 95% CI 48-63), third trimester (60 µmol/L, 95% CI 52–67), postpartum 
(75 µmol/L, 95% CI 67–82) (restricted log likelihood ratio test: χ2=293.6, df=4, p<1x10-5). 
Creatinine blood levels exhibited a similar longitudinal pattern as observed for lithium blood 
levels (reference period–preconception): first trimester (–17%, 95% CI –11 to –24), second 
trimester (–20%, 95% CI –14 to –27), third trimester (–14%, 95% CI –9 to –21), postpartum 
(+7%, 95% CI +2 to +12). We did not observe a significant difference in creatinine blood 
levels when comparing the first postpartum week with the final week of pregnancy (restricted 
log likelihood ratio test: χ2=3.6, df=2, p=0.165). In total, 6.5% (n=40/620) of all creatinine 
blood levels were beyond the upper threshold of 90 µmol/L, suggestive of renal dysfunction. 
The median of these 40 suprathreshold measurements was 98 µmol/L (IQR 93–109), of which 
the highest observed value was 130 µmol/L.
 The association of renal dysfunction and lithium blood level was evaluated among the 
subsample of lithium blood levels for which corresponding creatinine measurements were 
available (n=558/1101). The correlation between these measurements is shown graphically in 
Figure 3 of the data supplement. In this subsample, we observed creatinine blood levels beyond 
the clinical threshold for renal dysfunction (>90 µmol/L) in 3.8% of measurements (n=21/558) 
(median 98 µmol/L, IQR 92–108). Mixed model analysis revealed that renal dysfunction was 
significantly associated with elevated lithium blood levels (restricted log likelihood ratio test: 
χ2=21.2, df=1, p=0.00001).
Lithium blood levels and relapse
Five women relapsed during pregnancy despite continuous use of lithium. Three women had 
sub-therapeutic lithium blood levels (0.41, 0.36 and 0.31 mmol/L, respectively), one woman 
discontinued lithium against medical advice and one woman relapsed without a recent lithium 
blood level. Further, of these five women with relapse during pregnancy, three women also relapsed 
postpartum (their postpartum blood levels were 0.64, 0.58 and 0.57 mmol/L, respectively).  
 Five women had a relapse exclusively in the postpartum period – one woman had a sub-
therapeutic lithium blood level (0.55 mmol/L), while the remaining four women had lithium 
blood levels of 0.88, 0.82, 0.76 and 0.74 mmol/L.
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Lithium blood levels above the therapeutic window
Eight women (n=8/85, 9.4%) had lithium blood level measurements above the therapeutic 
window (>1.2 mmol/L) (Table 3). A thorough review of their medical records yielded no 
evidence to suggest that these measurements were erroneous (for example shortened time 
interval between administration and blood sampling). Patients 1, 5 and 6 used substantially 
higher lithium doses than the mean prescribed dose in the overall cohort (Table 1).
TABLE 3. Characteristics of patients (n=8) with lithium blood level measurements beyond 
the therapeutic threshold (1.2 mmol/L)
Patient
Day of 
blood level 
measurement 
(delivery is  
day 0)
Total 
pregnancy 
duration, 
weeks
Lithium 
blood 
level, 
mmol/L
Corresponding 
lithium dose, 
mg
Creatinine 
blood
level, 
µmol/La
Plausible cause
1 - 6 36 1.21 1600 68 Pre-eclampsia
2
 b
- 4 26
 c
1.90 889
 d
107 (↑) Decreased renal function
(pre-eclampsia)
3 + 1 39 1.33 1000 92  (↑) Decreased renal function
(pre-eclampsia)
4 + 1 30
 c
1.26 800 61 Non-steroidal anti-
inflammatory drug 
prescriptione
 
5
 f,g
+ 2 41 1.38 1600 56 Aimed at high target levelh
6
 f
+ 2 40 1.24 2000 66 Insufficiently anticipated on 
shift in renal function
7 + 2 34
 c
 1.21 1100 119 (↑) Decreased renal function
8 + 48 40 1.27 1000 53 Aimed at high target level
h
a Creatinine levels were obtained within a maximum of  2 weeks prior to obtaining the lithium blood measurement 
except for patient 5 (+1 day)  and patient 6 (–16 days).
b Twin pregnancy. This patient had a lithium blood level of 1.51 mmol/L on the subsequent day. 
c 
Preterm birth.
d 
Lithium carbonate equivalent of 2256 mg lithium citrate (Litarex©).
e Non-steroidal anti-inflammatory drug use can decrease renal function (indication was pain relief after caesarean 
section).
f 
Lithium treatment initiated during pregnancy.
g This patient also had an elevated lithium blood level (1.24 mmol/L) 35 days postpartum while treated for the same 
relapse episode.
h Higher target blood level because of hospital admission for severe relapse episode.
In the majority of women (n=7/8), the supratherapeutic lithium blood levels occurred during 
the week preceding (n=2) or following (n=5) delivery. Notably, four of these seven women 
had pre-eclampsia and decreased renal function (patient 1, 2, 3 and 7), one was using non-
steroidal anti-inflammatory medication (patient 4), another was prescribed a dose with the 
documented intention to achieve a therapeutic blood level for acute treatment (patient 5) 
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and another had evidence of insufficient anticipation of pregnancy-induced changes in GFR 
(patient 6). With regard to partient 6, the difficulty in interpreting blood level fluctuations might 
have been further exacerbated by the de novo initiation of lithium treatment during pregnancy. 
Two women (patient 5 and 8) were found to have supratherapeutic blood measurements 
outside the peripartum period. In both cases these women were being treated for acute relapse. 
Therefore, the physician prescribed a lithium dose with the documented intention of achieving 
a higher therapeutic blood level.
DISCUSSION
Main findings
In this study, we have quantified for the first time the longitudinal pattern of lithium blood levels 
during the peripartum period using 1101 lithium blood level measurements in 113 pregnancies 
of 85 women. Lithium blood levels decreased an average of 24% and 36% during the first and 
second trimesters, respectively. In the third trimester and postpartum period, lithium blood levels 
gradually returned to the preconception level. Interestingly, we did not observe a shift towards 
higher lithium and creatinine blood levels immediately following delivery.
Comparison of our findings with existing guidelines
During pregnancy, dynamic changes in GFR necessitate careful monitoring of lithium blood 
levels, as highlighted in several prominent international guidelines (including ones from the 
British Association for Psychopharmacology (BAP) (14), American Psychiatric Association 
(APA) (5), Canadian Network for Mood and Anxiety Treatments and International Society 
for Bipolar Disorders (CANMAT/ISBD) (15) and Royal Australian and New Zealand College 
of Psychiatrists (RANCP) (4)). Although these guidelines emphasize the importance of close 
monitoring, they lack specific recommendations regarding the frequency of monitoring and 
the methodology by which dosing should be adjusted, because of the previously limited 
available data. The UK National Institute for Health and Care Excellence (NICE) (16) and the 
Netherlands Association for Psychiatry (NVVP) (17) guidelines currently recommend monthly 
monitoring during the initial 7-8 months of pregnancy. Notably however, our results suggest 
that more frequent monitoring could be considered because of declining blood levels. We 
found that most women used multiple daily dosing in pregnancy;  the rationale for this strategy 
is to minimize peak lithium levels (10). Given the increased risk of non-adherence with multiple 
daily dosing, we recommend twice-daily dosing rather than more frequent administration (18). 
As expected, lithium and creatinine blood levels showed a highly similar longitudinal pattern 
throughout the study period. Therefore, the simultaneous evaluation of lithium and creatinine 
blood levels during pregnancy can be helpful to distinguish between lithium blood level 
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alterations because of fluctuations in renal function versus other factors such as non-adherence.
 In line with the current NICE (16) and NVVP (17) guidelines, we recommend weekly 
monitoring beginning in the thirty-fourth week of pregnancy until delivery. For the majority of 
women in our study, it was necessary to decrease the prescribed lithium dose in the final months 
preceding delivery. Especially in those patients with a relatively large decrease in lithium blood 
levels during the first half of pregnancy, a strong rebound effect in the third trimester should be 
expected. In these cases, in particular, close monitoring of lithium blood levels during the final 
phase of the third trimester is clearly warranted. Preconception blood levels and corresponding 
preconception doses can be used as personalized reference values. Particular attention is 
required for women presenting with symptoms of preterm birth, pre-eclampsia or other illnesses 
that can affect renal function (7, 9, 19).
 Several guidelines suggest to decreasing (4, 5, 14) or even discontinuing (16, 17) lithium 
prophylaxis when a woman exhibits the first signs of labor, because of the association between 
elevated maternal lithium blood levels and neonatal complications (9). This strategy will indeed 
minimize lithium levels in the newborn, but should also be weighed against the risk of maternal 
relapse during a period of exceptionally high risk (11). Accordingly, we share the opinion of 
Deligiannidis and colleagues in recommending careful lithium blood level monitoring instead 
of discontinuation in all cases (7). Finally, medications (such as non-steroidal anti-inflammatory 
drugs) that are known to increase lithium blood levels should be avoided (7). 
 We recommend relapse prevention prophylaxis in women with bipolar disorder with a 
higher lithium target level (for example ≥0.8 mmol/L) during the first month postpartum. In 
our recent meta-analysis (n=5105 pregnancies), 37% (95% CI 29-45%) of women with a 
history of bipolar disorder experienced a postpartum relapse (11). Given this very high risk 
of relapse, we hold the view that the benefits of higher lithium target blood levels during the 
1-month period following delivery outweighs the potential risks. In our study we observed that 
normalization of renal function can take up to a few weeks after delivery as both mean lithium 
and creatinine blood levels were higher in the postpartum period than in the preconception 
period (+9% and +7% respectively). Therefore, we recommend frequent monitoring (twice 
weekly) of lithium blood levels for the first 2 weeks postpartum. 
Limitations and directions for future research
Our study has a number of limitations. The observational study design might have introduced 
information bias. Most women were treated in an out-patient setting. As a result, it is 
uncertain that a 12-hour interval between dose intake and blood level measurement was 
always strictly maintained. This effect might have caused higher variability of measured 
blood levels. Furthermore, some degree of non-adherence might have occurred without our 
knowledge, particularly during delivery and among women using multiple daily dosing. 
Finally, preconception blood level measurements were unavailable for most women. Besides 
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the potential risk of neonatal complications, an important concern among clinicians is the 
potential for lithium-induced teratogenicity. Several older studies have reported that lithium 
exposure during the first trimester increased the risk of Ebstein’s anomaly (20, 21). In contrast, a 
recent meta-analysis found no increase in the odds of any congenital malformations, including 
Ebstein’s anomaly (22). However, the authors of the meta-analysis also concluded that an 
accurate estimate of the risk of teratogenicity because of lithium exposure still remains uncertain 
because of the potential that many of the included studies were inadequately powered to 
detect such rare events (22). Clearly, there is an urgent need for larger studies regarding the 
potential adverse effects of lithium during pregnancy as well as acute and long-term outcomes 
for children with in utero lithium exposure. These studies should include women with untreated 
bipolar disorder as a control group, because bipolar disorder itself seems to be associated with 
adverse pregnancy outcomes (23). 
Recommendations
Women of childbearing age requiring mood stabilization should be given the opportunity to 
weigh the risks and benefits of lithium treatment during pregnancy and the postpartum period 
and to develop an individualized treatment plan together with their healthcare providers in a 
specialized centre (24-27). Women with bipolar disorder are at very high risk for postpartum 
relapse without medication during pregnancy (66%, 95% CI 57–75), and for some women 
the benefits of lithium therapy may outweigh the potential risks (11, 28). However, for those 
women that are clinically stable without mood stabilization for an extended period prior to 
pregnancy, initiation of lithium prophylaxis immediately postpartum is probably sufficient (11, 
29). In this study, we evaluated the pharmacokinetics of lithium during pregnancy and in the 
period closely surrounding delivery. We confirmed that lithium dosing is challenging in this 
period and we have therefore summarized suggestions for dosing strategies: 
Pregnancy
1)  Monitor lithium blood levels frequently (for example once every 3 weeks) until 34 weeks of 
pregnancy, and then at least once weekly until delivery.
2) Before 17 weeks of pregnancy, anticipate progressively decreasing lithium levels. 
Afterwards, expect lithium levels to begin increasing. 
3)  Lithium blood levels should be maintained using a therapeutic blood level as low as 
possible and based on the personal history of the patient. It is therefore important to obtain 
preconception (reference) lithium and creatinine blood levels, and the corresponding 
lithium doses. 
4) Consider twice-daily lithium dosing to minimize peak lithium blood levels.
5) Consider regular creatinine blood level monitoring. A significant decrease in creatinine 
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levels during the first or second trimester suggests a clinically-meaningful pregnancy-
related increase in renal function.
6) Increase the frequency of lithium and creatinine blood level monitoring for women exhibiting 
signs of preterm birth, pre-eclampsia, dehydration or other illnesses that can affect renal 
function.
Delivery/postpartum
1)  Obtain lithium blood levels after delivery and twice weekly during the first 2 postpartum 
weeks. 
2)  Consider increasing the target therapeutic lithium blood level immediately after delivery 
and during the first month postpartum to optimize relapse prevention (for example ≥0.8 
mmol/L).
3)  Be aware of pharmacokinetic interactions with other medications such as non-steroidal 
anti-inflammatories.  
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DATA SUPPLEMENT 
FIGURE 1. Observed lithium blood levels in the perinatal periodFig. DS1 Observed lithium blood levels in the perinatal period
 
FIGURE 2. Creatinine blood levels during the peripartum period Fig. DS2 Creatinine blood levels during the peripartum period
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FIGURE 3. Correlation between lithium and corresponding creatinine blood levelsa
Fig. DS3 Correlation between lithium and corresponding creatinine blood levelsa
 
aDotted lines indicate upper thresholds for lithium and creatinine blood levels
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ABSTRACT
Background: Women with bipolar disorder are at high risk for relapse/recurrence 
postpartum. Among all mood stabilizers, lithium has the largest evidence base for efficacy in 
the peripartum period, but lamotrigine is increasingly prescribed for bipolar spectrum disorders 
during pregnancy. The aim of this study was to investigate whether lamotrigine use during 
pregnancy is as effective as lithium in the prevention of severe episodes postpartum.
Methods: Danish National registries were used to identify pregnancies of women with a 
diagnosis of bipolar spectrum disorders at the time of conception who used lamotrigine or 
lithium during pregnancy. We compared the risk of inpatient psychiatric admission within three 
months postpartum between women who used lamotrigine (N=55) versus lithium (N=59) 
during pregnancy. A logistic regression model was used to calculate crude and adjusted odds 
ratios.
 
Results: We did not find a significant difference in the risk of postpartum psychiatric admission 
between women who used lamotrigine versus lithium during pregnancy (7.3% versus 15.3% 
respectively, adjusted OR 0.83; 95% CI 0.22–3.14). We adjusted for year of delivery, parity, 
previous admissions and antidepressant/benzodiazepine use during pregnancy. Other 
variables did not differ substantially between groups. 
Limitations: We used an observational design and therefore patients were not randomized 
to lamotrigine or lithium. The study has a small sample size.
Conclusions: Lamotrigine was not inferior to lithium in the prevention of severe postpartum 
episodes. Our findings suggest lamotrigine could be a reasonable alternative treatment option 
for bipolar disorder during pregnancy in patients with vulnerability for depression and may 
prevent severe episodes postpartum. 
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INTRODUCTION
Guiding women with bipolar disorder through pregnancy and the postpartum period is a 
challenge for psychiatrists and obstetricians, especially because these women are at very high 
risk for relapse and recurrence postpartum (37%, 95% confidence interval 29% - 45%) (1). 
Treatment with a mood stabilizer increases the likelihood of maintaining mood stability during 
pregnancy and preventing postpartum episodes (2, 3). However, the benefits of medication 
use during pregnancy need to be carefully weighed against the risks to the fetus. Lithium is the 
most effective known mood stabilizer and therefore remains the gold standard for the treatment 
of bipolar disorder (4). However, data on lithium teratogenicity have been inconclusive, 
thereby complicating decision-making for women with bipolar disorder during pregnancy. 
In a recent meta-analysis, the association between lithium use during pregnancy and fetal 
malformations was non-significant, but the results were mainly based on small case-control 
studies (total n=264, range n=13-89 cases) (5). Over the past couple of decades, lamotrigine 
has increasingly been used during pregnancy as an alternative treatment option to lithium, due 
to its more favorable reproductive profile (6, 7). Large register-based studies including women 
with epilepsy (n=1019 and n=1280) reported finding no evidence for an increased risk of fetal 
malformations associated with in utero lamotrigine exposure (8, 9). However, the efficacy of 
lamotrigine during the peripartum period is largely unknown (3). Therefore, the aim of this study 
was to compare mood stabilization during pregnancy with lamotrigine versus lithium in the 
prevention of severe postpartum episodes. 
METHODS
We conducted a population-based cohort study using Danish National registers. This was 
possible as all live births and residents in Demark are assigned an unique personal identification 
number and registered in the Danish Civil Registration System, which allows linkage of data 
at the individual level within and between registers (10). Women with a history of bipolar 
spectrum disorder (including bipolar disorder I, II and not otherwise specified classifications) 
were identified in the Danish Psychiatric Central Research Register (DPCRR) (11) with 
International Classification of Diseases (ICD) codes 296.xx, 298.19 (ICD-8, 1969 - 1993) 
and F30-F31 (ICD-10, 1994 – present). Afterwards, pregnancies of women with at least one 
live born child in the period of 1996–2012, occurring after the diagnosis of bipolar disorder, 
were identified by linking the DPCRR to the Danish Medical Birth Registry (12) Our exposure of 
interest was lamotrigine or lithium use during pregnancy. The information on the dispensation 
of prescriptions was extracted from the Danish National Prescription Registry (13). We defined 
medication use during pregnancy as at least two prescriptions dispended between conception 
and delivery, with at least one prescription after the first trimester. Pregnancies in which women 
were prescribed more than one of the following mood stabilizers were not eligible for inclusion: 
lithium, lamotrigine, carbamazepine, oxcarbazepine, valproic acid, topiramate, or gabapentin. 
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 The primary outcome of the study was severe psychiatric relapse or recurrence, defined 
as any psychiatric admission for mental disorders (ICD-10 codes F00–F99) within three 
months postpartum. Unfortunately, we were not able to examine less severe psychiatric 
relapse/recurrence (operationally defined as episodes not resulting in an inpatient psychiatric 
admission). The Danish Registers do not allow for access to individual patient records, and 
therefore symptom-based information at outpatient visits during pregnancy and in the 
postpartum period was not available. We analyzed the data using Stata 13.1 (StataCorp, 
College Station, TX, USA). To compare the postpartum relapse/recurrence risk between 
women with lamotrigine or lithium use during pregnancy, a logistic regression model was used 
to calculate crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Robust 
standard errors were used to account for multiple pregnancies in the same woman during the 
study period. We divided the total dose of all prescriptions during pregnancy by gestational 
age (in days), in order to calculate the average prescribed dose of lamotrigine and lithium 
during pregnancy.
 Antipsychotic co-medication during pregnancy may prevent relapse/recurrence. 
Therefore, we performed a sensitivity analysis by repeating the analyses after exclusion of 
women with prescriptions of concurrent antipsychotic medication during pregnancy. The study 
was approved by the Danish Data Protection Agency. No informed consent is required for a 
register-based study with public health interest based on encrypted data in Denmark.
RESULTS
We identified N=891 women with bipolar spectrum disorders and N=1201 corresponding 
pregnancies. In the majority of pregnancies (N=1066) women received prescriptions of 
antidepressants, antipsychotics, other mood stabilizers, a combination of these prescriptions 
or no medication. In N=135 pregnancies, women received lamotrigine or lithium prescriptions. 
We excluded N=21 pregnancies because prescriptions were restricted to the first trimester 
(lamotrigine N=10, lithium N=0) or because women were prescribed more than one mood 
stabilizer (N=11). In total we included N=114 pregnancies with either lamotrigine (N=55) or 
lithium (N=59) use in our study. During pregnancy, the estimated average daily lamotrigine 
dose was 206 mg (SD 145); the average daily lithium dose was 721 mg (SD 330).
 A detailed overview of relevant patient characteristics of both groups is presented in Table 
1. We found a sharp increase of lamotrigine use during pregnancy across our study period 
(1996-2007 N=11 pregnancies; 2008-2012 N=44 pregnancies).
 Within the two-year period before conception, the proportion of outpatient visits was higher in 
the lamotrigine group compared to the lithium group (81.8% versus 49.2%); similarly the proportion 
of psychiatric admissions was higher in the lamotrigine group (43.6% versus 28.8%). Finally, in 
the lamotrigine group, women more frequently had depressive episodes (30.9% versus 8.5%). 
Risk of postpartum episodes after lamotrigine or lithium use during pregnancy
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TABLE 1. Characteristics of women with either lamotrigine or lithium use during pregnancya,b
Lamotrigine 
(N=55)
Lithium 
(N=59)
Postpartum psychiatric admission (<3 months) 4 (7.3) 9 (15.3)
Demographics
   Age at delivery (years), mean ± SD 31.8 ± 4.7 34.1 ± 4.5
   Year of deliveryc
   1996 – 2007 11 (20.0) 34 (57.6)
   2008 – 2012 44 (80.0) 25 (42.4)
   Married or cohabiting 39 (70.9) 46 (78.0)
   Income above the lowest quartile 38 (69.1) 33 (55.9)
Preconception
   Age at bipolar disorder diagnosis (years), mean ± SD 26.8 ± 4.1 25.2 ± 4.6
   First lithium/lamotrigine prescription <1 year before     
   conception 
8 (14.5) 7 (11.9)
   Other mood stabilizer prescriptions <1 year before 
   conception
<4 (<7.3) 0
   Psychiatric admissions < 2 years before conceptionc 24 (43.6) 17 (28.8)
   Psychiatric outpatient visit(s) < 2 years before conception 45 (81.8) 29 (49.2)
   Depressive episodes < 2 years before conception 17 (30.9) 5 (8.5)
   (Hypo)manic episodes < 2 years before conception 8 (14.5) 12 (20.3)
Pregnancy 
   Antipsychotic co-medication 18 (32.7) 19 (32.2)
   Antidepressant co-medicationc 34 (61.8) 20 (33.9)
   Benzodiazepine co-medicationc 8 (14.5) 17 (28.8)
   Psychiatric admissions(s) <4 (<7.3) 4 (6.8)
   Outpatient visit(s) 23 (41.8) 23 (39.0)
   Primiparityc 30 (54.5) 27 (45.8)
   Caesarean section 12 (21.8) 14 (23.7)
   Preterm birth 8 (14.5) 10 (16.9)
   Obstetric complicationsd 17 (30.9) 14 (23.7)
Postpartume
   Continuation lamotrigine / lithium postpartum 45 (81.8) 53 (89.8)
   Antipsychotic co-medication 19 (34.5) 35 (59.3)
   Antidepressant co-medication 40 (72.7) 30 (50.8)
   Benzodiazepine co-medication 17 (30.9) 32 (54.2)
a Medication use during pregnancy was defined as the dispensation of two prescriptions between conception and 
delivery, with at least one prescription after the first trimester.
b Figures are numbers (%) unless stated otherwise.
c Variables included in a multivariate logistic regression model: year of delivery, psychiatric admission <2 years prior 
to conception, antidepressant and benzodiazepine co-medication during pregnancy and primiparity.
d Pre-eclampsia, fetal stress, gestational diabetes, gestational hypertension, nausea/vomiting or postpartum 
hemorrhage.
e These proportions are likely to be an underestimation, because we could not include prescriptions written during 
inpatient hospitalization.
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During pregnancy, combination therapy with antidepressants was used more often in the 
lamotrigine group (61.8% versus 33.9%); whereas benzodiazepines were prescribed more 
often in the lithium group (28.8% versus 14.5%). Other variables relevant to our analyses 
included age, marital status, income, parity, obstetric complications, age of disease onset, use 
of antipsychotic co-medication, and admissions/outpatient visits during pregnancy, but none 
of these differed substantially between the two groups.
 We found an overall risk for postpartum psychiatric admission of 11.4% (N=13/114). 
There was no significant difference in risk of postpartum psychiatric admission between 
women with lamotrigine use during pregnancy (N=4, 7.3%) compared to those with lithium 
use (N=9, 15.3%). We further adjusted for variables that were unequally distributed between 
groups (year of delivery, psychiatric admission <2 years prior to conception, antidepressant 
and benzodiazepine co-medication use during pregnancy) and for primiparity because this 
variable is strongly related to relapse/recurrence risk. After these adjustments, lamotrigine 
use during pregnancy was not associated with an increased risk of postpartum psychiatric 
admission compared to lithium use (adjusted OR 0.83; 95% CI 0.22 – 3.14). The polarity of 
the N=13 postpartum episodes was as follows: mania or psychosis (N=7, 53.8%), depression 
or other diagnosis (N=6, 46.2%). We observed no significant difference in the polarity of 
postpartum episodes between the lamotrigine and lithium group (Fisher exact test, p=0.20).
 A sensitivity analysis among women without concurrent antipsychotic medication during 
pregnancy showed no significant difference between the lamotrigine and lithium group in 
the risk of a subsequent postpartum psychiatric admission (adjusted OR 0.55; 95% CI 0.12–
2.51).
DISCUSSION
In this population-based study, we found similar postpartum inpatient admission risks after 
lamotrigine and lithium use during pregnancy. If replicated, this finding is of clinical importance, 
since lamotrigine is considered to be a more favorable option than lithium with regard to the 
risk of adverse neonatal outcomes (14). In line with a previous study from the United Kingdom 
(7), we found an increase in lamotrigine use over the last decades in Denmark. Previous studies 
demonstrated that lamotrigine is particularly effective in bipolar disorder for the prevention of 
depressive episodes (15). Indeed, in our study women using lamotrigine were more likely to 
have a history of depressive episodes. Accordingly, two-thirds of the women in the lamotrigine 
group used antidepressant co-medication. Therefore, in an effort to reliably compare outcomes 
of women using lamotrigine or lithium, we adjusted for several clinical variables, including the 
use of antidepressant medication.
 Overall, our study sample is likely to reflect women with a more severe disease course, 
as exemplified by the high proportion with psychiatric admissions in the two years prior to 
Risk of postpartum episodes after lamotrigine or lithium use during pregnancy
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conception and the high rate of antipsychotic and antidepressant co-medication. Moreover, 
the vast majority of women received their initial lamotrigine or lithium prescription more than 
one year before conception, indicating long-term use of maintenance treatment. 
 Our study has several limitations. First, our study has a small sample size. Consequently, 
we may have insufficient statistical power to detect significant difference between the two 
groups. Second, our study could suffer from confounding by indication because lithium was 
predominantly prescribed in patients with a history of manic episodes, while lamotrigine was 
primarily prescribed to women with a particular vulnerability for depressive episodes. Notably, 
this is consistent with the current bipolar disorder treatment guidelines. Third, we had an 
insufficient number of cases to conduct any stratified analyses for postpartum medication use. 
Fourth, our study was not designed to detect less severe postpartum episodes, and therefore our 
results cannot be generalized to such episodes. Lastly, the perinatal effectiveness of lamotrigine 
is largely unknown for patients with predominantly manic episodes in history. 
Clinical considerations
In women with bipolar disorder, discontinuation of mood stabilizing medication has been 
associated with an increased risk of relapse/recurrence during pregnancy (2, 3). Accordingly, 
the benefits of continuing medication during pregnancy appear to outweigh the potential risks, 
especially in patients with a recent history of severe mood episodes. If patients and clinicians 
decide to continue medication, dosing can be challenging because pregnancy-related 
physiological changes induce substantial blood level fluctuations (16, 17). Both lithium and 
lamotrigine blood levels decrease across pregnancy, with a resultant increased risk of symptom 
worsening. To maintain mood stability, the doses of both lithium and lamotrigine often need to 
be increased to adjust for declining blood concentrations. Accordingly, frequent blood level 
monitoring is recommended during pregnancy for both lithium and lamotrigine (e.g., once 
every three to four weeks) (16, 17).
 For lithium, blood levels usually start to increase during the third trimester and therefore 
monitoring should be performed once a week beginning in week 34 (16). Postpartum, 
clinicians could aim at higher lithium blood levels (e.g. 0.8 mmol/L) because of the high 
relapse/recurrence risk during this period, and monitoring twice a week is advised (16). 
Lamotrigine blood levels rapidly normalize to pre-pregnancy concentrations during the early 
postpartum period. If the dose is titrated during pregnancy, it must be tapered immediately 
postpartum to the therapeutic preconception dose to prevent toxicity. During the postpartum 
period, lamotrigine plasma concentrations should be monitored weekly for patients with dose 
increases during pregnancy (17).
 With regard to breastfeeding, lamotrigine may be a more favorable option than other mood 
stabilizers according to a recent review (18). However, close monitoring of infants exposed to 
lamotrigine via breastmilk for signs of toxicity (e.g. apnea and rash) is recommended. With the 
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exception of one case of apnea, no adverse reactions have been reported in infants exposed 
to lamotrigine through breastmilk (18).
 Although the literature is inconsistent regarding whether lithium is contraindicated during 
breastfeeding, case series from breastfeeding mothers with lithium do not report toxicity or 
developmental delays. Although no serious adverse effects have been observed, close 
observation and monitoring of thyroid and renal function is recommended (18).
Conclusions
Management of bipolar disorder during and after pregnancy is challenging, especially 
because the postpartum period is associated with the highest lifetime risk of hospitalization 
for women with bipolar disorder (19). In this study, lamotrigine was not inferior to lithium in 
the prevention of severe postpartum episodes. Lamotrigine could be a reasonable alternative 
treatment option for bipolar disorder during pregnancy in patients with vulnerability for 
depression and may prevent severe episodes postpartum. Notably, our results will require 
replication before reaching definitive conclusions.
Risk of postpartum episodes after lamotrigine or lithium use during pregnancy
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MAIN CONCLUSIONS OF THIS THESIS
Bipolar disorder during pregnancy and the postpartum period 
- Women with a history of bipolar disorder are at very high risk of recurrence during the 
postpartum period (chapter 2).
- Lithium use during pregnancy and the postpartum period is associated with a low recurrence 
risk (chapter 7 and 8).
- Lamotrigine use during pregnancy and the postpartum period may be a reasonable 
alternative to lithium for women with vulnerability for depressive episodes (chapter 8).
- There is substantial fluctuation in lithium blood levels during the peripartum period because 
of physiological adaptions of renal function. Sub-therapeutic lithium blood levels may 
increase the risk of recurrence, while toxic lithium blood levels increase the risk of (neonatal) 
adverse effects. Accordingly, it is important to perform regular monitoring of lithium blood 
levels and renal function (chapter 7).
- The benefits of continuing moodstabilizing medication both during pregnancy and the 
postpartum period may outweigh the potential risks in women with bipolar disorder that 
suffered of recent and severe mood episodes (chapter 2, 3 and 8).
 
Postpartum psychosis: prevention, course and phenomenology
- Women with a history of postpartum psychosis are at higher risk of severe postpartum 
episodes than women with bipolar disorder (chapter 2)
- In case of a subsequent pregnancy, the initiation of lithium prophylaxis immediately 
postpartum is sufficient to prevent postpartum recurrence. Consequently, in utero medication 
exposure to the fetus can be avoided (chapter 2 and 3).
- Postpartum psychosis is an affective disorder. Besides psychotic symptomatology, 
its phenomenology is characterized by the presence of depressive and/or manic 
symptomatology. In some cases, women also present with atypical symptoms such as 
disturbance of consciousness, disorientation and depersonalization (chapter 4).
- Even though there is a close link between postpartum psychosis and bipolar disorder, it is 
of clinical importance to maintain the diagnostic concept of postpartum psychosis (chapter 
1, 2 and 3).
 
First-onset postpartum depression and auto-immune dysfunction
- A positive TPO-ab status during early pregnancy is associated with an increased risk of 
self-reported first-onset postpartum depression. This finding suggests that auto-immune 
dysregulation may be an underlying biological mechanism that is related to the etiology of 
first-onset postpartum depression (chapter 5).
- Evaluation of thyroid function is essential in women with first-onset postpartum depression 
(chapter 5). 
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EFFICACY OF MAINTENANCE TREATMENT DURING THE 
PERIPARTUM PERIOD IN WOMEN WITH BIPOLAR DISORDER
Previous literature
In this thesis we demonstrated that the postpartum period is a major trigger of recurrence among 
women with bipolar disorder. The efficacy of moodstabilizing medication during this vulnerable 
period is poorly studied. In our systematic review and meta-analysis, we could not identify 
any randomized controlled trials. This is probably a result of concerns among researchers 
regarding ethical aspects and feasibility. Regarding observational research, two studies (n=28; 
n=89) (1, 2) specifically assessed the efficacy of lithium during pregnancy. One additional 
study compared the risk of recurrence between n=10 patients that continued lamotrigine 
versus n=5 patients that discontinued (n=5) lamotrigine during pregnancy (3). The results 
showed that discontinuation of both lithium and lamotrigine during pregnancy was associated 
with an increased risk of recurrence. Six small studies (4-10) (range n=11-41) assessed the 
efficacy of maintenance treatment during the postpartum period (lithium n=4, olanzapine n=1, 
valproate n=1). Women that used lithium and olanzapine during the postpartum had a lower 
risk for recurrence than medication-free women. Immediate initiation of valproate during the 
postpartum period was not effective in the prevention of postpartum episodes (control group 
medication-free women).
 Previous studies regarding the efficacy of maintenance treatment during the peripartum 
period have several important limitations. First, all studies have a (very) small sample size. 
Second, in none of the studies estimates were adjusted for potential confounders (this is 
particularly concerning because of the high risk of confounding by indication). Third, none of 
the studies compared the efficacy of different moodstabilizers. Notably, no studies focused on 
the antenatal efficacy of second generation antipsychotics, while this group of medication is 
increasingly used during pregnancy (11). 
This thesis
The results of this thesis increase the knowledge about the efficacy of mood-stabilizing 
medication during the peripartum period in women with bipolar disorder. First, the results of our 
meta-analysis showed that women who used maintenance treatment during pregnancy and 
the postpartum period were at much lower risk for recurrence than medication-free women. 
Notably, this pooled analysis included only n=66 women that used maintenance treatment 
postpartum (mostly lithium). Second, we demonstrated that maintenance treatment with lithium 
during pregnancy and the postpartum period was associated with a low recurrence risk in both 
a Dutch clinical cohort (n=89 women) and a Danish population based cohort (n=59 women). 
Third, we performed the first study comparing the efficacy of two different moodstabilizers 
(lithium versus lamotrigine) and adjusted our analyses for several potential confounders. We 
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observed low and similar postpartum inpatient admission risks after lamotrigine and lithium use 
during pregnancy. This is of clinical importance, because lamotrigine might be a safer option 
than lithium with regard to the risk of adverse neonatal outcomes.
 The studies in this thesis have several limitations. In our Danish population based cohort 
study, we compared the risk of recurrence postpartum between women that used lithium and 
lamotrigine during pregnancy. Although we adjusted for several potential confounders, our 
study may still be at risk of confounding by indication because detailed clinical information 
(e.g. disease severity) is not available in the Danish registers. Second, because of the 
limited sample size and small number of events (postpartum episodes) our study may have 
been underpowered for appropriate adjustment for confounders and to detect a potential 
difference between the two groups. Finally, we were not able to perform stratified analyses 
for postpartum medication use. Accordingly, it is unclear to what extend potential changes in 
postpartum medication regimes (e.g. sub-therapeutic blood levels, dose adjustments, initiation 
of co-medication) have influenced the observed recurrence rates.
 In our meta-analysis, we observed substantial heterogeneity across studies regarding 
the risk of recurrence. Methodological differences in study design (e.g. clinical cohort 
versus population based studies) and the severity of recurrence were important sources of 
heterogeneity. However, data from included studies was insufficient to take into account clinical 
predictors of recurrence that have been previously described in the literature, such as psychiatric 
history (e.g. number of previous (peripartum) mood episodes, recent admissions), psychosocial 
factors, parity, recurrence during pregnancy, family history, obstetric complications and co-
medication (6, 12-19). Accordingly, the recurrence risk estimates of our meta-analysis are 
probably not accurate for individual patients.
 
RISKS OF MAINTENANCE TREATMENT DURING PREGNANCY 
IN WOMEN WITH BIPOLAR DISORDER
In utero exposure to (psychiatric) medication can potentially result in an increased risk of neonatal 
complications (20). Examples include spontaneous abortion, congenital malformations, preterm 
birth, low birth weight, persistent pulmonary hypertension of the newborn (PPHN) syndrome, 
poor neonatal adaptation syndrome (PNAS), and an increased risk of autism or other negative 
long-term effects on neuro-cognitive development (20). Accordingly, cautiousness is required 
when prescribing medication to women during their childbearing ages/pregnancy (20).
 A careful evaluation of potential teratogenic effects of medication is particularly relevant for 
women with bipolar disorder because the onset of the illness is typically during the childbearing 
ages, maintenance treatment is often prescribed for a long period and there is an increased 
risk of unplanned pregnancies (21, 22). In the next paragraphs, we will briefly summarize the 
current evidence regarding potential risks of in utero exposure to medication that is commonly 
used as maintenance treatment for women with bipolar disorder.
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Lithium
The evidence regarding the potential risks of lithium use are already subject of debate for several 
decades. The first study about the association between lithium use during pregnancy and neonatal 
malformations in humans was published in 1973 (23). In this retrospective study, data from 
“the register of lithium babies” (n=118) showed a high prevalence of congenital malformations 
(7.6%). In a subsequent study (published in 1975), including data from the same register 
(n=212), the authors observed an even higher risk of malformations (10.4%) and a specifically 
increased risk of cardiac malformations (24). Notably, the authors emphasized in the abstract 
of their publication that the data probably overestimates the risk of teratogenicity (high risk of 
selection bias) (23). Several subsequent cohort- and case control studies showed conflicting 
results. In a recent meta-analysis of case-control studies (2012), the association between lithium 
exposure during pregnancy and both the risk of overall malformations and Ebstein’s anomaly 
was not significant (25). However, the authors stated that the risk the risk of teratogenicity 
is still uncertain because only a small number of events were included in the analyses (25). 
Recently, Patorno and colleagues (26) published the largest study to date about the association 
between lithium use during the first trimester of pregnancy and (cardiac) malformations. 
The study was conducted with non-private US health care insurance data (Medicaid) and 
included lithium exposed pregnancies (n=663), lamotrigine exposed pregnancies (n=1945; 
control group 1) and non-exposed pregnancies (n=1,322,955; control group 2). Lithium 
use was associated with an increased risk of both overall malformations (OR 1.85, 95% CI 
1.23-2.78) and cardiac malformations (OR 2.25 95% CI 1.17-4.34) (reference=lamotrigine 
exposed pregnancies). The authors also observed a dose-response effect regarding the risk of 
cardiac malformations. Taken together, lithium is probably associated with an increased risk 
of (cardiac) malformations, but the magnitude is much lower than initially was reported (26). 
 Because of its small therapeutic window, lithium use during pregnancy can also potentially 
result in other neonatal complications. However, data about this topic is scarce. The results of 
a small cohort study (n=32) suggested that high lithium blood levels may increase the risk of 
several neonatal adverse events (lower APGAR-scores, longer hospital stays, low muscle tone) 
(27). In this thesis, we performed the first pharmacokinetic study that focused on the longitudinal 
course of lithium blood levels during the peripartum period. We found that pregnancy induces 
substantial fluctuation in lithium blood levels and that there is a particularly increased risk of 
high lithium blood levels during the last phase of the third trimester. Accordingly, the risk of 
neonatal adverse effects can be reduced with regular blood monitoring.
 
Anticonvulsants and second generation antipsychotics
The results of studies on teratogenic effects of in utero exposure to valproate are consistent: 
there is a ~10% risk of malformations (including neural tube defects, cranio-facial anomalies, 
cardiac defects) (20, 28, 29). In addition, studies reported an increased risk of PPHN 
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syndrome, delayed neuro-cognitive development and autism (20, 29-31). Therefore, use of 
valproate should be avoided during the childbearing ages. Use of carbamazepine is also 
associated with an increased risk of malformations (neural tube defects, cranio-facial anomalies 
and several other malformations) (20, 29, 32), but the risks are smaller than for valproate. 
According to a systematic review, the prevalence of major congenital malformations after use 
of carbamazepine (monotherapy) during the first trimester is 3.3% (95% CI 2.7-4.2) (32). 
In an additional case control-study regarding the risk for specific malformations, the authors 
only found a significantly increased risk for spina bifida (OR 2.6, 95% CI 1.2-5.3). Studies on 
potential negative neuro-cognitive development reported conflicting results (29).
 Lamotrigine has a more favorable risk profile than other anticonvulsants (valproate and 
carbamazepine) (33). Several large register studies showed no increased risk of malformations 
after lamotrigine during pregnancy (34, 35). However, potential risks of neonatal and long-
term developmental adverse effects are poorly studied (36, 37).
 A recent very large study that included n=9,237 women that used atypical antipsychotics 
during the first trimester of pregnancy found no increased risk of congenital malformations 
after adjustment for a wide range of potential confounders. The analyses for individual agents 
showed that risperidone was associated with a slightly increased risk of overall malformations 
(OR 1.26, 95% CI 1.02-1.56) (38). The risk for other adverse effects need further investigation 
because some studies indicated that use of second generation antipsychotics may be associated 
with an increased risk of obstetric or neonatal complications such as prematurity, both low and 
high birth weight, gestational diabetes and PNAS (39, 40). Potential negative long term effects 
of in utero exposure to second generation antipsychotics are poorly studied (40).
 
CLINICAL RECOMMENDATIONS
Clinicians encounter a lot of uncertainty with regard to the treatment of women with bipolar 
disorder during the peripartum period. The efficacy of maintenance treatment during this 
vulnerable period is poorly studied. Data on the risks of in utero exposure to medication are 
often inconclusive or lacking, especially with regard to potential long-term adverse effects. 
Decision making is highly complex because the potential risks of maintenance treatment 
should be carefully weighed against a higher vulnerability for the onset of mood-episodes in 
medication-free women, with resultant illness-related risks for both the mother and her (unborn) 
child (39). In Table 1 we provide general clinical recommendations that may be helpful to 
guide women with bipolar spectrum disorder throughout the peripartum period (20, 41-43).
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TABLE 1. General clinical recommendations
- Encourage shared-decision making.
- Use clinical information (e.g. current use of maintenance treatment, recent mood episodes) to 
estimate a patients’ individual risk of (postpartum) recurrence.
- Carefully weigh both medication and illness related risks of maintenance treatment during 
pregnancy. 
- In case women are not using maintenance treatment during pregnancy and there are no signs of 
recurrence, we recommend to initiate prophylaxis with moodstabilizing medication immediately 
after childbirth (e.g. lithium, ≥0.8 mmol/l). 
- Be aware of pharmacokinetic alterations that occur because of pregnancy related physiological 
adaptations in renal and hepatic function. 
- Do not prescribe valproate during pregnancy because of a highly increased risk of teratogenicity.
- Prescribe the lowest effective dose.
- Avoid polypharmacy.
- Draft an individualized peripartum plan, if possible before the onset of pregnancy. 
- Work in a multidisciplinary setting, together with gynecologists and pediatricians.
- Ensure close monitoring during the first weeks postpartum period, be aware of potential signs of 
recurrence.
DIRECTIONS FOR FUTURE RESEARCH
The National Postpartum Psychosis Prevention study (NP3-study)
The NP3-study is part of the OPPER-study (Onderzoeksprogramma Postpartum Psychose, 
Erasmus MC Rotterdam) and was designed to further investigate the efficacy and potential 
(long term) neonatal/child adverse effects of maintenance treatment during the peripartum 
period in women with a history of bipolar disorder and/or postpartum psychosis. In this study, 
we prospectively assess the outcome of pregnancies of women at high risk of recurrence. 
The primary outcome of the NP3-study is recurrence during the postpartum period. We 
ask participants to complete digital questionnaires at 32 weeks gestation and at 1 week, 6 
weeks and one year postpartum. We collect demographic information and use validated 
questionnaires to assess symptoms of anxiety, depression and/or (hypo)mania, social support 
and potential symptoms of physical distress (repeated measurements). In addition, we use 
psychiatric/obstetric medical records to collect detailed information regarding psychiatric 
history (e.g. number of mood-episodes, family history), current use of maintenance treatment 
and/or other medication (including dose adjustments/blood levels), the occurrence of 
mood episodes during pregnancy and the postpartum period, somatic comorbidity and 
obstetric complications/neonatal complications (e.g. congenital malformations). If necessary, 
information is verified during a telephone interview. If patients are included in Erasmus MC, 
we also collect blood cells and serum biomarkers during the third trimester. Finally, we will 
soon start with follow-up measures at 2 and 3.5 year postpartum. With face-to-face interviews 
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and questionnaires we will assess the development of the child and the disease course of the 
mother.
 The design of the NP3-study was adapted to match with the design of the Holistic 
approach to Pregnancy and first Postpartum Year (HAPPY(-Follow)) study. The HAPPY-study is 
a population based prospective cohort study (n=2269 pregnant women) that was conducted 
by Prof. dr. V.J.M. Pop (Tilburg University) and will be used as a control group for several NP3-
study objectives.
 The prospective recruitment of patients for the NP3-study started in 2013 in Erasmus MC 
and at fifteen hospitals throughout the Netherlands, in collaboration with investigators of the 
SLEEPREGBD-study (A. Stevens, Prof. dr. R.W. Kupka and Prof. dr. A. Honig). The main aim of 
the SLEEPREGBD-study is to investigate whether sleep disturbance is a predictor of recurrence 
during the postpartum period in women with a history of bipolar disorder and/or postpartum 
psychosis.
 To date, we were able to include approximately n=100 patients in the NP3-study, which is 
convincing giving the low prevalence of pregnant women with a history of bipolar disorder/
postpartum psychosis. Moreover, the NP3-study includes retrospective data of n=150 
pregnancies (referrals to Erasmus MC and LUMC between 2003-2013). In the coming years, 
we will enlarge the NP3-study cohort. The data of the NP3-study will be used for the following 
topics/objectives:
Individualized postpartum recurrence risk prediction
An individual accurate postpartum recurrence risk estimate is essential to properly weigh the 
risk and benefits of maintenance treatment during the peripartum period. In our meta-analysis, 
we observed an one out of three recurrence risk during the postpartum period for women with 
a history of bipolar disorder or postpartum psychosis. However, as mentioned earlier, this 
estimate may not be accurate because clinical determinants will influence the risk of recurrence 
across patients. Accordingly, the data of the NP3-study will be used to identify potential 
determinants of recurrence (e.g. psychiatric family history, number of previous mood episodes), 
that can be used to determine the risk of recurrence for individual patients.
Efficacy of maintenance treatment during the peripartum period
Enlargement of the NP3-study cohort and international collaboration will enable us to (further) 
investigate the efficacy of maintenance treatment during pregnancy and the postpartum period. 
Specifically, it will be interesting to replicate the findings of our population based study on the 
efficacy of lamotrigine. In addition, we will compare the efficacy of lithium, lamotrigine and 
second-generation antipsychotics (quetiapine, olanzapine, risperidone). Detailed clinical data 
will be used to adjust for potential confounders such as disease severity and the occurrence of 
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previous mood-episodes during the postpartum period. In addition, it is important to differentiate 
between women with bipolar I and II disorder and to take into account co-medication. In 
women with an isolated history of postpartum psychosis, use of maintenance treatment during 
pregnancy can be avoided. Accordingly, in this group we will focus on the optimal duration of 
prophylactic treatment after a subsequent delivery.
Risks of maintenance treatment during pregnancy
We will mainly focus on the potential risks of in utero exposure to lithium, because this is the 
most commonly used moodstabilizer among women that are included in the NP3-study. We are 
currently investigating whether lithium use during pregnancy is associated with a broad range 
of adverse effects including pregnancy complications, delivery outcomes, malformations, and 
neonatal admissions. For this project, we included n=115 children born to mothers with lithium 
use during pregnancy and a control group of n=88 children born to mothers with a bipolar 
spectrum disorder. Because of the low prevalence of several outcome measures, we are 
collaborating with other investigators in an international consortium: the data of the NP3-study 
will be analysed together with data from five other international study sites in a meta-analysis 
(aggregate level).
Child development after in utero exposure to maintenance treatment
The follow-up measurements at 2 and 3.5 year postpartum will be used to investigate 
potential negative long-term effects of in utero-exposure to maintenance treatment on child 
development. We will focus on language, cognitive and social-emotional development and 
behavior. Children born to mothers with a bipolar spectrum disorder without in utero exposure 
to medication and children that are participating in the HAPPY-follow study will be used as 
control groups.
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PART I. MOOD DISORDERS DURING THE POSTPARTUM PERIOD
Bipolar disorder and postpartum psychosis
Women with a history of bipolar disorder or postpartum psychosis are at high risk for 
postpartum recurrence. However, there is high variability in reported recurrence rates 
across studies. A weighted recurrence risk estimation is essential in order to carefully 
weigh the risks and benefits of medication use during pregnancy and the postpartum 
period. Therefore, the aim of the systematic review and meta-analysis that is described in 
chapter 2 was to estimate the risk of postpartum recurrence in women with a history of bipolar 
disorder or postpartum psychosis. We conducted a systematic literature search in all public 
medical electronic databases and included 37 articles describing the outcome of 5,700 
deliveries in the quantitative analyses. We observed an one out of three overall recurrence 
risk in the combined analysis. The distinction between women with bipolar disorder and those 
with a history of postpartum psychosis is of substantial clinical relevance because patients 
with a history of postpartum psychosis were at higher risk for severe episodes postpartum than 
patients with bipolar disorder. 
 Studies that assessed the efficacy of moodstabilizing medication during the peripartum 
period were scarce. Even though we were able to conduct a small sub-analysis that indicated 
that prophylactic medication (mostly lithium) use during pregnancy was highly effective in the 
prevention of postpartum recurrence. However, as mentioned earlier, the benefits of prophylactic 
pharmacotherapy during pregnancy should be weighed against the potential adverse effects of 
in utero medication exposure. In general, the benefits of continuing moodstabilizing medication 
during pregnancy appear to outweigh the potential risks, especially in patients with a recent 
history of severe mood episodes. Polypharmacy should always be avoided, and clinicians 
should aim at the lowest effective dose. 
The aim of chapter 3 was to discuss diagnostic considerations, treatment and the prevention of 
postpartum psychosis, and to give clinical recommendations. Postpartum psychosis is a severe 
psychiatric disease which occurs in the early postpartum period after approximately 1 per 
1000 deliveries. Postpartum psychosis is in general considered as a mood disorder, because 
affective symptoms are a hallmark of the disorder, but is not classified as a separate disorder 
in the Diagnostic and Statistical Manual of Mental Disorders (DSM–5). The main reason for 
the absence of a separate disease status is the close link between postpartum psychosis and 
bipolar disorder. In a substantial proportion of women, first-onset postpartum psychosis is 
the incipient episode of a bipolar disorder disease course. However, it is of major clinical 
importance to maintain the diagnostic concept of postpartum psychosis because a substantial 
group of women with a history of postpartum psychosis is only vulnerable for illness episodes 
during the postpartum period. Those women have a favorable prognosis and therefore there is 
no indication for long-term maintenance treatment.
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 If the diagnosis postpartum psychosis is suspected, an inpatient psychiatric admission 
(preferably at a mother-baby unit) is necessary to ensure the safety of mother and baby and to 
exclude known organic causes (e.g. thyroid disorders, encephalitis) of postpartum psychosis. 
A combined treatment with an antipsychotic and lithium is highly effective. With adequate 
treatment, almost all patients achieve complete remission. After a subsequent pregnancy, 
Initiation of prophylaxis immediately postpartum is highly effective for the prevention of 
postpartum recurrence. 
In chapter 4, we describe the outcome of a study on the phenotypical characteristics of 
postpartum psychosis. Besides the presence of psychotic symptomatology, most women also 
suffer of a broad spectrum of other symptoms. The aim of this study was to describe postpartum 
psychosis symptomatology, and to identify subgroups of patients based on symptom profiles. 
Participants in this study were obtained from the OPPER-cohort. We included n=130 women 
with postpartum psychosis that were admitted to the psychiatric mother-baby inpatient unit of 
Erasmus MC (2005-2015). We prospectively assessed a wide range of symptoms with several 
repeated (self-rating) questionnaire assessments and by using information from medical records 
and a diagnostic interview. The most prevalent symptoms were irritability (73%), abnormal 
thought content (72%), and anxiety (71%). Using a person-centered analytic approach (latent 
class analysis), we identified three symptom profiles, a depressive (41%), manic (34%), or 
atypical (25%) profile, respectively. The depressive profile was characterized by depressive 
and anxiety symptoms, the manic profile by manic symptoms and agitation and the atypical 
profile by disturbance of consciousness, disorientation, depersonalization and derealisation. 
Based on or findings, we concluded that atypical symptoms were less prevalent than previously 
suggested in the literature. Instead, the depressive profile was the most prevalent, but the 
depressive profile can easily remain undetected, which could lead to treatment delay and risk 
of suicide/infanticide.
Thyroid auto-immunity and postpartum depression
During the postpartum period, women are at risk for new onset of both auto-immune thyroid 
disorders and depression. The presence of thyroid peroxidase antibodies (TPO-ab) during 
early gestation is predictive for postpartum auto-immune thyroid dysfunction. Interestingly, TPO 
has also been named as a predictor for postpartum depression. However, previous studies 
that investigated the association between a positive TPO-ab status during early gestation and 
postpartum depression are likely to be confounded by the presence of antenatal depression. 
Therefore, the aim of the study that is described in chapter 5 was to investigate the association 
between TPO-ab status during early gestation and first-onset postpartum depression. The study 
population was recruited from a large prospective cohort (HAPPY-study). We included n=1075 
women without a history of psychiatric illness that were followed throughout pregnancy and 
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the first postpartum year. Women with a self-reported lifetime history of depression were 
excluded. Since our outcome variable was first-onset depression, we excluded women with a 
self-reported lifetime history of depression as well as women with depression during the course 
of their pregnancy. Postpartum depression was defined with a commonly used and validated 
cut-off score of ≥13 on the Edinburg Depression scale (EDS). The cumulative incidence of first-
onset postpartum depression within one year after delivery was 6.3%. A positive TPO-ab status 
was associated with an increased risk for first-onset depression at four months postpartum, 
but not at other postpartum time points. Interestingly, the longitudinal pattern of postpartum 
depression in the TPO-ab positive group was similar to the typical course of postpartum TPO-
ab titers changes. This suggests overlap in the etiology of first-onset postpartum depression and 
auto-immune thyroid dysfunction. Based on the findings of our study we advise to evaluate 
thyroid function in women with first-onset postpartum depression. 
PART II. LITHIUM USE DURING PREGNANCY AND THE 
POSTPARTUM PERIOD IN BIPOLAR DISORDER 
Lithium is the most effective moodstabilizer for the treatment of bipolar disorder but its use has 
declined over the last decades. In chapter 6, we provide a general introduction on the history, 
potential mechanisms of action and clinical aspects of lithium therapy. 
 In chapter 7, we describe a retrospective cohort study that focuses on lithium dosing 
strategies during pregnancy and the postpartum period. Lithium has a narrow therapeutic 
window and careful monitoring is specifically warranted during the peripartum period because 
of physiological changes in renal function. Current clinical guidelines provide limited details 
regarding the optimal approach for monitoring lithium blood levels during pregnancy and the 
postpartum period. Therefore, in an effort to define an evidence-based strategy for dosing 
lithium during pregnancy, we quantified the longitudinal pattern of lithium blood levels during 
the peripartum period. 
 All pregnant women that were referred to the psychiatric and obstetric out-patient clinics of 
Erasmus MC and LUMC between 2003 and 2015 were screened for inclusion. We included 
n=113 pregnancies for which lithium blood levels were measured during pregnancy and the 
postpartum (n=1,101). On average, lithium blood levels decreased up to -36% in the second 
trimester. During this period, it is often necessary to increase a patients’ lithium dose to maintain 
adequate prophylactic blood levels. In the third trimester and postpartum period, lithium blood 
levels gradually returned to the preconception level. During this period, there is an increased 
risk for toxic lithium blood levels. Delivery itself was not associated with an acute change 
in lithium and creatinine blood levels. Based on the findings of our study, we summarized 
recommendations regarding peripartum lithum dosing that are useful to minimize the risk for 
both sub-therapeutic and toxic blood levels.
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As mentioned earlier, lithium has the largest evidence base for efficacy in the peripartum period 
among all mood stabilizers. However, data on lithium teratogenicity have been inconclusive, 
thereby complicating decision-making for women with bipolar disorder during pregnancy. Over 
the past couple of decades, lamotrigine has increasingly been used during pregnancy as an 
alternative treatment option to lithium, due to its more favorable reproductive profile. However, 
the efficacy of lamotrigine during the peripartum period is largely unknown. Therefore, the 
aim of the study that is presented in chapter 8 was to compare mood stabilization during 
pregnancy with lamotrigine versus lithium in the prevention of severe postpartum episodes. 
Danish National registries were used to identify pregnancies of women with a diagnosis of 
bipolar spectrum disorders at the time of conception who used lamotrigine or lithium during 
pregnancy (1996-2012). Afterwards, we compared the risk of inpatient psychiatric admission 
within three months postpartum between women who used lamotrigine versus lithium during 
pregnancy. The overall risk for postpartum psychiatric admission was 11.4%. We did not find a 
significant difference in the risk of postpartum psychiatric admission between women who used 
lamotrigine versus lithium during pregnancy, even after adjustment for potential confounders. 
This finding is of clinical importance, since lamotrigine is considered to be a more favorable 
option than lithium with regard to the risk of adverse neonatal outcomes. However, the findings 
of our study should be interpreted with caution, because of the small study sample and the risk 
of confounding by indication. Therefore, our results will require replication before reaching 
definitive conclusions. We concluded that lamotrigine could be a reasonable alternative 
treatment option for bipolar disorder during pregnancy in patients with vulnerability for 
depression and may prevent severe episodes postpartum. 
In chapter 9, we present the main conclusions of this thesis. Afterwards, we discuss the current 
evidence regarding the risks and benefits of maintenance treatment during the peripartum 
period in women with bipolar disorder, followed by general clinical recommendations. 
Finally, we provide an overview of the design and aims of the National Postpartum Psychosis 
Prevention study (NP3-study). The NP3-study was designed to further investigate the efficacy 
and potential risks of maintenance treatment during the peripartum period in women with a 
history of bipolar disorder and/or postpartum psychosis. 
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DEEL I. STEMMINGSSTOORNISSEN TIJDENS DE POSTPARTUM 
PERIODE
Bipolaire stoornis en postpartumpsychose
Vrouwen met een bipolaire stoornis en/of postpartumpsychose in de voorgeschiedenis hebben 
een sterk verhoogd risico op psychiatrische ziekte-episoden in de postpartum periode. Echter, 
in de literatuur worden grote verschillen in het risico op een recidief beschreven. Het doel van 
hoofdstuk 2 was om met behulp van een meta-analyse een meer precieze benadering te geven 
van dit risico zodat patiënten samen met hun psychiater een betere afweging kunnen maken 
tussen de voor- en nadelen van medicatiegebruik tijdens de zwangerschap en postpartum 
periode. Een systematische zoekopdracht in de meest gebruikte medische databanken 
resulteerde uiteindelijk in de inclusie van 37 studies, waarin de uitkomst van 5.700 bevallingen 
werd beschreven. In de gecombineerde analyse werd een postpartum recidiefkans van 1 op 
3 gevonden. Vrouwen met alleen een postpartumpsychose in de voorgeschiedenis hadden 
een hoger risico op een ernstige ziekte-episode dan vrouwen met een bipolaire stoornis. Het is 
daarom van klinisch belang om onderscheid te maken tussen deze twee groepen.
 Buiten de peripartum periode is lithium het best onderzochte en meest effectieve middel ter 
preventie van stemmingsepisoden bij de bipolaire stoornis. Andere (in meerdere of mindere 
mate) effectief gebleken psychofarmaca zijn valproïnezuur, carbamazepine, lamotrigine en 
tweede generatie antipsychotica (olanzapine, quetiapine, risperidon). De effectiviteit van 
onderhoudsbehandeling tijdens de peripartum periode is echter zeer beperkt onderzocht. 
Desondanks konden we een meta-analyse uitvoeren met de uitkomsten van een klein aantal 
studies. De resultaten lieten zien dat vrouwen die tijdens de zwangerschap medicatie (veelal 
met lithium) gebruikten een lager risico hadden op een recidief dan vrouwen die geen 
medicatie gebruikten. Echter, medicatiegebruik tijdens de zwangerschap brengt ook potentiële 
risico’s met zich mee. Deze risico’s moeten zorgvuldig worden afgewogen tegen de voordelen 
van medicatiegebruik. Lithiumgebruik tijdens de zwangerschap is mogelijk geassocieerd met 
een licht verhoogd risico op aangeboren hartafwijkingen. Valproïnezuur en carbamazepine 
dienen niet te worden gebruikt tijdens de zwangerschap in verband met een verhoogd risico 
op onder andere neuralebuisdefecten. Tweede generatie antipsychotica en lamotrigine lijken 
vooralsnog de meest veilige opties, maar zijn minder effectief gebleken dan lithium. Tot slot 
geldt dat voor al deze middelen de eventuele schadelijke effecten op de lange termijn beperkt 
of nauwelijks zijn onderzocht.
  In algemene zin kan worden gesteld dat indien er sprake is van recente/ernstige 
stemmingsepisoden, de voordelen van onderhoudsbehandeling tijdens de zwangerschap 
meestal opwegen tegen de potentiële risico’s voor moeder en (het ongeboren) kind. Hierbij 
dient polyfarmacie echter altijd te worden vermeden. Daarnaast moet worden gezocht naar 
de laagst effectieve dosering. 
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Het doel van hoofdstuk 3 was om een overzicht te geven van de beschikbare literatuur 
op het gebied van de diagnostiek, behandeling en preventie van postpartumpsychose, 
gevolgd door klinische aanbevelingen voor de dagelijkse praktijk. Postpartumpsychose is een 
zeldzaam maar ernstig ziektebeeld dat snel na de bevalling ontstaat en potentieel gevaarlijk is 
voor moeder en kind. Het ziektebeeld wordt beschouwd als een stemmingsstoornis omdat het 
naast psychotische symptomen wordt gekenmerkt door de aanwezigheid van depressieve en/
of manische symptomen. Bovendien is een postpartumpsychose in een deel van de gevallen 
een eerste uiting van een bipolaire stoornis (manische depressiviteit). Postpartumpsychose 
wordt dan ook niet als aparte diagnose vermeld in het handboek voor de classificatie van 
psychische stoornissen (DSM-5). Het is echter van groot belang om het diagnostische concept 
postpartumpsychose te handhaven omdat een substantieel deel van de vrouwen met een 
postpartumpsychose niet gevoelig is voor stemmingsepisoden buiten het kraambed. Bij deze 
vrouwen is de prognose gunstig en om deze reden geen onderhoudsbehandeling nodig.
 Bij het vermoeden van een postpartumpsychose is er sprake van een indicatie voor een 
psychiatrische (moeder-kind)opname en is het van belang om tijdens de diagnostische fase 
eventuele bekende lichamelijke oorzaken zoals schildklierziekte of een hersenontsteking 
(encefalitis) uit te sluiten. Een gecombineerde behandeling met lithium en antipsychotica is 
zeer effectief en leidt binnen korte tijd tot volledig herstel. Kortdurende profylaxe met lithium na 
een volgende zwangerschap is effectief ter preventie van een postpartumpsychose.
In hoofdstuk 4, beschrijven we de uitkomsten van een studie naar de fenotypische 
karakteristieken van postpartumpsychose. Zoals eerder gezegd is er naast psychotische 
symptomen namelijk meestal ook sprake van een breed scala aan andere symptomen die 
tegelijk of afwisselend kunnen optreden. Het doel van de studie was om op basis van deze 
symptomen meer homogene patiëntengroepen te onderscheiden. De studiepopulatie bestond 
uit patiënten met een postpartumpsychose die tussen 2005 en 2015 werden opgenomen op de 
moeder-kindafdeling van het Erasmus MC en werden geïncludeerd in de OPPER-studie. Deze 
studie vormt het grootste cohort ter wereld van vrouwen met een postpartumpsychose. Met 
behulp van vragenlijsten, een gestructureerd interview en dossier-onderzoek werd herhaaldelijk 
en nauwkeurig navraag gedaan naar een groot aantal symptomen. Er werden 130 patiënten 
geïncludeerd en de meest voorkomende symptomen waren prikkelbaarheid (73%), abnormale 
gedachte inhoud (72%) en angst (71%). Met behulp van statistische technieken konden drie 
profielen worden onderscheiden: in het eerste profiel stonden depressieve symptomen op de 
voorgrond (41%), in het tweede profiel manische symptomen (34%) en in het derde profiel 
atypische symptomen (25%) (stoornis in het bewustzijn, desoriëntatie, depersonalisatie en 
derealisatie). Op basis van deze bevindingen concluderen we dat atypische kenmerken minder 
vaak voorkomen dan eerder werd verondersteld. Het depressieve profiel komt vaak voor maar 
kan gemakkelijker onontdekt blijven doordat het onderscheid met een postpartum depressie 
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minder duidelijk is dan bij het manische of atypische profiel. Dit kan leiden tot vertraging in 
behandeling en een hoger risico op suïcide en infanticide. 
Schildklier auto-immuniteit en postpartum depressie
De postpartum periode is geassocieerd met een verhoogd risico op het ontstaan van auto-
immuun schildklierziekten. Gedurende de zwangerschap is het immuunsysteem minder actief 
om te voorkomen dat het ongeboren kind (dat voor de helft uit lichaamsvreemd materiaal 
bestaat) wordt afgestoten. Na de bevalling kan er echter sprake zijn van een te sterke activatie 
van het immuunsysteem. Dit is waarschijnlijk de reden dat auto-immuunziekten vaak optreden 
of verergeren gedurende de postpartum periode. Bij een auto-immuunziekte treedt er een 
afweerreactie op tegen lichaamseigen cellen. De aanwezigheid van auto-antistoffen tegen 
de schildklier (TPO-ab) in de vroege zwangerschap is een belangrijke voorspeller voor het 
ontstaan van postpartum auto-immuunschildklierziekten, waarbij ook vaak stemmingsklachten 
optreden. Daarnaast speelt een verstoring van het immuunsysteem waarschijnlijk ook een rol bij 
het ontstaan van psychiatrische ziekten, zeker wanneer die vaker of specifiek in de postpartum 
periode optreden, zoals bij postpartumpsychose en postpartum depressie het geval is.   
 Eerdere studies vonden een verband tussen een verhoogde TPO-ab titer en postpartum 
depressie. Echter, het gevonden verband in deze studies is mogelijk niet oorzakelijk omdat niet 
of onvoldoende werd gecorrigeerd voor de aanwezigheid van depressie eerder in het leven 
en/of de zwangerschap en andere mogelijk verstorende factoren. Dit is problematisch omdat 
een over-activatie van het immuunsysteem waarschijnlijk vooral betrokken is bij het ontstaan 
van depressie gedurende de postpartum periode. 
 Het doel van de studie die we beschrijven in hoofdstuk 5 was daarom om te onderzoeken 
of er een relatie bestaat tussen een verhoogde TPO-ab titer in het eerste trimester van de 
zwangerschap en het ontstaan van een eerste depressie in de postpartum periode. De 
studiepopulatie was onderdeel van de HAPPY-studie en bestond uit een groot cohort van 
1.075 zwangere vrouwen zonder een psychiatrische voorgeschiedenis die intensief werden 
gevolgd tot een jaar na de bevalling. Vrouwen die reeds bekend waren met schildklierziekte 
en/of depressieve klachten tijdens de zwangerschap kwamen niet in aanmerking voor 
deelname aan deze studie. Postpartum depressie werd gedefinieerd met een gevalideerde 
afkapwaarde (≥13) op een veelgebruikte zelfinvulvragenlijst voor depressieve klachten 
(Edinburgh Postnatal Depression Scale), die herhaaldelijk werd ingevuld tot een jaar na de 
bevalling. In de hele groep werd een risico gevonden van 6,3% op het ontstaan van een eerste 
postpartum depressie. De aanwezigheid van een verhoogde TPO-ab titer was gerelateerd 
aan een hoger risico op het ontstaan van postpartum depressie vier maanden postpartum. 
Uit eerder onderzoek is gebleken dat bij vrouwen met een verhoogde TPO-ab titer tijdens de 
zwangerschap vaak in diezelfde periode (3-4 maanden postpartum) een ontregeling optreedt 
van het immuunsysteem. De bevindingen uit deze studie suggereren dat er mogelijk overlap 
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bestaat tussen de ontstaanswijze van een eerste postpartum depressie en auto-immuun 
schildklierziekten. Wij adviseren om bij iedere vrouw waarbij depressieve klachten ontstaan in 
de postpartum periode de schildklierfunctie te controleren.
DEEL II: LITHIUMGEBRUIK TIJDENS DE ZWANGERSCHAP EN 
POSTPARTUM PERIODE BIJ DE BIPOLAIRE STOORNIS
In hoofdstuk 6 beschrijven we kort de geschiedenis en potentiële werkingsmechanismen van 
lithium. Daarna bespreken we een aantal klinische aspecten die in het algemeen van belang 
zijn bij lithiumgebruik. 
 In hoofdstuk 7 beschrijven we een studie die zich specifiek richt op het monitoren van 
lithiumgebruik tijdens de zwangerschap en postpartum periode. Tijdens de zwangerschap 
is er sprake van een natuurlijke aanpassing van de nierfunctie, waardoor veranderingen in 
de lithiumbloedspiegel optreden. Aangezien lithium een smal therapeutisch venster heeft, 
brengt dit risico’s met zich mee voor zowel moeder als het ongeboren kind. Tot op heden is er 
echter nooit gedegen onderzoek gedaan naar dit klinisch relevante onderwerp.   
 Het doel van deze studie was daarom om te kwantificeren hoe groot deze veranderingen 
zijn en te onderzoeken op welk moment ze optreden. Voor deze studie verzamelden we data 
middels statusonderzoek in het Erasmus MC en het LUMC (NP3-studie). We gebruikten 1.101 
lithiumbloedspiegels die afkomstig waren van 113 zwangerschappen. De resultaten laten 
zien dat lithiumbloedspiegels geleidelijk tot gemiddeld 36% dalen in het tweede trimester, 
in deze fase moet de lithiumdosis meestal worden verhoogd. In het derde trimester begint de 
lithiumbloedspiegel zich te normaliseren en moet de lithiumdosis vaak weer worden verlaagd. 
De bevalling was niet geassocieerd met een acute verandering in de lithiumbloedspiegel. In het 
hoofdstuk worden een aantal praktische klinische aanbevelingen gedaan waarmee het risico op 
te lage en te hoge lithiumbloedspiegels tijdens de peripartum periode kan worden verkleind.  
  
Zoals eerder gezegd bestaat er bij vrouwen met een bipolaire stoornis gedurende de peripartum 
periode de meeste evidentie voor de effectiviteit van een onderhoudsbehandeling met lithium. 
Lamotrigine wordt toenemend als alternatief gebruikt tijdens de zwangerschap omdat het een 
veiligere optie is wat betreft het risico op neonatale complicaties. De effectiviteit van lamotrigine 
tijdens de peripartum periode is echter nauwelijks onderzocht. Het doel van de studie die wordt 
gepresenteerd in hoofdstuk 8 was daarom het vergelijken van de effectiviteit van lithium- 
en lamotriginegebruik tijdens de zwangerschap bij vrouwen met een bipolaire stoornis. De 
uitkomstmaat van de studie was het risico op een ernstige stemmingsepisode postpartum die 
resulteerde in een ziekenhuisopname. De data voor dit cohortonderzoek (periode 1996-2012), 
werd verkregen uit verschillende Deense registers waarin (medische) informatie van de gehele 
Deense bevolking wordt vastgelegd. Uiteindelijk werd de uitkomst van 114 zwangerschappen 
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geanalyseerd. Het risico op een ernstige recidief ziekte-episode postpartum was 11,4%. Een 
vergelijking tussen patiënten die lithium of lamotrigine gebruikten tijdens de zwangerschap liet 
geen significant verschil zien op een ernstige recidief episode postpartum, ook niet na correctie 
voor verschillen in klinische karakteristieken tussen de twee patiëntengroepen. De uitkomsten 
van dit onderzoek zijn van klinisch belang omdat lamotrigine veiliger kan worden gebruikt 
dan lithium gedurende de zwangerschap. Echter, de resultaten moeten voorzichtig worden 
geïnterpreteerd gezien de kleine studiepopulatie en andere methodologische tekortkomingen 
van het onderzoek. We concluderen dat een onderhoudsbehandeling met lamotrigine tijdens 
de zwangerschap kan worden overwogen, in het bijzonder bij patiënten die kwetsbaar zijn 
voor depressieve episodes.
 
In hoofdstuk 9 vermelden we de belangrijkste conclusies van de studies uit dit proefschrift. 
Daarna bespreken we de beschikbare evidentie wat betreft de effectiviteit en risico’s van 
medicatiegebruik tijdens de zwangerschap bij vrouwen met een bipolaire stoornis. Tenslotte 
bespreken we de onderzoeksopzet en doelen van de Nationale Postpartum Psychose Preventie 
studie (NP3-studie). De NP3-studie is opgezet om de effectiviteit en risico’s te onderzoeken 
van medicamenteuze onderhoudsbehandeling tijdens de peripartum periode bij vrouwen met 
in de voorgeschiedenis een bipolaire stoornis en/of postpartum psychose. 
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- Methods of public health research
- Clinical trials
- Health economics
- Cohort studies
- Case-control studies 
- Causal mediation analysis
- Markers and prediction research
- Logistic regression
Electives
- Repeated measurements in clinical studies
- Psychiatric epidemiology
- Advanced analysis of prognosis studies
- Principles of epidemiologic data-analysis
- Women’s health
2014-2016 70
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176 
PhD training and activities (Continued) Year ECTS
Other courses
- Teach the teacher I
- Biomedical English writing and communication
- Research integrity
- Corsendonk cursus, Belgium (one week)
- Good clinical practice (BROK)
- Systematic literature retrieval in PubMed
- Workshop Endnote 
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Conference presentations
- NVVP Voorjaarscongres, Maastricht (oral)
- MARCE Conference, Melbourne, Australia (oral)
- NVVP Voorjaarscongres, Maastricht (oral)
- ISBD Conference, Amsterdam (oral)
- NVVP Voorjaarscongres, Maastricht (oral)
- SAP Najaarsdag, Utrecht (oral)
- ECNP Conference, Amsterdam (poster)
- MARCE Conference, Swansea, UK (oral)
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2014
Supervision and teaching
- Master thesis Laurine Alderlieste (MSc)
- Master thesis Fatima El Morabit (MSc)
- Minor in psychiatry (BSc)
2014
2014
2015
Nominations and prizes
- The publication “Wesseloo et al. Risk of postpartum 
relapse in bipolar disorder and postpartum psychosis: 
a systematic review and meta-analysis” was selected 
by the New England Journal of Medicine as one of the 
10 most important clinical studies in the entire field of  
psychiatry in 2015. 
- Winner of the Tijdschrift voor Psychiatrie resident 
publication price (€ 1000)
2015
2015
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Uitnodiging
Voor het bijwonen van 
de openbare verdediging 
van het proefschrift
Bipolar Spectrum Disorder 
During Pregnancy and 
the Postpartum Period
door
Richard Wesseloo
Woensdag 21 maart 2018 
om 13.30 uur
Prof. Andries Queridozaal (Eg-370), 
Onderwijscentrum, Erasmus MC
Dr. Molewaterplein 50, Rotterdam
Parkeren is mogelijk in de parkeergarages 
Wytemaweg, Westzeedijk en Museumpark.
Na afl oop bent u van harte welkom op 
de receptie ter plaatse.
Paranimfen
Nick Brinkman
brinkman.jn@gmail.com
06 38 326 981
Benno Bakker
bennobakker@gmail.com
06 28 216 103
Richard Wesseloo
Zonnebloemstraat 23a
3051SP Rotterdam
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